

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
4 April 2002 (04.04.2002)

PCT

(10) International Publication Number  
**WO 02/27028 A1**

- (51) International Patent Classification<sup>7</sup>: C12Q 1/68, C07H 21/02, 21/04, C12N 15/00
- (74) Agents: EAGLEMAN, Patrick, S. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).
- (21) International Application Number: PCT/US01/30366
- (22) International Filing Date:  
27 September 2001 (27.09.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/676,052 28 September 2000 (28.09.2000) US
- (71) Applicant (*for all designated States except US*): ATAIRGIN TECHNOLOGIES, INC. [US/US]; 101 Theory Street, Suite 150, Irvine, CA 92612-3045 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): SKINNER, Michael, K. [US/US]; 770 SW Staley Drive, Pullman, WA 99163 (US). PATTON, Jodi, L. [US/US]; 738 NE Campus, Pullman, WA 99163 (US). CHAUDHARY, Jaideep [IN/US]; 2416 Calle Alcorisa, Tustin, CA 92782 (US).
- Published:  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/27028 A1

(54) Title: A METHOD OF DETERMINING TUMOR CHARACTERISTICS BY DETERMINING ABNORMAL COPY NUMBER OR EXPRESSION LEVEL OF LIPID-ASSOCIATED GENES

(57) Abstract: The present invention relates to a method of determining tumor characteristics in tissue samples taken from a patient by determining the copy number or expression level of genes associated with lipid metabolism, synthesis, or action in the sample. This determination may be made by directly quantifying the gene copy number in the chromosomal material of the tissue sample, or by determining the transcription level of the gene in the tissue sample. The present invention is also drawn to physical platforms which are useful in carrying out the diagnostic method, specifically arrays of nucleic acids useful for determining the copy number of the lipid associated genes by hybridization techniques.

A METHOD OF DETERMINING TUMOR CHARACTERISTICS  
BY DETERMINING ABNORMAL COPY NUMBER OR EXPRESSION LEVEL  
OF LIPID-ASSOCIATED GENES

TECHNICAL FIELD

The present invention relates to a method of determining tumor characteristics in tissue samples taken from a patient by determining the copy number or expression level of genes associated with lipid metabolism, synthesis, or action in the sample. This determination may be made by directly quantifying the gene copy number in the chromosomal material of the tissue sample, or by determining the transcription level of the gene in the tissue sample. The present invention is also drawn to physical platforms which are useful in carrying out the diagnostic method, specifically arrays of nucleic acids useful for determining the copy number or expression level of the lipid associated genes by hybridization techniques.

BACKGROUND

Cancer is the second leading cause of death in the United States, after heart disease: one in every four Americans dies of cancer. As predicted by the SEER program at the National Cancer Institute, there will be over 1.2 million new cases of cancer diagnosed, and over a half-million cancer related deaths in the year 2000 alone. Cancer is characterized by several stages. First, there is an increase in the number of abnormal, or neoplastic, cells which arise from the normal cells in a tissue. Then, these neoplastic cells proliferate to form a tumor mass. Progression of the disease is then characterized by the growth of the tumor and the invasion of adjacent tissues by these neoplastic tumor cells. Finally, the tumor will generate malignant cells which spread via the blood or lymphatic system to regional lymph nodes and to distant sites. The latter progression to malignancy is referred to as metastasis.

Cancer can be viewed as a breakdown in the cell growth regulatory system, in which proper communication between tumor cells, their normal neighboring cells, and the rest of the body is impaired. Signals, both growth-stimulatory and growth-inhibitory, are routinely exchanged between cells within a tissue. The maintenance of proper organ shape and function is dependant upon cell number stasis at particular positions in an organ. Normally, cells do not divide in the absence of stimulatory signals, and, likewise, will cease dividing in the presence of inhibitory signals. In a cancerous state, a cell bypasses this system of regulatory signals and proliferates under conditions in which normal cells would not.

Tumor cells must acquire a number of distinct aberrant traits to proliferate. Reflecting this requirement is the fact that the genomes of certain well-studied tumors carry several different independently altered genes, including activated oncogenes and inactivated tumor suppressor genes. Each of these genetic changes appears to be responsible for imparting some of the traits that, in aggregate, define a neoplastic cell (Land, H. et al., 1983, *Science* 222:771; Ruley, H. E., 1983, *Nature* 304:602; Hunter, T., 1991, *Cell* 64:249).

In addition to unhindered cell proliferation, cells must acquire several traits for tumor progression to occur. For example, early on in tumor progression, cells must evade the host immune system. Scientists expect that the immunosuppression exhibited by tumor cells, reflects a specific gene expression pattern that actively represses the ability of the host immune system to respond normally to tumor progression. Further, as tumor mass increases, the tumor must acquire vasculature to supply nourishment and remove metabolic waste. Additionally, cells must acquire an ability to invade adjacent tissue, and, ultimately, the capacity to metastasize to distant sites.

An increasing body of evidence implicates genetic mutations as causally important in the induction of human cancers. Advances in recombinant DNA technology have led to the discovery of normal cellular genes (proto-oncogenes and tumor suppressor genes) that control growth, development, and differentiation. Under certain circumstances, the regulation of these genes is altered, causing normal cells to assume neoplastic growth behavior. There are over 40 known proto-oncogenes and suppressor genes to date, which fall into various categories depending on their functional characteristics. These include, (1) growth factors and growth factor receptors, (2) messengers of intracellular signal transduction pathways, for example, between the cytoplasm and the nucleus, and (3) regulatory proteins influencing gene expression and DNA replication. Differential expression of the following suppressor genes has been demonstrated in human cancers: the retinoblastoma gene, RB; the Wilms' tumor gene, WT1 (11p); the gene deleted in colon carcinoma, DCC (18q); the neurofibromatosis type 1 gene, NF1 (17q); and the gene involved in familial adenomatous polyposis coli, APC (5q) (Vogelstein, B. and Kinzler, K. W., 1993, *Trends Genet.* 9:138-141).

Point mutations have been directly implicated in the causation of many human tumors. Some tumors carry oncogenes of the ras gene family, which differ from their normal cellular counterpart proto-oncogenes by the presence of a point mutation at one of a limited number of sites in these genes. Similarly, point mutations in critical regions of tumor suppressor genes, such

as p53, are often detected in tumor cells. Mutation of the p53 suppressor gene is the most common alteration seen in epithelial tumors and, indeed, in all human tumors (Hollstein, M. et al., *Science* 253:49-53, 1991). When a tumor suppressor gene, such as p53, becomes mutated, cell proliferation accelerates in the absence of the suppressor. On the other hand, mutations in proto-oncogenes that transform them to active oncogenes, such as a mutant ras oncogene, produces cell proliferation caused by presence of the mutant gene itself.

The mutations that create active oncogenes have been explored with the hopes of providing important diagnostic and prognostic clues for tumor development. For example, a number of mutations have been found to alter the 12th codon of the ras oncogenes, causing replacement of a normally present glycine by any of a number of alternative amino acid residues. Such amino acid substitutions create a potent transforming allele. Thus, the presence of a particular nucleotide substitution may be a strong determinant of the behavior of the tumor cell (e.g., its rate of growth, invasiveness, etc.). As a result, nucleotide hybridization probes of oncogene mutations have been targeted for research as promising diagnostic reagents in clinical oncology.

In addition to point mutations, it has been shown that the amplification of single oncogenes can be linked to malignancy and proliferation of cancerous tumor cells. It is believed that many solid tumors, such as breast cancer, progress from initiation to metastasis through the accumulation of several such genetic aberrations. (Smith et al., *Breast Cancer Res. Treat.*, 18 Suppl. 1: S 514 (1991); van de Vijver and Nusse, *Biochim. Biophys. Acta*, 1072: 33-50 (1991); Sato et al., *Cancer Res.*, 50: 7184-7189 (1990).) These genetic aberrations, as they accumulate, may confer proliferative advantages, genetic instability and the attendant ability to evolve drug resistance rapidly, and enhanced angiogenesis, proteolysis and metastasis. Deletions and recombination leading to loss of heterozygosity (LOH) are believed to play a major role in tumor progression by uncovering mutated tumor suppressor alleles.

Gene amplification is a common mechanism leading to up-regulation of gene expression. (Stark et al., *Cell*. 75: 901-908 (1989).) Evidence from cytogenetic studies indicates that significant amplification occurs in over 50% of human breast cancers. (Saint-Ruf et al., *supra.*) A variety of oncogenes have been found to be amplified in human malignancies. Examples of the amplification of cellular oncogenes in human tumors are shown in Table 1 below.



TABLE 1

Amplified Gene	Tumor	Degree of Amplification
c-myc	Promyelocytic leukemia, cell line, HL60	20x
	Small-cell lung carcinoma cell lines	5-30x
N-myc	Primary neuroblastomas (stages III and IV) and neuroblastoma cell lines,	5-1000x
	Retinoblastoma cell line and primary tumors,	10-200x
	Small-cell lung carcinoma cell lines and tumors	50x
L-myc	Small-cell lung carcinoma cell lines and tumors	10-20x
c-myb	Acute myeloid leukemia	5-10x
	Colon carcinoma cell lines	10x
c-erbB	Epidermoid carcinoma cell	30x
	Primary gliomas	
c-K-ras-2	Primary carcinomas of lung colon, bladder, and rectum	4-20x
N-ras	Mammary carcinoma cell line	5-10x

For example, as disclosed in U.S. Patent No. 5,846,749, the amplification of the Her-2 gene has been linked to invasive breast cancer phenotypes. In a study of node-negative invasive breast carcinomas, the degree of HER-2/neu gene amplification was determined by Southern blot analysis of EcoRI digested tumor tissue and the relative amount of HER-2/neu mRNA was determined by Northern hybridization of total RNA. The amount of HER-2/neu gene expression was roughly proportional to the number of copies of the gene in tumor cells. In addition, increasing levels of HER-2/neu gene amplification in these carcinomas were also associated with an increased risk of recurrent breast cancer. In human breast carcinomas, other proto-oncogenes, such as MYC, INT2, HST, and ERBB2, are frequently found either amplified or overexpressed. Although other similar correlations have been shown for other single oncogene amplifications or deletions, these approaches have limited predictive value for prognoses or treatment.

Chromosomal deletions involving tumor suppressor genes may also play an important role in the development and progression of solid tumors. The retinoblastoma tumor suppressor

gene (Rb-1), located in chromosome 13q14, is the most extensively characterized tumor suppressor gene (Friend et al., *Nature*, 323: 643 (1986); Lee et al., *Science*, 235: 1394 (1987); Fung et al., *Science*, 236: 1657 (1987)). The Rb-1 gene product, a 105 kDa nuclear phosphoprotein, apparently plays an important role in cell cycle regulation (Lee et al., *supra* (1987); Howe et al., *PNAS (U.S.A.)*, 87: 5883 (1990)). Altered or lost expression of the Rb protein is caused by inactivation of both gene alleles either through a point mutation or a chromosomal deletion. Rb-1 gene alterations have been found to be present not only in retinoblastomas (Friend et al., *supra* (1986); Lee et al., *supra* (1987); Fung et al., *supra* (1987)) but also in other malignancies such as osteosarcomas (Friend et al., *supra* (1986)), small cell lung cancer (Hensel et al., *Cancer Res.*, 50: 3067 (1990); Rygaard et al., *Cancer Res.*, 50: 5312 (1990)) and breast cancer (Lee et al., *Science*, 241: 218 (1988); T'Ang et al., *Science*, 242: 263 (1988); Varley et al., *Oncogene*, 4: 725 (1989)).

In addition to single gene centered approaches to studying cancer genetics, changes in chromosomal loci associated with cancer have been studied. Chromosome abnormalities have long been associated with genetic disorders, degenerative diseases, and exposure to agents known to cause degenerative diseases, particularly cancer, German, "Studying Human Chromosomes Today," *American Scientist*, 58: 182-201 (1970); Yunis; "The Chromosomal Basis of Human Neoplasia," *Science*, 221: 227-236 (1983); and German, "Clinical Implication of Chromosome Breakage," in *Genetic Damage in Man Caused by Environmental Agents*, Berg, Ed., pgs. 65-86 (Academic Press, New York, 1979). Chromosomal abnormalities include translocations (transfer of a piece from one chromosome onto another chromosome), dicentric (chromosomes with two centromeres), inversions (reversal in polarity of a chromosomal segment), insertions, amplifications, and deletions.

In cancer, deletion or multiplication of copies of whole chromosomes or chromosomal segments, and higher level amplifications of specific regions of the genome, are common occurrences. With the advent of cloning and detailed molecular analysis, recurrent translocation sites have been recognized as involved in the formation of chimeric genes such as the BCR-ABL fusion in chronic myelogenous leukemia. Deletions have been recognized as frequently indicating the location of tumor suppressor genes; and amplifications have been recognized as indicating overexpressed genes.

Human breast carcinomas are also characterized cytogenetically by various anomalies that may be the chromosomal counterpart of the molecular anomalies: regions of amplification

are found in more than one-third of the tumors, and various deletions e.g., 1p, 11p, 11q, 13, and 17p, are found recurrently. Although amplification of genetic material is a frequent and probably important event in breast carcinogenesis, the relevant genes involved in such amplifications remain unknown, and do not seem to correspond to the proto-oncogenes commonly considered important in breast cancer. Since these regions of amplification in tumors are most often not at the site of the amplified genes in normal cells, standard cytogenetics does not yield any information that could assist with identification of the gene. Dutrillaux et al., *Cancer Genet. Cytogenet.*, 49: 203-217 (1990) report (at page 203) that "(a)lthough human breast carcinomas are among the most frequent malignant tumors, cytogenetic data remain scarce, probably because of their great variability and of the frequent difficulty of their analysis." In their study of "30 cases with relatively simple karyotypes to determine which anomalies occur the most frequently and, in particular, early during tumor progression" (p. 203), they concluded that "trisomy 1q and monosomy 16q are early chromosomal changes in breast cancer, whereas other deletions and gain of 8q are clearly secondary events." (Abstract, p. 203.) Dutrillaux et al. further state (at page 216) that deletions within tumor suppressor genes "characterize tumor progression of breast cancer."

Restriction fragment length polymorphism (RFLP) studies have indicated that several tumor types have frequently lost heterozygosity at 13q, suggesting that one of the Rb-1 gene alleles has been lost due to a gross chromosomal deletion (Bowcock et al., *Am. J. Hum. Genet.*, 46: 12 (1990)). The deletion of the short arm of chromosome 3 has been associated with several cancers, for example, small cell lung cancer, renal and ovarian cancers; it has been postulated that one or more putative tumor suppressor genes is or are located in the p region of chromosome 3 (ch. 3p) (Minna et al., *Symposia on Quantitative Biology*, Vol. LI: 843-853 (SCH Lab 1986); Cohen et al., *N. Eng. J. Med.*, 301: 592-595 (1979); Bergerham et al., *Cancer Res.*, 49: 13901396 (1989); Whang-Peng et al., *Can. Genet. Cytogenet.*, II: 91-106 (1984; and Trent et al., *Can. Genet. Cytogenet.*, 14: 153-161 (1985)).

The Cancer Genome Anatomy Project, sponsored by the National Cancer Institute, has catalogued changes at particular chromosomal locations and correlated them with disease in the Breakpoint Map of Recurrent Chromosomal Aberrations. Unfortunately, the chromosomal change data consists of thousands of often conflicting anecdotal case studies, and chromosomal changes can only be mapped to large areas covering dozens of genes. Thus, although much data

has been collected in this area, it has not yielded any discernable patterns in chromosomal change which are clinically useful for characterizing tumors or predicting the progress of cancers.

A universally accepted classification of cancer stages allows evaluation of treatment management, prognosis and statistical comparison for the various anatomic sites of cancer. Although several organizations dedicated to cancer exist, including the American Joint Committee on Cancer (AJCC), International Union Against Cancer (UICC); World Health Organization (WHO); Federation Internationale de Gynecologie et d'Obstertrique (FIGO), there has been a concerted effort to establish a uniform standard accepted world-wide for classification of cancer. In 1988, the AJCC in cooperation with the TNM Committee of the UICC accepted the TNM (Tumor, Node, and Metastasis) description to indicate the classification and stage of growth for the various anatomical sites of human cancer known. The AJCC Cancer Staging Manual (1997) is now in its 5<sup>th</sup> edition, and corresponds with the Fifth Edition of the UICC TNM Classification of Malignant Tumors.

The TNM system is based on three significant events in the anatomical history of a cancer: the size of the untreated primary cancer (T), its spread to regional lymph nodes (N) and finally, distant metastasis beyond the regional lymph nodes (M). Classification of a cancer by TNM, therefore, indicates the extent of disease and progression for any cancer growth. Staging classifications are based on documentation of the anatomic extent of disease, derived from morphologic studies and clinical biopsies.

The AJCC, knowing that new information on diagnosis, treatment and etiology will affect the classification system, assigns task committees to meet periodically and recommend revisions. While now based mainly on anatomical criteria, it is very likely that molecular, genetic and other prognostic indicators will be included into the TNM classification system when recommended by the appropriate AJCC committee.

Clinical classification utilizing the TNM system is based on evidence acquired before primary treatment. Pathologic classification includes the evidence acquired before treatment, as well as evidence acquired from surgery. The three components, T, M and N, are assessed. The use of numerical subsets of the TNM components indicates the progressive extent of the malignant disease. Any of the T, N, or M classifications can be divided into subgroups for testing. The TNM components can then be evaluated to determine the stage grouping (I-IV) of growth for the patient's cancer. The clinical stage is used as a guide to the selection of primary therapy, usually a form of surgery to remove the cancerous lesions. The pathologic stage can

also be used as a guide for adjuvant therapy (chemotherapy), prognosis, and reporting end results.

For example, over 90% of all ovarian cancers are derived from a single layer of surface epithelial cells that surrounds the ovary that are known as the ovarian surface epithelium (OSE). The cancerous epithelial cells initially form tumors on the ovary (stage I), slough off and migrate to the fallopian tubes and the uterus (stage II) and ultimately metastasize throughout the peritoneum and into such organs as the liver, bowel and bladder (stage III and IV). Stage I and II tumors are treatable with conventional management (up to 90% survival after five years for Stage IA and 70% survival for stage II), however, a lack of accurate diagnostics has made detecting early stage disease difficult with only 20% of all cases presenting at stage I or II. Most late stage ovarian cancer patients present with large volumes of ascites in the peritoneum. This accrual is thought to be a consequence of impaired lymphatic drainage as well as an increased rate of lymphatic production potentially due to effects of vascular permeability factor also known as vascular endothelial growth factor, which is present at high levels in ascites.

Treatment of all cancers depends on the tumor stage as determined by clinical evaluation and surgical resection. The standard technique for assessing the spread of a tumor is surgical resection of a primary tumor followed by careful review using light microscopy of surgical margins and other tissue, including lymph nodes. Under existing procedure, the adjacent tissue is stained by standard techniques and assessed under light microscopy for the presence of tumor cells. Using the TNM scale, the tumor can then be assessed and assigned to a particular stage. Accurate histopathologic assessment is critical since it provides important prognostic indicators that determine the probability of survival for a given patient following surgical resection of the primary tumor.

Despite many years of research and billions of dollars in expenditures, the long term survival of patients with malignancies remains disappointingly low, even where no tumor cells were detected in the tumor margins or more distant tissues. This ability to more accurately determine the stage of tumor progression in each patient is complicated by limitations inherent in the standard histopathologic methodology which is based upon visual observation and morphologic assessment under light microscopy of adjacent tissue and regional lymph nodes. Thus, a method which uses a more precise technique capable of determining spread of the disease at an earlier stage might provide a more accurate indication of the extent of tumor metastases into adjacent and regional tissues. Although limited advances have been made in the characterization

of tumors and pre-cancerous tissues by studying changes in individual genes or at particular loci of chromosomes, these approaches do not take into consideration the interaction of various gene products which is necessary for the myriad steps of tumor progression. Thus, a need exists for a different approach towards the study of the progression of cancer and the development of better tumor diagnostic tools.

Bioactive lipids have recently been recognized to be an integral and pervasive part of cell regulation and signaling. Lysoglycerolphospholipids and sphingoid-based lipids are two important classes of bioactive lipid mediators that have been extensively studied in recent years and have known effects on ovarian cancer cells. LPA and lysophosphatidylcholine (LPC), as well as their sphingoid relatives, S1P and SPC along with the closely related platelet activating factor (PAF) can induce numerous cellular responses including cell proliferation, smooth muscle contraction, platelet aggregation, angiogenesis and tumor cell invasion. These mediators are produced by numerous cell lineages and are normal constituents of sera. Thus they can be viewed in terms of being a necessary part of physiological responses to specific cellular stresses. Furthermore, these lysophospholipids elicit their effects through classical signal transduction pathways including the regulation of heterotrimeric G-proteins, kinase signaling cascades, calcium mobilization, transcriptional regulation, focal adhesion kinase (p125 FAK) and the actin cytoskeleton. Over the past few years, LPA receptors have been cloned and identified as members of the seven-transmembrane-domain G-protein coupled receptor class and fall into two subfamilies: PSP24 and the Edg-family (endothelial cell differentiation gene) of receptors. The Edg-family is comprised of eight members of which Edg1, Edg2, Edg4 and Edg7 have been demonstrated to bind LPA and to activate a variety of signal transduction pathways in response to exogenous LPA. Edg1, Edg3, Edg5 and Edg6 have demonstrated to be receptors for S1P.

Phosphatidyl choline (PC), also named lecithin, is one of the major sources of polyunsaturated fatty acids such as arachidonic and linoleic acids. The former is a precursor of eicosanoids which have numerous biological activities. Hydrolysis of PC yields lysophosphatidyl choline (LPC) and constituent fatty acids, which have been implicated in signal transduction. An increasing body of evidence indicates that LPC, which is present in high concentrations in oxidized low density lipoproteins may play a significant role in atherogenesis and other inflammatory disorders. LPC has been reported to increase the transcription of genes encoding platelet derived growth factor A and B chains, and heparin-binding epidermal growth factor-like protein (HB-EGF) in cultured endothelial cells, and to increase mRNA encoding HB-

EGF in human monocytes. These gene products are mitogens for smooth muscle cells and fibroblasts. LPC has also been shown to activate protein kinase C in vitro, to potentiate the activation of human T lymphocytes and to potentiate the differentiation of HL-60 cells to macrophages induced by either membrane-permeable diacylglycerols or phorbol esters.

LPC may also provide a source of bioactive lysophosphatidic acid (1-acyl-sn-glycero-3-phosphate, LPA) through hydrolysis by lysophospholipase D. LPA is a naturally occurring phospholipid with a wide range of growth factor-like biological activities. It is well established that LPA can act as a precursor of phospholipid biosynthesis in both eukaryotic and prokaryotic cells. The ability of LPA to act as an intercellular lipid mediator has been noted (Vogt, Arch. Pathol. Pharmacol. 240:124-139 (1960); Xu et al., J. Cell. Physiol. 163:441-450 (1995); Xu et al., Biochemistry 309:933-940 (1995); Tigyi et al., Cell Biol. 91:1908-1912 (1994); Panetti et al., J. Lab. Clin. Med. 129(2):208-216 (1997)). LPA is rapidly generated by activated platelets and can stimulate platelet aggregation and wound repair.

Ascites from ovarian cancer patients contain an activity or activities that are very effective at supporting the growth of ovarian cancer cell lines and of freshly isolated ovarian cancer cells but not of ovarian surface epithelial cells (OSE) or SV-40 large T-antigen-immortalized surface epithelial cells (IOSE). This growth factor-like activity in ascites (originally termed OCAF for Ovarian Cancer Activating Factor) was identified as lysophosphatidic acid (LPA) based on chemical and physical characteristics as well as the ability of synthetic LPA (but not other growth factors such as platelet-derived growth factor, also present in ascites) to completely desensitize the calcium mobilization response of ovarian cancer cells to ascites fluid and on the ability of phospholipases to destroy OCAF activity in ascites. (Mills et al., Cancer Res. 48:1066 (1988); Mills et al. J. Clin. Invest. 86:851 (1990) and U.S. Patent Nos. 5,326,690 and 5,277,917)

LPA at concentrations present in ascites has multiple effects on ovarian cancer cells including increased cell proliferation, increased cell survival by decreasing apoptosis and anoikis, decreased sensitivity to cisplatin, increased invasiveness, increased production of vascular endothelial growth factor, increased production and activity of urokinase-type plasminogen activator (uPA) as well as the activity of the metalloproteinases MMP2 and MMP9 and finally, increased production of LPA itself. LPA does not produce similar responses in freshly isolated OSE and IOSE.

Other lysophospholipids associated with various conditions include lysophosphatidyl serine (LPS), lysophosphatidyl ethanolamine (LPE), lysophosphatidyl glycerol (LPG) and lysophosphatidyl inositol (LPI). Activated platelets secrete two kinds of phospholipase: sPLA2 and PS-PLA1. sPLA2 is reported to be elevated in inflammatory reactions and inhibition of this enzyme reduced inflammation. PS-PLA1 hydrolyzes phosphatidylserine or lysophosphatidyl serine (LPS) specifically to produce GPS or Glycerol-3-P serine. LPS strongly enhances degranulation of rat mast cells induced by concanavalin A and potentiates histamine release, and can stimulate sPLA2-elicited histamine release from rat serosal mast cells. LPS is an inflammatory lipid mediator and Spla2 has been implicated in inflammation processes. LPI has been shown to stimulate yeast adenylyl cyclase activity with implications for modulating the activity of downstream effector molecules and their interaction with RAS proteins.

#### DESCRIPTION OF THE INVENTION

The varied biological activities of bioactive lipids indicate that they are important cell regulation and signaling molecules. As mentioned above, elevated LPA levels have been linked to ovarian cancer, and several sphingolipids and lysophospholipids have been implicated in cell signaling events. These altered lysophospholipid and sphingolipid levels reflect a bioactive lipid metabolism that reflects the initiation or progress of cancer development as a function of gene expression. Using this unique metabolic approach, applicants have developed a novel method of monitoring cancer progression. The added information concerning tumor characteristics that is supplied to the clinical practitioner by this method can be used to choose more appropriate and effective cancer therapies.

The present invention is drawn to a method for identifying tumor characteristics of the cells of tissue samples taken from a patient by determining the copy number or expression level of genes associated with lipid metabolism, synthesis, or action in the cells of the sample. Although not bound to any particular theory, the alteration of the chromosomal copy number or loss of control over the expression of lipid associated genes is a very significant event in the genesis and progression of cancer. Thus, the relative stage and characteristics of the disease is monitored by determining the copy number or expression level of lipid associated genes in the cancerous and pre-cancerous cells of a tumor or surrounding tissues. This determination may be made by directly quantifying the gene copy number in the chromosomal material of the tissue sample, or by determining the transcription level of the gene in the tissue sample. The present



invention is also drawn to physical platforms which are useful in carrying out the diagnostic method, specifically arrays of nucleic acids useful for determining the copy number or expression level of the lipid associated genes by hybridization techniques.

Thus, one aspect of the present invention is an *ex-vivo* method for identifying tumor characteristics of the cells of a tissue sample obtained from a patient, wherein the method comprises determining whether the cells of the tissue sample have an abnormal copy number or expression level of at least two genes associated with lipid metabolism, synthesis, or action. A non-exclusive list of preferred genes for monitoring in making the determination includes Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidyltransferase 1 (choline specific, alpha form), Phosphate cytidyltransferase 2 (ethanolamine specific), Sphingosine kinase, Phosphatidic Acid Phosphatase type 2c, Human Lysophospholipase Homolog, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lysophospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Glycerol-3-phosphate Acyltransferase, Triacylglycerol lipase, Phosphatidylserine decarboxylase, CDP Diacylglycerol inositol-3-phosphatidyltransferase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7; and also includes Sphingosine Kinase Type 2, MAP kinase1, LYPLA2, MAP kinase phosphatase like, LPA phosphatase, Phospholipid scramblase 4, Protein kinase B and Lipid activated protein kinase, IL6, IL8, ROCK1, uPA, tPA, gro1 VEGF and hbEGF. Particularly preferred genes for monitoring in the method of the invention are Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, EDG 1, Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7. In other preferred alternative embodiments, two or more genes which may be indirectly influenced by bioactive lipids and their metabolic products are also monitored in addition to the lipid associated genes. In especially preferred embodiments, these are selected from the group consisting of ERK1, JNK1, Actin B, LH receptor, FSH receptor, LRP, SPARC,

Ras inhibitor (RIN1), IGF binding protein 4, SERPINA8, TIMP1, PIP5K2B, Secretory leukocyte protease inhibitor, FLJ20258, Id4, GNA14, SYK, MAP2K4, G protein coupled receptor 39, SIR2, Prostate epithelium specific Ets transcription factor, Cathepsin D, GnRH receptor, Profilin, CA 125, CDKN1A, RAB13, FCGRT, RPS9, LATS1, JunD, FGFR4, p66shc, Id3, human polo like kinase, MDM2, Hras, CTNNB1, CDKN1B, AKT2, MGMT, Actin bundling protein, MMP7, MMP2, Mesothelin, MUC5AC, and MAS1.

Although useful information concerning tumor characteristics may be gleaned by determining the copy number or expression level of as few as two lipid associated genes, it is preferred that more than two genes be so monitored in the methods of the invention. The copy number or expression level of each gene can usually be used to answer one question about the tumor characteristics of the tissue sample, such as "Is the cell metastatic?" or "Is the tumor at stage 2?" Furthermore, where the source of the tumor is not known with complete certainty, the copy number or expression level of each gene can indicate the source of the tumor and provide important information about the origin or source of the tumor and yield insight into the diagnosis or treatment thereof. If more lipid-associated genes are monitored, more information will be available to the clinician. In addition, the correlation between tumor stages and the amplification or deletion of any particular gene is usually not 100%. Thus, certainty as to the tumor characteristics identified through the method can be increased by monitoring more than one lipid associated gene that has been correlated to a particular characteristic, or "redundant" genes. Thus, methods employing at least three, four, five, six, seven, eight, nine, ten, fifteen, or twenty genes are all more preferred embodiments of the method of the invention. A most preferable embodiment of the method would determine the copy number or expression level of at least ten lipid associated genes, as this will provide several pieces of information concerning the stage and metastatic potential of the cells in the tissue sample with redundant genes to verify that information.

The method of the invention may be applied to a tissue sample from any organ, including muscle, dermal tissues, lung, liver, pancreas, stomach, colon/rectal tissues, bone, prostate, testicles, or other organs in which cancer is known to occur. However, especially preferred embodiments of the invention utilize tissue samples from gynecological organs, including breast, cervix, uterus, and ovaries. It is also contemplated that connective, muscle, or lymphoid tissues surrounding the organ of interest will also be a source of tissue samples, as it may be advantageous for a clinician to test these tissues for evidence of invading or metastasizing tumor

cells.

The determination of whether the cells of the tissue sample have an abnormal copy number or expression level of the genes associated with lipid metabolism, synthesis, or action may be achieved by any of several methods known in the art for determining gene copy number or expression level. For example, in situ fluorescence hybridization techniques can be used to microscopically "count" the number of gene copies in a cell. Preferred methods for determining the copy number or expression level of lipid associated genes are those which use hybridization probes. Such methods generally include the steps of:

- a) isolating sample nucleic acid polymers from the cells of the tissue sample;
- b) hybridizing the sample nucleic acid polymers with nucleic acid polymers specific for the selected genes under conditions wherein the extent of hybridization may be quantified;  
and
- c) comparing the hybridization data thus obtained with data obtained from the hybridization of reference nucleic acid polymers isolated from a normal cell of the same tissue type as that of the tissue sample from the patient with the nucleic acid polymers specific for the selected genes under the same conditions.

In the methods of the present invention, the sample nucleic acid polymers and the reference nucleic acid polymers may be either genomic DNA or mRNA encoding expressed genes. It is also contemplated to be within the scope of the claimed method to amplify the sample nucleic acid polymer by a polymerase chain reaction (PCR) technique prior to hybridization in order to increase the amount of the sample nucleic acid polymer available for detection.

The nucleic acid polymer probes specific for the selected genes used in the methods or arrays of the invention are preferably derived from the naturally occurring gene sequence of the gene for which the probe is designed. It is preferable that the nucleic acid probe comprise at least about 19 nucleotides which hybridize under the hybridization conditions used in the method to a similarly sized portion of the naturally occurring gene sequence. However, it is more preferable to use nucleic acid probes with at least about 25 nucleic acids which hybridize to the naturally occurring gene, so that allelic variations and point mutations will not significantly interfere with the detection of the lipid associated gene copy number or expression level. The nucleic acid probe may hybridize with a coding region of one of the selected genes, or with a non-coding sequence functionally linked to the coding region of one of the selected genes, wherein the

functionally linked sequence is unique to that gene. In various embodiments of the invention, the probes may be full-length cDNA sequences, which are often available commercially as cloned DNA plasmid inserts. These embodiments have the advantage of being able to hybridize under conditions of moderate stringency with mRNA sub-species of the genes of interest, in spite of rather significant sequence variations such as, for example, the insertion or deletion of exons in splice variants.

It is also preferred in embodiments of the methods of the present invention to immobilize the nucleic acid polymer probes specific for the selected genes on a solid support, so that a nucleic acid polymer specific for each selected gene is located at a different predetermined position on the solid support. When the nucleic acid polymer probes are so arranged, the copy number or expression level of several lipid associated genes in the sample nucleic acid polymers may be determined at the same time by sandwich hybridization assay techniques.

Thus, another aspect of the present invention is an array of nucleic acid polymers immobilized on a solid support, in which the array comprises:

- a) a solid support;
- b) at least two different nucleic acid polymers which are each specific for a different gene associated with lipid metabolism, synthesis, or action;

wherein a nucleic acid polymer specific for each gene associated with lipid metabolism, synthesis, or action is located at a different predetermined position on the solid support, and wherein the array comprises less than 100 nucleic acid polymers which are specific for genes other than the selected genes. Although the arrays of the present invention may be part of a larger array for testing nucleic acid polymers isolated from a tissue sample, and such embodiments are envisioned as within the scope of the invention, the arrays are nonetheless intended to be used as relatively focused tools for gathering information about tumor characteristics. Thus, arrays which contain nucleic acid polymer probe sequences specific for each and every human gene, or those which consist of probe sequences specific for every gene expressed by a certain cell type (also referred to as "cDNA library arrays"), are not considered to be within the scope of the present invention.

It is preferred that at least two of the nucleic acid polymers which are specific for genes associated with lipid metabolism, synthesis, or action be specific for genes selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase

D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidyltransferase 1 (choline specific, alpha form), Phosphate cytidyltransferase 2 (ethanolamine specific), Sphingosine kinase, Phosphatidic Acid Phosphatase type 2c, Human Lysophospholipase Homolog, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lysophospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Glycerol-3-phosphate Acyltransferase, Triacylglycerol lipase, Phosphatidylserine decarboxylase, CDP Diacylglycerol inositol-3-phosphatidyltransferase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7; and also Sphingosine Kinase Type 2, MAP kinase1, LYPLA2, MAP kinase phosphatase like, LPA phosphatase, Phospholipid scramblase 4, Protein kinase B and Lipid activated protein kinase, IL6, IL8, ROCK1, uPA, tPA, gro1 VEGF and hbEGF. It is more preferred that at least one of the nucleic acid polymers which is specific for a gene associated with lipid metabolism, synthesis, or action is specific for a gene selected from the group consisting of:

Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, EDG 1, Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7. In other preferred alternative embodiments, the array also includes nucleic acid polymer sequences specific for two or more genes which may be indirectly influenced by bioactive lipids and their metabolic products in addition to probes for the lipid associated genes. In especially preferred embodiments, these additional sequences are specific for genes selected from the group consisting of ERK1, JNK1, Actin B, LH receptor, FSH receptor, LRP, SPARC, Ras inhibitor (RIN1), IGF binding protein 4, SERPINA8, TIMP1, PIP5K2B, Secretory leukocyte protease inhibitor, FLJ20258, Id4, GNA14, SYK, MAP2K4, G protein coupled receptor 39, SIR2, Prostate epithelium specific Ets transcription factor, Cathepsin D, GnRH receptor, Profilin, CA 125, CDKN1A, RAB13, FCGRT, RPS9, LATS1, JunD, FGFR4, p66shc, Id3, human polo like kinase, MDM2, Hras, CTNNB1, CDKN1B, AKT2, MGMT, Actin bundling protein, MMP7, MMP2, Mesothelin, MUC5AC, and MAS1.

### BRIEF DESCRIPTION OF DRAWINGS

**FIGURE 1:** A diagram of the pathways for various metabolism and synthesis of phospholipids.

**FIGURE 2:** A diagram of the pathways for various metabolism and synthesis of sphingolipids.

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

### DESCRIPTION OF MODES FOR CARRYING OUT THE INVENTION AND INDUSTRIAL APPLICABILITY

The present invention is directed to a method of identifying tumor characteristics by determining the copy number or expression level of genes associated with lipid metabolism, synthesis, or action in the cells of a tissue sample from a patient, and to arrays used as a tool in the claimed methods. Although the examples and guidance given below primarily concern embodiments of the invention which include the use of array-based nucleic acid hybridization techniques, one of ordinary skill in the art will readily recognize that the invention is not limited to this particular type of methodology for determining lipid-associated gene copy number or expression level. Thus, the method of identifying tumor characteristics taught by the present invention can be readily modified by those of skill in the art to utilize any other acceptable methods of determining gene copy number or expression level in the cells of a sample, and such modifications are considered to be within the scope of the present invention.

As used herein, "tumor characteristic" means any morphological characteristic associated with tumors or the development and progression of cancers, such as tumor stage and serous, mucinous, metastatic, or endometroid character. Especially, The metastatic nature and potential of the tumor cells, or the degree of their invasive and migratory nature, may be determined by particular lipid-associated gene copy number or expression level profiles. Tumor stage, defined according to traditional pathological criterion, is of particular interest as a tumor characteristic. Although the traditional methods of describing tumor stages (size, degree of invasion into regional tissues, and the presence of distant metastasis (or colonies of cells from the original tumor)) are not directly determined by the present method, the underlying biochemical changes which allow the tumor cells to drastically increase in size, to live detached from the tumor

surface, and to infiltrate the cell layers of surrounding tissues are often linked to changes in the copy number or expression level of lipid-associated genes. In addition, resistance to particular chemotherapies or radiation may be determined from the lipid-associated gene copy number or expression level profile, as the success of particular therapies often depends upon the cell characteristics of the tumor.

“Tissue sample” means any tissue or an extract thereof obtained from a patient which is suspected of comprising cancer or tumor cells, including tissues from the tumor body, tissues surrounding the tumor, or tissues obtained from vicinal lymph nodes.

“Patient,” as used herein, is not limited exclusively to human patients. However, the exemplary methods described herein are intended for use with human patients. Modification of the methods described herein, particularly with respect to the particular genes assayed for copy number or expression level, are probably necessary for application of these methods to non-human patients. Several genes associated with lipid metabolism, synthesis, or action are known for a number of non-human mammalian species, and the modification of the present methods for use with these species would be well within the skill of the ordinary practitioner in the biochemical arts.

“Abnormal copy number,” as used herein, denotes a higher or lower number of copies of a gene in a cell’s genome, as compared to the normal number of gene copies in a cell of a particular type in a particular organism. Although ordinarily two copies of most genes are contained in most diploid cells, greater or fewer copies may be considered “normal” for the cell. For instance, only one copy of some genes on the X chromosome is present in a normal diploid cell from a male organism (XY heterozygous).

“Expression level,” as used herein, denotes the level of transcription of a gene in a cell, as determined by the number of mRNA’s encoding a particular protein gene product present in the cell. The number of mRNA copies of most genes will vary by cell tissue type. Thus, an abnormal expression level would be one in which a significantly higher or lower number of mRNA’s for a particular protein exist in the cell as compared to a normal cell of the same tissue type under approximately the same conditions.

“Genes associated with lipid metabolism, synthesis, or action,” include genes whose proteins modify, oxidize, reduce, cleave, bind, or otherwise utilize bioactive lipids as substrates or ligands. Such bioactive lipids include sphingosine-1-phosphate (S1P), sphingophosphatidylcholine (SPC), sphingophosphatidylinositol (SPI),

sphingophosphatidylserine (SPS), shingophosphatidylglycerol (SPG), sphingophosphatidylethanolamine (SPE), lysophosphatidic acid (LPA), lysophatidylcholine (LPC), lysophosphatidylserine (LPS), lysophosphatidylinositol (LPI), lysophosphatidyl ethanolamine (LPE), and lysophosphatidyl glycerol (LPG), as well as metabolites of these lipids such as glycerol-3-phosphate (G3P). A non-exhaustive list of such genes include Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidyltransferase 1 (choline specific, alpha form), Phosphate cytidyltransferase 2 (ethanolamine specific), Sphingosine kinase, Phosphatidic Acid Phosphatase type 2c, Human Lysophospholipase-Homolog, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lyosphospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Glycerol-3-phosphate Acyltransferase, Triacylglycerol lipase, Phosphatidylserine decarboxylase, CDP Diacylglycerol inositol-3-phosphatidyltransferase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7; lipid associated genes also include Sphingosine Kinase Type 2, MAP kinase1, LYPLA2, MAP kinase phosphatase like, LPA phosphatase, Phospholipid scramblase 4, Protein kinase B and Lipid activated protein kinase, IL6, IL8, ROCK1, uPA, tPA, gro1 VEGF and hbEGF.

The term "isolating nucleic acid polymers" means any acceptable method of extracting nucleic acid polymers (such as deoxyribonucleic acids or ribonucleic acids) from the cells of a sample. Normally, such methods will include steps such as lysing the cells in a sample and purifying the nucleic acids from the lysed cells. Traditional methods of purification include solvent partition of cell components or absorption of nucleic acids onto a matrix which has a high affinity for nucleic acids, such as silica. However, "isolation" of the nucleic acid in a sample, as the term is used in this application, can also be accomplished by fixing the nucleic acid within the cell at a known or knowable location, such as in paraffin fixed tissues whose chromosomal DNA can be examined microscopically by microkeratotomy and histopathology techniques. These methods are well known to those of ordinary skill in the art.



The term "hybridizing" denotes a procedure in which complementary, or nearly complementary, nucleic acid polymers are allowed to associate in solution. Usually, if a sample nucleic acid polymer is double stranded chromosomal DNA, the hybridization procedure will include a denaturation or "melting" step. It is preferred that buffers and temperature conditions in the hybridization procedure be such that minimal non-specific interactions between the associating nucleic acid polymers occur. These are usually referred to as "stringent" conditions by those of skill in the art. This will prevent non-specific binding of the probe nucleic acid polymer to the sample nucleic acid polymers. However, a slight tolerance for mismatched base pair association is also preferable in a hybridization procedure for use in the present invention. This will account for minor allelic variations in the human genetic make-up and for small numbers of substitution mutations (a not uncommon occurrence in tumor cell genomes.) Thus, the conditions used in the hybridization procedure will preferably allow approximately one mismatched base pair association per 15-20 associated based pairs. Hybridization conditions and methods are well known in the art, and it is within the capabilities of one of ordinary skill in the art to adjust such methods to allow for the preferred level of stringency.

The term "conditions wherein the extent of hybridization may be quantified" means any accepted method for quantifying the amount of nucleic acid polymers derived from a sample tissue which associate specifically with the nucleic acid polymer probe used to measure the copy number of the gene of interest. Many methods have been disclosed in the art for making such a quantitative determination. They range from in situ fluorescence hybridization using fluorescently labeled nucleic acid polymer probes to visualize gene copy number on interphase chromosomes (such a system specific for the HER2 gene is offered by Vysis, Downers Grove, IL, USA), to electrically enhanced hybridization systems with fluorescently labeled probes (such as that described in U.S. Patent No. 6,017,696.) Preferred methods for use in the present invention are those which utilize arrays of nucleic acid probed in which different populations of nucleic acid probes are affixed to predetermined locations in the array. Such arrays allow for the hybridization of the sample nucleic acid polymers with several different probes specific for different genes at the same time.

The term "a normal cell of the same tissue type" means a non-cancerous, non-tumor cell of the same tissue type of the tumor's originating cells, or of the surrounding tissue from which the tissue sample is taken. For instance, a normal cell for comparison with a ovarian tumor tissue sample would be obtained from a healthy ovary.

The term "amplified" in the context of sample nucleic acid polymers means that the nucleic acid polymer is replicated in order to obtain a detectable amount of the nucleic acid polymer. Usually, such amplification is effected by self-replicating the nucleic acid polymer through the polymerase chain reaction. Methods of utilizing DNA and RNA polymerases to amplify sample nucleic acid polymers are well known to those of ordinary skill in the biological arts. When amplifying nucleic acids for use in the methods of the present invention, it is preferable that care be taken to normalize the data obtained from the amplified samples in order to obtain quantifiable results. Such a normalization may be achieved by subjecting a substantially similar amount of the reference nucleic acid polymers to the same or similar amplification procedure and obtaining hybridization data to compare to the hybridization data obtained with the amplified sample nucleic acid polymers.

The term "coding region" means a region of the gene which is translated into the amino acid sequence of the gene product, including signal peptides or portions of a pro-peptide which are cleaved from the gene product in order to form a mature protein. Generally, such regions are termed expressed sequences, or "exons." One of skill in the art will realize that several of the lipid-associated genes have splice variant isoforms, and that all exons are not necessarily expressed in all isoforms. Thus, in order to monitor all mRNA isoform transcripts of a particular expressed protein, the utilization of probes which hybridize to exons common to all or most isoforms may be desired.

The term "non-coding sequence functionally linked to the coding regions of the gene" means nucleic acid sequences which are normally not translated into the amino acid sequence of the gene product, but nevertheless form a part of the functional gene. Such sequences include introns, promoters, enhancers, and nucleic acid sequences which fill in between these elements of the gene and the coding regions of the gene.

The term "immobilized on a solid support" means that the nucleic acid polymer is bound, covalently or through an affinity reaction, to a relatively contiguous surface. The solid support may consist of any appropriate material for binding nucleic acids, including glass, silicas, hydrogels (such as agarose or polyacrylamide), polymers (such as polystyrene or polypropylene), and cellulose derivatives (such as nitrocellulose). The solid support may be in any convenient form for quantifying the amount of hybridization, including beads, resins, microtiter wells, flat surfaces, rods, and the like. For use in the arrays of the present invention, flat silicate surfaces, such as used in U.S. Patent No. 5,744,305, are preferred. Immobilization formats adapted to these

surfaces have been developed which can be easily loaded with the lipid associated gene probe sequences described in the invention, and which can be easily read with automated equipment.

The term "predetermined position" means that the location of immobilization on the solid support is known, and can be determined by reference to a detectable orientation point on or attached to the solid support. It is preferred that the surface of the solid support be divided into a grid-like arrangement of positions, in which a different population of nucleic acid polymers specific for a different gene resides at each position, or an "array". Although it is preferred that this array be arranged in a symmetrical and orderly fashion, such an arrangement is not necessary. The only requirement is that the position of the particular populations of nucleic acid polymers specific for each gene be identifiable. In this way, the hybridization of the sample nucleic polymers to a particular population of nucleic acid polymers in the array may be determined by the physical location of that hybridization, as visualized by fluorescence or detected by some other means.

The term "specific," as applied to nucleic acid polymers, means that the nucleic acid polymer probe contains a sequence substantially complementary to the lipid associated gene of interest, and not to other genes. Normally, a nucleic acid polymer will be specific for a gene if the probe sequence comprises at least about 19 contiguous nucleotides which are identical or complementary to 19 contiguous nucleotides of the lipid associated gene of interest. It is preferred that the nucleic acid polymer probe contain at least 1-5 additional contiguous identical or complementary nucleic acids: this will ensure hybridization under stringent conditions if a substitution mutation or allelic variation in the sample nucleic acid polymers is present. Those of ordinary skill in the art will recognize that the nucleic acid polymer probes may contain further nucleic acids in order to provide an anchor for immobilizing the nucleic acid polymer on a solid support or for attaching a detectable label to the nucleic acid polymer probe. In addition, entire or partial (about 100 to about 1000 bp section) cDNA sequences may be utilized as probes. Such probes may be easily made by amplifying the probe sequence from commercially available stably transfected prokaryotic or eukaryotic cells containing the cDNA sequence in plasmids, artificial chromosomes, or other vectors.

#### CHOICE OF LIPID-ASSOCIATED GENES FOR COPY NUMBER OR EXPRESSION LEVEL DETERMINATION

The first step in carrying out the methods of the invention is choosing which lipid-associated genes to monitor in the tissue samples. Genes associated with lipid metabolism, synthesis, or action suitable for monitoring in the present invention include genes whose proteins modify, oxidize, reduce, cleave, bind, or otherwise utilize bioactive lipids as substrates or ligands. Such bioactive lipids include sphingosine-1-phosphate (S1P), sphingophosphatidylcholine (SPC), sphingophosphatidylinositol (SPI), sphingophosphatidylserine (SPS), sphingophosphatidylglycerol (SPG), sphingophosphatidylethanolamine (SPE), lysophosphatidic acid (LPA), lysophosphatidylcholine (LPC), lysophosphatidylserine (LPS), lysophosphatidylinositol (LPI), lysophosphatidylethanolamine (LPE), and lysophosphatidyl glycerol (LPG), as well as metabolites of these lipids such as glycerol-3-phosphate (G3P). Several of the biological metabolic pathways involving these bioactive lipids and the enzymes involved are illustrated in Figures 2 and 3. A non-exhaustive list of genes associated with lipid metabolism, synthesis, or action suitable for monitoring in the present invention include those encoding Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidyltransferase 1 (choline specific, alpha form), Phosphate cytidyltransferase 2 (ethanolamine specific), Sphingosine kinase, Phosphatidic Acid Phosphatase type 2c, Human Lysophospholipase Homolog, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lysophospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Glycerol-3-phosphate Acyltransferase, Triacylglycerol lipase, Phosphatidylserine decarboxylase, CDP Diacylglycerol inositol-3-phosphatidyltransferase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7; and also include those encoding Sphingosine Kinase Type 2, MAP kinase1, LYPLA2, MAP kinase phosphatase like, LPA phosphatase, Phospholipid scramblase 4, Protein kinase B and Lipid activated protein kinase, IL6, IL8, ROCK1, uPA, tPA, gro1 VEGF and hbEGF. The copy number or expression level of at least two lipid-associated genes is monitored in the methods of the present invention. Most preferably, at least one of the genes monitored is chosen from the group

consisting of Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, EDG 1, Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.

In addition to genes which are directly associated with lipid metabolism and binding, one may wish to include in the array genes which are influenced by bioactive lipids or lipid metabolism products, most usually by indirect cell signaling events. Such genes whose expression levels may be influenced by the bioactive lipids directly or indirectly include ERK1, JNK1, Actin B, LH receptor, FSH receptor, LRP, SPARC, Ras inhibitor (RIN1), IGF binding protein 4, SERPINA8, TIMP1, PIP5K2B, Secretory leukocyte protease inhibitor, FLJ20258, Id4, GNA14, SYK, MAP2K4, G protein coupled receptor 39, SIR2, Prostate epithelium specific Ets transcription factor, Cathepsin D, GnRH receptor, Profilin, CA 125, CDKN1A, RAB13, FCGRT, RPS9, LATS1, JunD, FGFR4, p66shc, Id3, human polo like kinase, MDM2, Hras, CTNNB1, CDKN1B, AKT2, MGMT, Actin bundling protein, MMP7, MMP2, Mesothelin, MUC5AC, and MAS1. Thus, in alternative embodiments of the invention, one or more of these lipid-influenced genes are monitored for copy number or expression level in the cells of the sample. In preferred alternative embodiments, at least two, and more preferably at least five, of these genes are monitored in addition to the lipid-associated genes.

Usually, by monitoring the copy number or expression level of a particular gene one will be able to answer at most one question about the tumor characteristics of the tissue sample, such as "Is the cell metastatic?" or "Is the tumor at stage 2?". If more lipid associated genes are monitored, more information will be available to the clinician. Thus, although useful information concerning tumor characteristics may be gleaned by determining the copy number or expression level of as few as two lipid associated genes, it is preferred that more than two genes be so monitored in the methods of the invention. Preferably, a sufficient number of genes to fully characterize the tumor are monitored in the methods of the invention. Thus, complex profiles of increased and decreased lipid-associated gene copy number or expression level for all known lipid-associated genes may be established for various tumor stages and characteristics. However, simplified versions of the present method may be useful in some instances. For example, where a particularly strong correlation exists between metastasis and an increase in gene copy number or expression level, for instance in the Phosphatidylinositol-3-kinase (alpha polypeptide) and Phospholipase D1 (phosphatidylcholine specific) genes (See data in Table 2), a clinician may

choose to only assay the copy number of those particular genes in order to gather information about the metastatic potential of the cells. This situation could arise when a breast tumor biopsy specimen is being evaluated histologically, and an in-situ hybridization format for gene copy number counting is preferred. Even this limited amount of information can be very useful in assisting a physician in counseling a patient as to whether a breast-conserving lumpectomy or mastectomy is indicated.

As illustrated in Tables 2 and 3, several lipid-associated genes are present in altered copy numbers in significant numbers of ovarian cancer tumors. Percent loss and gain was determined by chromosomal genomic hybridization. These data indicate that the genes associated with lipid metabolism, synthesis, and action play an important role in tumor development and cancer progression. Altered numbers of these genes in tumor cells allow drastically increased (or decreased) production of these critical gene products, and thereby profoundly influence the morphology and physiology of the tumor cell.

As discussed previously, it is usually better to monitor several genes which have been correlated to the same tumor characteristic (metastatic, serous, mucinous, stage 3, etc.) at the same time. As indicated in the illustrative data collected in Tables 2 and 3, the correlation between the altered copy number or expression level of a particular gene and particular tumor characteristics is usually not 100%. Several alternative pathways exist for the synthesis and metabolism of bioactive lipid products, as is illustrated in Figures 2 and 3. Thus, loss of control over bioactive lipid synthesis at any one of a number of points can lead to particular tumor characteristics such as vascularization or the ability to grow detached from the tumor surface (a necessary condition for metastasis). Thus, several alternative profiles of differential gene expression may lead to the same phenotypic characteristic. Therefore, in order to more accurately determine the characteristics of the cells from a particular tumor sample in order to aid the clinician in his diagnosis and case management, it is preferable to monitor several lipid-associated genes simultaneously in order to gather "redundant" information about a particular tumor characteristic. Thus, methods employing at least three, four, five, six, seven, eight, nine, ten, fifteen, or twenty genes or 100 or more, including all integral values therein, are all more preferred embodiments of the method of the invention. A most preferable embodiment of the method would determine the copy number or expression level of at least ten lipid associated genes, as this will provide several pieces of information concerning the stage and metastatic potential of the cells in the tissue sample with redundant genes to verify that information.

As those of skill in the art will appreciate, it is ordinary to include positive and negative control genes within the monitored group in order to ensure that hybridization, amplification, or other assay conditions are suitable for the method. In addition, positive control genes are often useful to help quantify, at least in a relative manner, the amount of mRNAs for the various genes. Useful genes for positive and quantification controls in the methods and array constructs of the inventions include TMP21, CyclophilinB, alpha actin and glyceraldehyde 3-phosphate dehydrogenase. A suitable negative control is Chl a/b binding protein from *Arabidopsis*. Accession numbers for the cDNA sequences and commercial sources of these control sequences are listed in Table 4.

#### CONSTRUCTION OF NUCLEIC ACID POLYMER PROBES AND PRIMERS SPECIFIC FOR THE CHOSEN LIPID ASSOCIATED GENES

Once the lipid-associated genes to be monitored have been chosen, probes may be designed to assay the copy number or expression level of those genes in a tissue sample according to any number of conventional methods, including hybridization to immobilized arrays, dot-blot hybridizations, southern blot techniques, or even chromosomal counting through fluorescent in-situ hybridization. The choice of probe and probe production technique will depend on the method used.

For instance, solid-support based synthesis techniques are favored for the production of short probes for immobilization or to use as labeled in-situ hybridization probes. Techniques for synthesizing short oligonucleotides include conventional phosphotriester and phosphodiester methods or automated derivatives thereof. In one such automated method, diethylphosphoramidites are used as starting materials and may be synthesized as described by Beaucage, et al. (Tetrahedron Letters, 22:1-1862, 1981). Another method for synthesizing oligonucleotides on a modified solid support is described in U.S. Pat. No. 4,458,066. DNA solid support synthesis is a routine matter for one of skill in the biochemical arts, and several commercial services currently exist which will synthesize DNA sequences of up to 500 bp in length, and which may include fluorescent, biotin, or hapten labeled nucleotides (e.g., Genset of La Jolla, CA). Thus, once designed, labeled or unlabeled short DNA probes may simply be purchased from a vendor.

Shorter (under 500 bp) nucleic acid polymer probes specific for the lipid associated genes may be designed according to general principles familiar to those of ordinary skill in the

biochemical arts. Usually, it is preferable to use a probe containing at least 19 contiguous base pairs which are identical or complementary to 19 contiguous base pairs of the naturally occurring sequence in the lipid-associated gene. Thus, any portion of the sequences SEQ ID NO. 1-52 larger than 19 base pairs would be suitable for use as a lipid-associated gene probe in the present invention. This number of bases allows for hybridization under relatively stringent conditions, and also contains enough sequence information to ensure that the sequence is usually unique to that particular lipid-associated gene. Of course, one of ordinary skill in the art would understand that common enhancer sequences, polyadenylation sequences, and other sequences which tend to be repeated amongst several mammalian genes should not be used as probe sequences for the lipid-associated genes.

In order to ensure that the probe will hybridize to the lipid-associated gene DNA in the sample if some allelic variation or mutation difference exists between the probe sequence and the sample DNA sequence, it is more preferable that the probe sequence include at least 1-5 additional nucleotides which are identical or complementary to the nucleotide sequence of one of the lipid associated genes, or 20-24 contiguous nucleotides which are identical or complementary to the nucleotide sequence of one of the lipid associated genes. This will account for a small amount of mismatching during hybridization. Due to the prominent role of point mutations in oncogenesis, accounting for such slight variations is preferred in order to correctly assess the copy number or expression level of the lipid-associated genes to be assayed.

The maximum length of the probes to be used will be ascertainable by one of ordinary skill in the art based upon such considerations as the propensity for the formation of secondary structures in the probe DNA, the likelihood of interactions between probe strands in an immobilized matrix embodiment, and the difficulties in reproducing DNA of certain lengths through methods such as the polymerase chain reaction. Although full length gene sequences, including all introns, exons, regulatory sequences, and intervening DNA, may be used as lipid-associated gene probes, such sequences are often several dozen kilobases in length. Sequences of this length have a propensity to form secondary structures and are difficult to replicate by polymerase chain reaction techniques (which is often a necessary step in the production of longer sequence probes). Thus, probe sequences shorter than the full length gene are preferred as lipid-associated gene probes. Suitable longer probes would include whole exons, or multiple exons as found in a cDNA sequence. One of ordinary skill in the art would be able to choose a suitable



long portion of any of SEQ ID NO. 1-52 for use as a long lipid-associated gene probe. Such probes are produced in Example 1.

In order to produce a DNA probe sequence longer than about 250 bp, it is preferable to amplify and clone the sequence from a cDNA or genomic library according to methods familiar to those of ordinary skill in the molecular biology arts. Briefly, one synthesizes short (~20-25 nucleotide) forward and reverse polynucleotide primers which flank the portion of the lipid-associated gene's sequence to be cloned. Then, one amplifies the sequence from a cDNA library or genomic DNA utilizing the polymerase chain reaction technique, as described below for amplification of sample nucleic acids. Once a sufficient amount of amplified DNA sequence has been produced, it may be ligated into a suitable plasmid vector, and replicated/maintained in a bacterial host. The DNA sequence may then be cut out of the plasmid with suitable restriction enzymes and either labeled or immobilized for use as a lipid-associated gene probe. Alternatively, cDNA sequences for use as probes may be purchased as stably transfected clones containing cDNA inserts in vectors (e.g., plasmids) from commercial sources such as Research Genetics, Incyte Genomics, Stratagene and Clontech.

Probes which are to be immobilized in an array are not labeled for detection. Rather, they are covalently linked to a predetermined position in the array, and thus identifiable by location. In these embodiments, the sample DNA to be hybridized with the array is usually labeled utilizing labeled primers during PCR amplification, or by other techniques known in the art. If the probe is to be hybridized to immobilized sample DNA (as in, for example, dot-blot hybridization, the reporter probe in a sandwich hybridization, or in-situ hybridization), then the probe itself is labeled for detection.

### Labeling

The particular label or detectable group attached to the probe or primer nucleic acids is not a critical aspect of the invention, so long as it does not significantly interfere with the hybridization of the probe to the lipid-associated gene sequence in the sample DNA. The detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of nucleic acid hybridizations and in general most any label useful in such methods can be applied to the present invention. Thus a label is any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels in the present invention

include fluorescent dyes (e.g., Cy3, Cy5, fluorescein isothiocyanate, Texas red, rhodamine, and the like) radionuclide labels (e.g.,  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^{32}\text{P}$ ), and enzymes (e.g., horse radish peroxidase, alkaline phosphatase and others commonly used in an ELISA).

The nucleic acids can be indirectly labeled using ligands for which detectable anti-ligands are available. For example, biotinylated nucleic acids can be detected using labeled avidin or streptavidin according to techniques well known in the art. In addition, antigenic or haptenic molecules can be detected using labeled antisera or monoclonal antibodies. For example, N-acetoxy-N-2-acetylaminofluorene-labelled or digoxigenin-labelled probes can be detected using antibodies specifically immunoreactive with these compounds (e.g., FITC-labeled sheep anti-digoxigenin antibody (Boehringer Mannheim)). In addition, labeled antibodies to thymidine-thymidine dimers can be used (Nakane et al. ACTA Histochem. Cytochem. 20:229 (1987)).

Generally, labels which are detectable in as low a copy number as possible, thereby maximizing the sensitivity of the assay are preferred. A label is preferably chosen that provides a localized signal, thereby providing spatial resolution of the signal from each probe. The labels may be coupled to the DNA in a variety of means known to those of skill in the art. In a preferred embodiment the probe or sample DNA will be labeled using nick translation or random primer extension (Rigby, et al. J. Mol. Biol., 113:237 (1977) or Sambrook, et al., Molecular Cloning--A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1985)).

#### CONSTRUCTION OF IMMOBILIZED NUCLEIC ACID POLYMER PROBE ARRAYS

In preferred embodiments of the invention, nucleic acid polymer probes specific for the chosen lipid-associated genes are immobilized on a solid surface in order to create an array of lipid-associated-gene probes. As discussed above, the solid surface may be in any desirable shape which facilitates the hybridization reaction and the detection of hybridized sample nucleic acids. The solid support may be in any convenient form for quantifying the amount of hybridization, including beads, resins, microtiter wells, flat surfaces, rods, and the like. Illustrative solid materials for use in the support include nitrocellulose, nylon, glass, diazotized membranes (paper or nylon), silicones, polyformaldehyde, cellulose, and cellulose acetate. In addition, plastics such as polyethylene, polypropylene, polystyrene, and the like can be used. Other materials which may be employed include paper, ceramics, metals, metalloids, semiconductive materials, cements or the like. In addition substances that form gels can be used. Such materials include proteins (e.g., gelatins), lipopolysaccharides, silicates, agarose and polyacrylamides. Where the solid

surface is porous, various pore sizes may be employed depending upon the nature of the system. For use in the arrays of the present invention, flat coated or uncoated silicate surfaces are preferred. Immobilization formats adapted to these surfaces have been developed which can be easily loaded with the lipid associated gene sequences described in the invention, and which can be easily read with automated equipment.

In preparing the solid support for binding the nucleic acid polymer probes to it, several different materials may be employed, particularly as laminates, to obtain various properties. For example, proteins (e.g., bovine serum albumin) or mixtures of macromolecules (e.g., Denhard's solution) can be employed to avoid non-specific binding, simplify covalent conjugation, enhance signal detection or the like. If covalent bonding between the probe and support is desired, the surface will usually be polyfunctional or be capable of being polyfunctionalized. Functional groups which may be present on the surface and used for linking can include carboxylic acids, aldehydes, amino groups, cyano groups, ethylenic groups, hydroxyl groups, mercapto groups and the like. The manner of linking a wide variety of compounds to various supports is well known and is amply illustrated in the literature. For example, methods for immobilizing nucleic acids by introduction of various functional groups to the molecules is known (see, e.g., Bischoff et al., *Anal. Biochem.* 164:336-344 (1987); Kremsky et al., *Nuc. Acids Res.* 15:2891-2910 (1987)). In order to introduce these functional groups, modified nucleotides (such as biotin, halogen, or azo-derivatized nucleotides) can be placed on the nucleic acid probe using PCR primers containing the modified nucleotide, or by enzymatic end labeling with modified nucleotides.

Use of membrane supports (e.g., nitrocellulose, nylon, polypropylene) for the nucleic acid arrays of the invention is advantageous because of well developed technology employing manual and robotic methods of arraying nucleic acid probes at relatively high element densities (e.g., up to 30-40/cm<sup>2</sup>) while maintaining each probe population as a distinct element. In addition, such membranes are generally available and protocols and equipment for hybridization to membranes is well known. Many membrane materials, however, have considerable fluorescence emission, where fluorescent labels are used to detect hybridization. To optimize a given assay format one of skill can determine sensitivity of fluorescence detection for different combinations of membrane type, fluorochrome, excitation and emission bands, spot size and the like. In addition, low fluorescence background membranes have been described (see, e.g., Chu et al., *Electrophoresis* 13:105-114 (1992)).

Arrays on substrates with much lower fluorescence than membranes, such as glass, quartz, or silicon, can achieve much better sensitivity. For example, elements of various sizes, ranging from the ~1 mm diameter down to ~1  $\mu\text{m}$  can be used with these materials. Small array members containing small amounts of concentrated target DNA are conveniently used for the methods of the invention since the total amount of sample DNA available for binding to each probe will be limited. Thus it is advantageous to have small array members that contain a small amount of concentrated probe DNA so that the signal that is obtained is highly localized and bright. Such small array members are typically used in arrays with densities greater than  $10^4/\text{cm}^2$ . Relatively simple approaches capable of quantitative fluorescent imaging of  $1\text{ cm}^2$  areas have been described that permit acquisition of data from a large number of members in a single image (see, e.g., Wittrup et. al. *Cytometry* 16:206-213 (1994)).

Covalent attachment of the target nucleic acids to glass or synthetic fused silica can be accomplished according to a number of known techniques. Such substrates provide a very low fluorescence substrate, and a highly efficient hybridization environment. There are many possible approaches to coupling nucleic acids to glass that employ commercially available reagents. For instance, materials for preparation of silanized glass with a number of functional groups are commercially available or can be prepared using standard techniques. Alternatively, quartz cover slips, which have at least 10-fold lower auto fluorescence than glass, can be silanized. Recently, several refined techniques have been developed to array nucleic acid polymers on silicon or coated silicon surfaces, such as those disclosed in U.S. Patent Nos. 5,143,854 and 6,017,696. These methods, which utilize photomasking or electrostatic techniques to couple nucleic acid polymers at specific sites on the support, are able to achieve high concentrations of each nucleic acid polymer probe at specific locations on the silicon support. These techniques are preferred for creating the arrays of the present invention, as the resulting arrays can be readily utilized in automated hybridization and fluorescence detection equipment.

The nucleic acid probes can also be immobilized on commercially available coated beads or other supports. For instance, biotin end-labeled nucleic acids can be bound to commercially available avidin-coated beads or a layer of avidin-permeated hydrogel. Streptavidin or anti-digoxigenin antibody can also be attached to silanized glass slides by protein-mediated coupling using e.g., protein A following standard protocols (see, e.g., Smith et al. *Science*, 258:1122-1126 (1992)). Biotin or digoxigenin end-labeled nucleic acids can be prepared according to standard techniques.

Any of these techniques can be utilized by the person of ordinary skill in the art to create an array of probes specific for lipid-associated genes for use in the present invention. An illustrative array, utilizing probes generated from the cDNA sequences of several lipid-associated genes, is constructed on a silanized glass slide in Example 1.

## TISSUE SAMPLE PREPARATION AND NUCLEIC ACID ISOLATION

In order to carry out the method of identifying tumor characteristics of the present invention, it is necessary to obtain a tissue sample from the patient. Several standard techniques for biopsy of tissue samples are well known in the prior art. Preferably, the tissue samples are obtained by endoscopic biopsy, or by a biopsy needle gun. When obtaining a tissue sample from a solid tumor in the patient, care should be taken not to allow portions of the tumor to escape from the tumor body into the other tissues of the patient.

The tissue which is isolated can be used directly, frozen, or it can be embedded in, for example, paraffin and stored for future use. Preferably, the tissue is frozen and stored at temperatures of -20° to about -80° C. The term "embedded" refers to a sample that has been infiltrated with a material to provide mechanical support and thereby reduce sample deformation during processes such as sectioning (preparing thin slices for viewing using a microscope). Embedding materials include waxes, such as paraffin wax, epoxies, gelatin, methacrylate, nitrocellulose, various polymers and the like. The term "non-embedded" refers to a sample that is not embedded, and was not previously embedded. When a tissue sample is embedded in, for example, paraffin, for future use, it will preferably be in sections of about 6 micron thickness. Upon removal from storage, the paraffin-embedded tissue sections will be deparaffinized using a relatively non-polar aprotic organic solvent such as xylene, and then rehydrated using graded alcohols followed by phosphate-buffered saline (PBS). Other suitable solvents for removing the embedding support include aliphatic or aromatic hydrocarbon solvents such as toluene, heptanes, octanes, benzene, acetone and acetonitrile. If a technique such as in situ fluorescent hybridization is used to determine the copy number of the lipid-associated genes, then the preparation of the embedded tissue sample should be carried out according to methods known in the art which maintain the fixed position of the sample nucleic acids in the cell.

If the tissue sample is to be analyzed by an array hybridization technique, or another technique which requires purified isolated nucleic acids, the cells of the tissue sample may be treated to liberate and isolate their nucleic acid polymers. For lysing, chemical lysing will

conveniently be employed utilizing detergents or cell membrane degrading enzymes. Several methods of isolating nucleic acids from lysed cells are well known in the art, such phenol extraction followed by ethanol or polyethylene glycol precipitation, or the ketone method disclosed in U.S. Patent No. 5,063,162. Several kits are commercially available to perform genomic DNA or RNA extractions on tissue samples.

Often, the hybridization data obtained from the sample nucleic acid polymers will be compared to that of reference nucleic acid polymers obtained from normal tissues of the same type as the tissue sample. In order to facilitate accurate comparison, the normal tissue sample should be obtained in a similar method as the tissue sample to be tested, and the reference nucleic acids should be isolated from the normal tissue sample in the same manner as the nucleic acids from the patient's sample are isolated. Practitioners of ordinary skill in the art are capable of devising such "controls" for a quantitative comparison based on the specific nucleic acid isolation and hybridization methods which are to be used in any particular embodiment of the method of the invention.

#### Amplification of Sample Nucleic Acid Polymers

In practicing the methods of the present invention, it is often preferable to amplify the sample nucleic acid polymer sequence before hybridization in order to increase the hybridization signal. The tissue samples obtained from biopsy are often very small in size, and contain a limited amount of sample nucleic acids for detection. In addition to increasing the amount of DNA or RNA available to produce a hybridization signal, amplification reactions may be used to label the sample nucleic acids by utilizing radiolabeled, biotinylated, or fluorescent-moiety substituted nucleic acids or primers. Amplification of the sample nucleic acid polymers can be accomplished using oligonucleotide primers for amplification specifically designed for the lipid-associated gene to be assayed, or random primers such as hexanucleotide primer mixtures.

Gene-specific oligonucleotide primers may be based upon identification of the flanking regions contiguous with the nucleotide sequence of the lipid-associated genes chosen for copy number or expression level determination. In this manner, it is possible to selectively amplify the specific target nucleic acid sequence containing the nucleic acid of interest. For example, the flanking sequence of the primer may be before the gene in a normal genome, a complementary sequence (opposite strand) after the gene in the normal genome, or within the gene itself. The only requirement of the primer is that it hybridize at a position that will ensure that the portion of

the gene for which the nucleic acid probe has been designed will be amplified. As most amplification reactions do not produce nucleic acid products of more than a few hundred base pairs, it is preferred that the primer hybridize about 10 - 100 bases before the probe hybridization site. One of ordinary skill in the art would be capable of designing an appropriate primer for the amplification of any lipid-associated gene monitored, given the information supplied in SEQ ID NO. 1 - 52, and other available genetic information concerning lipid-associated genes. As an alternative to specifically designed gene-specific primers, a hexamer mixture (or other suitable random primer mixture) may be used to randomly prime the sample nucleic acids in order to amplify all sequences in the sample.

Experimental conditions conducive to synthesis include the presence of nucleoside triphosphates and an agent for polymerization, such as DNA polymerase, and a suitable temperature and pH. Preferably the reaction mixture will contain labeled nucleotides which can be used to detect the amplified sample nucleic acid polymers when bound to nucleic acid probes in an array. Any of the nucleotide derivatives described in the probe construction section above are suitable for use in the amplification reaction. The use of fluorescent derivatives of nucleic acids to label the sample nucleic acid polymers is particularly preferred in the embodiments of the method of the invention. The primer is preferably single stranded for maximum efficiency in amplification, but may be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent for polymerization. The exact length of primer will depend on many factors, including temperature, buffer, and nucleotide composition.

Typically, the amplification process is started by annealing two primers to the sample nucleic acid polymers: one primer is complementary to the negative (-) strand of the nucleotide sequence and the other is complementary to the positive (+) strand. Annealing the primers to denatured nucleic acid followed by extension with an enzyme, such as the large fragment of DNA Polymerase I (Klenow) or Taq DNA polymerase (or an RNA reverse-transcriptase, if the mRNA of a sample is to be amplified) and nucleotides or ligases, results in newly synthesized + and - strands containing the target nucleic acid. Because these newly synthesized nucleic acids are also templates, repeated cycles of denaturing, primer annealing, and extension results in exponential production of the region (i.e., the target mutant nucleotide sequence) defined by the primer. The product of the amplification reaction is a discrete nucleic acid duplex with termini corresponding to the ends of the specific primers employed. Those of skill in the art will know of

other amplification methodologies which can also be utilized to increase the amount of the sample nucleic acid polymers and label them for later detection. One method of amplification which can be used according to this invention is the polymerase chain reaction (PCR) described in U.S. Pat. Nos. 4,683,202 and 4,683,195.

## HYBRIDIZATION TECHNIQUES

The particular hybridization technique used will depend on the particular embodiment of the method of the invention. For instance, if the copy number of the lipid-associated genes is to be determined using in-situ gene counting techniques, then hybridization of labeled probes with fixed sample tissues on a slide would be performed according to techniques known in the art. Preferably, the copy number or expression level of the lipid-associated gene sequences in the sample nucleic acids is determined by hybridizing the labeled sample nucleic acids to an array of lipid-associated gene specific probes. The hybridization signal intensity produced by the labeled sample nucleic acids on each lipid-associated gene probe site is determined. Typically, the greater the signal intensity at a particular lipid-associated gene probe site, the greater the copy number or expression level of the lipid-associated gene sequence in the sample nucleic acid. Thus, a determination of the signal intensity at each probe site, as compared to a normal tissue standard, allows a determination of the copy number or expression level of the lipid-associated gene.

Standard hybridization techniques are used to probe the lipid-associated gene probe array. Suitable methods are described in references describing CGH techniques (Kallioniemi et al., *Science* 258:818-821 (1992) and WO 93/18186). Several guides to general techniques are available, e.g., Tijssen, *Hybridization with Nucleic Acid Probes*, Parts I and II (Elsevier, Amsterdam 1993). For a descriptions of techniques suitable for in situ hybridizations see, Gall et al. *Meth. Enzymol.*, 21:470-480 (1981) and Angerer et al. in *Genetic Engineering: Principles and Methods* Setlow and Hollaender, Eds. Vol 7, pgs 43-65 (plenum Press, New York 1985). In addition, several refinements of hybridization techniques relevant to microarray hybridization analysis are discussed in Khan, et al., "Expression Profiling in Cancer Using cDNA Microarrays," *Electrophoresis*, 20:223-229 (1999); and Cheung, et al., "Making and Reading Microarrays," *Nature Genetics Supp.*, 21: 15-19 (1999).

Generally, nucleic acid hybridizations comprise the following major steps: (1) immobilization of the probe nucleic acids; (2) prehybridization treatment to increase accessibility



of the immobilized DNA, and to reduce nonspecific binding; (3) hybridization of the sample nucleic acids to the probe nucleic acid on the solid support; (4) posthybridization washes to remove sample nucleic acid fragments not bound in the hybridization and (5) detection of the hybridized sample nucleic acid fragments. The reagents used in each of these steps and their conditions for use vary depending on the particular embodiment of the method of the present invention.

Pre-hybridization may be accomplished by incubating the microarray with the hybridization solution at room temperature or at a mildly elevated temperature for a sufficient time to thoroughly wet the array. Usually, incubation at about 35° to 42° C for about 15 minutes to an hour is sufficient to pre-hybridize a microarray on a glass slide.

Various hybridization solutions may be employed, comprising from about 20% to 60% volume, preferably 30%, of an inert polar organic solvent. A common hybridization solution employs about 50% formamide, about 0.5 to 1M sodium chloride, about 0.05 to 0.1M sodium citrate, about 0.05 to 0.2% sodium dodecylsulfate, and minor amounts of Denhardt's solution (EDTA, ficoll (about 300-500 kD), polyvinylpyrrolidone, (about 250-500 kD) and serum albumin.) Optionally, one may include other blocking agents in the hybridization solution, such as about 0.5 to 5 mg/ml of sonicated denatured DNA, e.g., calf thymus or salmon sperm; and optionally from about 0.5 to 2% wt/vol glycine. Other additives may also be included, such as dextran sulfate of from about 100 to 1,000 kD and in an amount of from about 8 to 15 weight percent of the hybridization solution, or a similarly sized polyethylene glycol.

Various degrees of stringency of hybridization may be employed in the methods of the invention. The more severe the conditions, the greater the complementarity that is required for hybridization between the sample nucleic acids and the lipid-associated gene specific probe for duplex formation. Severity can be controlled by temperature, probe concentration, probe length, ionic strength, time, and the like. Conveniently, the stringency of hybridization is varied by changing the polarity of the reactant solution by manipulating the concentration of formamide in the range of 20% to 50%. Temperatures employed will normally be in the range of about 20.degree. C. to 80.degree. C., usually 30.degree. C. to 75.degree. C. (see, generally, Current Protocols in Molecular Biology, Ausubel, ed., Wiley & Sons, 1989).

After the array has been contacted with a hybridization solution at a moderate temperature for a period of time sufficient to allow hybridization to occur (usually 8-24 hours), the filter is then introduced into a second solution having similar concentrations of sodium

chloride, sodium citrate and sodium dodecylsulfate as provided in the hybridization solution. The time the filter is maintained in the second solution may vary from five minutes to three hours or more. The second solution determines the stringency, dissolving cross duplexes and short complementary sequences. After rinsing the filter at room temperature with dilute sodium citrate-sodium chloride solution, the filter may now be assayed for the presence of hybridized sample nucleic acids according to the nature of the label.

#### ANALYSIS OF DETECTABLE SIGNALS FROM HYBRIDIZATION OF THE SAMPLE NUCLEIC ACIDS WITH THE LIPID-ASSOCIATED GENE PROBES

Standard methods for detection and analysis of signals generated by the hybridization of the sample nucleic acids to the lipid-associated gene specific probes can be used. The particular methods will depend upon the labels used, and the particular embodiment of the method. Generally, fluorescent labels are preferred. Thus, methods suitable in fluorescence in situ hybridization (FISH) are suitable in the present invention. The nucleic acid arrays are imaged in a fluorescence microscope with a polychromatic beam-splitter to avoid color-dependent image shifts. The different color images are acquired with a CCD camera and the digitized images are stored in a computer.

If the preferred microarray embodiments are utilized, such fluorescence data is conveniently gathered with an automated array scanner, such as the Affymetrix 418 Array scanner with epi-fluorescent confocal optics. A computer program is then used to analyze the signals produced by the array in order to determine the hybridization intensity at each lipid-associated gene probe site in the array. This data may then be compared with a standard curve generated from various amounts of DNA or mRNA obtained from normal tissue. This analysis technique is illustrated in Example 2.

The present invention is further described in the following examples. These examples do not, in any way, limit the scope of the claims of the present invention.

#### EXAMPLES

The following examples illustrate the preparation of the arrays of lipid-associated genes of the invention for use in the methods of the invention for determining tumor characteristics. The molecular biological techniques utilized in these examples are well-known to those of

ordinary skill in the biochemical arts, and could be modified in myriad ways to accomplish the same ends. Thus, the techniques and processes described below serve merely to illustrate an embodiment of the present invention, and should not be interpreted to limit the invention to any particular embodiment. Unless otherwise noted, all kits, reagents, and equipment were used in accordance with the protocols supplied by the producer. More detailed protocols for the techniques described in brief below may be found in a standard molecular biology reference text, such as Maniatis.

#### Example 1: Preparation of a Lipid-Associated Gene Probe Array

In this example, the preparation of a hybridization microarray of 100 probes for lipid-associated genes on a standard glass slide is prepared for use in the methods of the invention.

##### 1.1 Preparation of DNA probes for use in the Microarray

One option for the production of an array is to create clones comprising the cDNA sequences of the genes is to produce clones containing the cDNA sequences from a cDNA library. For each probe to be used in the array, an appropriate pair of unlabeled forward and reverse PCR primers, synthesized utilizing solid-support methods, may be ordered from Genset (La Jolla, CA). Using these primers, DNA for each probe is amplified by PCR from a human genomic or cDNA library (e.g., available from Invitrogen, Carlsbad, CA, Stratagene, La Jolla, CA, or Promega, Madison, WI) with *Taq* polymerase (obtained from Promega, Madison, WI) according to supplier's instructions. PCR is carried out in an Eppendorf Scientific Instruments Mastercycler™ thermal cycler for the recommended number of cycles. After PCR, the amplified DNA (which contains single adenine overhangs) is self-ligated into the AccepTor™ plasmid (Novagen, Madison, WI) and transformed into NovaBlue *E. coli* competent cells (Novagen).

Transformed cells are plated onto LB blue/white selection media and grown overnight. White colonies (which contain the amplified DNA insert) are picked, and grown overnight for freezer stocks. After verification of the DNA insert, a 1 liter culture of a clone containing the insert is prepared for each probe, and plasmid DNA is purified from the culture using a Wizard® Plus Megaprep DNA Purification System (Promega). The plasmid DNA is then digested with *EcoR* I (Promega), and the insert-probe DNA separated from the AccepTor™ plasmid DNA by agarose gel electrophoresis. Probe size in the agarose gel is double checked against DNA size standards to ensure that no cleavage with the restriction enzyme occurs. The probe DNA is then purified from the agarose gel slices and resuspended in 2 X SSC (Saline Sodium Citrate) buffer

at a concentration of about 1  $\mu\text{g}/\mu\text{l}$  for aminosilane linkage to the glass slide substrate of the array.

As an alternative method, cDNA-containing clones corresponding to particular genes may be purchased from a commercial source, as listed in Table 4. The cDNA sequence may be directly isolated from a sufficient number of insert-containing plasmids, as described above, or amplified from the insert-containing plasmids. This option was utilized by applicants to produce a glass-slide type nucleic acid array. The cDNA clones corresponding to particular genes (as listed in Table 4) were purchased from Research Genetics, Clontech, Stratagene, and Incyte. After confirming the identity of each clone by restriction enzyme digestion, and/or sequencing, the cDNA was amplified with a combination of two standard primers (taking advantage of primer sites flanking the cDNA on the commercial vectors.) The amplified cDNA was then gel purified as above, and resuspended in water for spotting onto the derivatized glass slide for the array.

## 1.2 Production of the Microarray

The probes are affixed to a glass slide using the aminosilane linkage chemistry described in Cheung, et al., "Making and Reading Microarrays," Nature Genetics Supp., 21:15-19 (1999). The probes may be arrayed in any pattern, such as a 10 by 10 square, on a CMT-GAPS™ aminosilane coated slide (Corning, Acton, MA). An asymmetrical pattern design may be preferred, as such designs facilitate orientation of the array and the subsequent rapid identification of each spot in the array. Approximately 10 ng of each probe DNA is deposited in spots approximately 125  $\mu\text{m}$  in diameter and about 300  $\mu\text{m}$  apart (from center to center). Probes are arrayed using an Affymetrix 417 Arrayer (Affymetrix, Santa Clara, CA) according to manufacturer's instructions.

The arrayed probes are allowed to air-dry on the slide at room temperature. The slides are then briefly moistened in hot water vapor before crosslinking the DNA to the silane surface with about 0.30  $\text{J}/\text{cm}^2$  of ultraviolet (254 nm) radiation. After crosslinking, the slides are briefly washed in 0.1% SDS to remove unbound DNA. The probes are then denatured in 95°C water for approximately three minutes.

The resulting microarray of lipid-associated gene probes is then ready for use in sample testing.

Example 2: Determination of Lipid-Associated Gene Copy Number in a  
Sample Utilizing the Lipid Associated Gene Probe Array

In this example, the copy number of several lipid-associated genes is determined simultaneously by hybridization to the probe array produced in Example 1.

2.1 Preparation of sample DNA

Genomic DNA is extracted from approximately 300 mg of sample tissue using a Wizard<sup>®</sup> Genomic DNA Purification Kit (Promega). The extracted DNA is further purified to remove any contaminating RNA and protein using standard procedures involving sequential digestion with proteinase K, RNase (DNase free), phenol- chloroform extractions, and ethanol precipitation. In order to optimize the sensitivity and specificity of the assay, the complexity of the isolated genomic DNA may be reduced by digesting the DNA with restriction enzymes. These restriction enzymes are ideally 4-base cutters. Following digestion of and subsequent clean up, the DNA is labeled with fluorescent dyes, radiolabels, or enzymes with either random priming, nick translation, or end labeling techniques.

After purification, the concentration of sample DNA is determined using spectrophotometric techniques. 40 µg of sample is then amplified by PCR with a mixture of fluorescein labeled random hexamer primers using *Taq* polymerase (obtained from Promega) according to supplier's instructions. PCR is carried out in an Eppendorf Scientific Instruments Mastercycler<sup>™</sup> thermal cycler for the recommended number of cycles. After PCR, the amplified sample DNA is separated from the labeled primers with a Wizard<sup>™</sup> PCR Preps DNA Purification System (Promega). Purified sample DNA is then resuspended in 15 µl of hybridization solution (50% formamide, 6 X SSC, 0.5% SDS, 5 X Denhard's reagent).

2.2 Hybridization of Sample DNA to the Array

The microarray is pre-hybridized with hybridization solution for about 30 minutes. The sample DNAs are denatured for about 4 minutes at 80° C in a hybridization oven. The amplified sample DNA in the hybridization solution is then applied to the microarray in a Corning CMT<sup>™</sup> Hybridization Chamber, and then allowed to anneal at 42° C for about 20 hours. After hybridization has been completed, the array slide is washed for five minutes in 0.1% SDS / 0.2 X SSC, and then for about five minutes with 0.2 X SSC. The array is then loaded into and

Affymetrix 418 Scanner (Affymetrix), and fluorescence of the hybridized sample DNA on the microarray is detected.

### 2.3 Data Analysis and Determination of Lipid Associated Gene Copy Number

A standard curve is generated for each probe site in the array utilizing the above procedure with 20 $\mu$ g (haploid), 40 $\mu$ g (normal), 80 $\mu$ g (tetraploid), 160 $\mu$ g (octaploid), and 320 $\mu$ g (hexadecaploid) of genomic DNA purified from normal tissue. By comparison of detected fluorescent intensity from the hybridization of the sample DNA at each probe site with the standard curve for that probe site, the relative copy number of the lipid-associated genes in the cells of the tissue sample is calculated.

#### Example 3: Demonstration of the Correlation Between Lipid-Associated Gene Copy Number and Tumor Characteristics

The correlation between lipid-associated gene copy number and certain tumor characteristics is demonstrated by determining the copy number of lipid-associated genes according to the method described in Example 2, utilizing a lipid-associated gene probe array produced as described in Example 1.

Tumor tissue samples from stage 1, 2, 3, and 4 tumors are assayed, as well as those characterized as "serous," "mucinous," "endometrioid," "low stage," and "high stage." Tumors from various types of cancers, including ovarian, breast, cervical, and uterine are analyzed, while normal tissues of each type provide a control and a standard curve. This analysis demonstrates that specific tumor stages and characteristics correlate to increases or decreases in the copy number of certain lipid-associated genes.

**TABLE 2**  
**Enzymes Involved with Lipid Metabolism**  
**Chromosome Location With Associated Ovarian Tumor Stage and Clinical Outcome**

Enzyme	% loss	% gain	Associated Tumor Stage	Associated Clinical Outcome
Phosphatidylinositol-3-Kinase, catalytic, alpha polypeptide	0	50	Low and High Stage	Reduced Survival Duration
Phospholipase D1 phosphatidylcholine specific	0	40	Low and High Stage	Reduced Survival Duration
Sphingosine kinase	-5	20	Low and High Stage	
Aldehyde dehydrogenase 5 family, member A1	-5	15	Borderline tumors	
Phospholipase D1 glycosylphosphatidylinositol specific	-5	15	Borderline tumors	
1-acylglycerol-3-phosphate acyltransferase	-5	15	Borderline tumors	
Sphingosine-1-phosphate lyase 1	0	5	Low Stage - Endometroid	
Phosphatase and tenson homolog (PTEN)	-2.5	5	Low Stage - Endometroid	
Phosphatidic Acid Phosphate type 2a	-2.5	2.5	Borderline tumors	
Sphingomyelin phosphodiesterase 1 (acid sphingomyelinase)	-5	0	High Stage - nonmucinous	Reduced Survival Duration

**TABLE 3**  
**Enzymes Involved with Lipid Metabolism**  
**Chromosomal Locations and Associated Genome Copy Number Changes in**  
**Ovarian Tumors**

Enzyme	% loss	% gain
Phosphatidylinositol-3-Kinase, catalytic, alpha polypeptide	0	50
Phosphate cytidylyltransferase 1, choline, alpha isoform	0	50
Phospholipase D1 phosphatidylcholine specific	0	40
dihydroxyacetone phosphate acyltransferase	0	22.5
Phosphate cytidylyltransferase 2, ethanolamine	-2.5	20
Sphingosine kinase	-5	20
Phosphatidic Acid Phosphate type 2c	0	20
Prostate differentiation factor PLAB (associated with Edg 3)	0	20
Phospholipase A2	-2.5	17.5
Phospholipase C, beta 3 (phosphatidylinositol specific)	-5	17.5
Phosphatidylinositol-3-Kinase, class 2, gamma polypeptide	0	17.5
Choline/ethanolamine phosphotransferase	-2.5	15
Lysophospholipase	0	15
Aldehyde dehydrogenase 5 family, member A1	-5	15
Phospholipase D1 glycosylphosphatidylinositol specific	-5	15
1-acylglycerol-3-phosphate acyltransferase	-5	15
Phosphatidic Acid Phosphate type 2b	-2.5	7.5
EDG 1	-2.5	7.5
Glycerol-3-phosphate dehydrogenase	0	5
Sphingosine-1-phosphate lyase 1	0	5
Phosphatase and tenson homolog (PTEN)	-2.5	5
Phosphatidic Acid Phosphate type 2a	-2.5	2.5
Sphingomyelin phosphodiesterase 1 (acid sphingomyelinase)	-5	0
N-acylsphingosine amidohydrolase (acid ceramidase)	-15	2.5
EDG 2	-17.5	0



**TABLE 4: GEN-BANK ACCESSION NUMBERS AND COMMERCIAL SOURCES**

GENE	Chromosome	GenBank Acc. No.	UniGene database	Source*
1. Phosphatidylinositol-3-Kinase, catalytic, alpha polypeptide [SEQ ID NO. 23]	3q26.3	Z29090	Hs.85701	RG
2. Phospholipase D1 phosphatidylcholine specific [SEQ ID NO. 18]	3q26	NM_002662	Hs. 82587	IN
3. Sphingosine Kinase (also named as SphK1) [SEQ ID NO. 32]	17q25.2	AF200328	Hs.68061	IN
4. Sphingosine Kinase type 2 [SEQ ID NO. 33]	19q13.2	AF245447	Hs.283562	ST
5. Aldehyde dehydrogenase 5 family, member A1 [SEQ ID NO. 2]	6p22	NM_001080	Hs. 5299	IN
6. Phospholipase D1 Glycosylphosphatidylinositol specific [SEQ ID NO. 19]	6p22.3-6p22.2	NM_001503	Hs.272529	IN
7. 1-acylglycerol-3-phosphate O acyltransferase [SEQ ID NO. 1]	6p21.3	Y09565	Hs.240534	RG
8. Sphingosine-1-phosphate lyase 1 [SEQ ID NO. 29]	10q21	AF144638	Hs.186613	ST
9. Phosphatase and tenson homolog (PTEN) [SEQ ID NO. 28]	10q23.3	NM_000314	Hs.10712	IN
10. Phosphatidic Acid Phosphate type 2a [SEQ ID NO. 21]	5	AF017116		RG
11. Sphingomyelin phosphodiesterase 1 (acid sphingomyelinase) [SEQ ID NO. 30]	11p15.4-p15.1	M59916	Hs.77813	IN
12. Phosphate cytidyltransferase 1, choline, alpha isoform [SEQ ID NO. 26]	3q	L28957	Hs.273558	IN
13. dihydroxyacetone phosphate acyltransferase [SEQ ID NO. 5]	1q42.11-42.3	AJ002190	Hs.12482	IN
14. Phosphate cytidyltransferase 2, ethanolamine specific [SEQ ID NO. 27]	17	D84307	Hs.226377	IN
15. Phosphatidic Acid Phosphatase type 2c [SEQ ID NO. 25]	19p13	NM_003712	Hs. 24879	IN
16. Prostate differentiation factor PLAB (associated with Edg 3) [SEQ ID NO. 24]	19p13.1-p13.2	AF003934	Hs.296638	RG
17. Phospholipase A2 Group IB [SEQ ID NO. 17]	12q23-q24.1	NM_000928	Hs. 992	IN
18. Phospholipase C, beta 3 (phosphatidylinositol specific) [SEQ ID NO. 31]	11q13	Z26649	Hs.37121	RG
19. Choline/ethanolamine phosphotransferase [SEQ ID NO. 3]	1	NM_006090	Hs. 125031	IN
20. Lysophospholipase I [SEQ ID NO. 14]	8	AF081281	Hs. 12540	IN
21. Phosphatidic Acid Phosphatase type 2b [SEQ ID NO. 20]	1	AF043329	Hs. 173717	IN
22. EDG 1 [SEQ ID NO. 6]	1p21	NM_001400	Hs.154210	ST
23. N-acylsphingosine amidohydrolase (acid ceramidase) [SEQ ID NO. 16]	8p22-p21.3	U70063	Hs. 75811	IN
24. EDG 2 [SEQ ID NO. 7]	9q31.3-9q34.11	Y09479	Hs. 75794	IN
25. Edg 3 [SEQ ID NO. 8]	9q22.1-q22.2	NM_005226	Hs.248107	RG
26. Edg 4 [SEQ ID NO. 9]	19p12	AF233092	Hs.122575	IN
27. Edg 5 [SEQ ID NO. 10]	19pter-19p13.3	AF034780	Hs.202672	RG
28. Edg 6 [SEQ ID NO. 11]	19p13.3	AJ000479	Hs.159543	IN
29. Edg 7 [SEQ ID NO. 12]	1p22.3-p31.1	AF127138	Hs.258583	CT
30. S3lil125 (TMP21)	14q24.3	U61734	Hs.74137	IN
31. MAPK1 (ERK2) [SEQ ID NO. 34]	22q11.21	NM_002745	Hs.66151	IN
32. ERK1 (p44ERK1/MAPK)-MAPK3	16p11.2	M84490	Hs.861	IN
33. JNK1 (MAPK8)	10	L26318	Hs.267445	RG
34. Cyclophilin B	15q21-q22	M60857	Hs.699	IN
35. Alpha actin 1	1q42.13-42.2	AF182035	Hs.1288	ST
36. Actin B	7p15-p12	NM_001101	Hs.288061	IN
37. Glyceraldehyde 3-phosphate dehydrogenase	12p13	M33197	Hs.169476	ST
38. LH receptor	2p21	S57793	Hs.1769	CT

GENE	Chromosome	GenBank Acc. No.	UniGene database	Source*
39. FSH receptor	2p21-p16	M65085	Hs.1428	CT
40. GnRH receptor	4q21.2	L07949	Hs.73064	CT
41. LRP	16p13.1-p11.2	X79882	Hs.80680	IN
42. SPARC	5q31.3-q32	NM_003118	Hs.111779	IN
43. Ras inhibitor (RIN1)	11	NM_004292	Hs.1030	RG
44. IGF binding protein-4	17q12-q21.1	M62403	Hs.1516	IN
45. SERPINA8	1q42-q43	NM_000029	Hs.3697	ST
46. TIMP1	Xp11.3-p11.23	NM_003254	Hs.5831	IN
47. PIP5K2B	17	U85245	Hs.6335	RG
48. Secretory leukocyte protease inhibitor	20pter-p12.3	NM_003064	Hs.251754	IN
49. FLJ20258	19	AK000265	Hs.28907	IN
50. Id4	6p22-p21	Y07958	Hs.34853	IN
51. GNA14	9q21	NM_004297	Hs.50612	RG
52. SYK	9q22	Z29630	Hs.74101	IN
53. MAP2K4	17p11.2	L36870	Hs.75217	IN
54. Profilin 1	17p13.3	J03191	Hs.75721	RG
55. G protein coupled receptor 39	2q21-q22	AF034633	Hs.85339	ST
56. LYPLA2 [SEQ ID NO. 35]	1p36.12-p35.1	NM_007260	Hs.283655	IN
57. Map kinase phosphatase like [SEQ ID NO. 36]	Chr. 7	AF069762	Hs.11615	IN
58. SIR2	19q	AF095714	Hs.44017	RG
59. Prostate epithelium specific Ets transcription factor	6p21.2-21.3	AB031549	Hs.79414	ST
60. Cathepsin D	11p15.5	M11233	Hs.79572	IN
61. RAB13, member RAS oncogene family	12q13	NM_002870	Hs.151536	IN
62. LPAP (LPA phosphatase) [SEQ ID NO. 37]		NM_016361	Hs.15871	IN
63. FCGR2 (Fc fragment of IgG, receptor, transporter, alpha)	19q13.3	U12255	Hs.160741	IN
64. RPS9 (ribosomal protein S9)	19q13.4	U14971	Hs.180920	ST
65. LATS1 (large tumor suppressor)	6q24-q25.1	NM_004690	Hs.324925	RG
66. JunD	19p13.2	NM_005354	Hs.2780	ST
67. FGFR4	5q35.1-qter	L03840	Hs.165950	IN
68. p66shc (SHC)	1q21	U73377	Hs.81972	IN
69. Phospholipid scramblase 4 [SEQ ID NO. 38]	3	AF199023	Hs.182538	RG
70. Phosphatidylinositol-3-Kinase gamma polypeptide [SEQ ID NO. 22]	7q22.1-7q31.33	AF327656	Hs.32942	RG
71. Id3	1p36.13-p36.12	NM_002167	Hs.76884	RG
72. Glycerol-3- phosphate dehydrogenase [SEQ ID NO. 13]	2q24.1	U79250	Hs.93201	IN
73. Diacylglycerol Kinase (gamma) [SEQ ID NO. 4]	3q27-q28	D26135	Hs.89462	IN
74. Human Lysophospholipase homolog [SEQ ID No. 15]		U67963	Hs.6721	ST
75. Akt1 (Protein Kinase B) [SEQ ID NO. 39]	14q32.32	X61037	Hs.71816	ST
76. Human polo-like Kinase (PLK)	16	U01038	Hs.77597	IN
77. MDM2	12q14.3-q15	NM_002392	Hs.170027	IN
78. CA125	17q21.1	NM_005899	Hs.277721	IN
79. Hras	11p15.5	NM_005343	Hs.37003	IN
80. CTNNA1	3p21	NM_001904	Hs.171271	IN
81. CDKN1B	12p13.1-p12	NM_004064	Hs.238990	IN
82. CDKN1A	6p21.2	NM_000389	Hs.179665	ST
83. AKT2	19q13.1-q13.2	M95936	Hs.290219	IN
84. MGMT	10q26	M29971	Hs.1384	IN
85. Actin bundling Protein (Fascin)	7p22	U09873	Hs.118400	IN
86. MMP7	11q21-q22	NM_002423	Hs.2256	IN
87. MMP2	16q13-q21	NM_004530	Hs.111301	IN
88. IL6 (Interferon beta 2) [SEQ ID NO. 40]	7p21	NM_000600	Hs.93913	IN
89. IL8 [SEQ ID NO. 41]	4q13-q21	AF385628	Hs.624	ST
90. ROCK1 [SEQ ID NO. 42]	18	NM_005406	Hs.17820	IN
91. uPA [SEQ ID NO. 43]	10q24	M15476	Hs.77274	IN
92. tPA [SEQ ID NO. 44]	8p12	M15518	Hs.274404	IN
93. gro1 [SEQ ID NO. 45]	4q21	NM_001511	Hs.789	IN

GENE	Chromosome	GenBank Acc. No.	UniGene database	Source*
94. VEGF [SEQ ID NO. 46]	6p12	AF022375	Hs. 73793	IN
95. Mesothelin	16	NM_005823	Hs.155981	IN
96. hb EGF [SEQ ID NO. 47]	5q23	M60278	Hs.799	RG
97. Lipid Activated Protein Kinase [SEQ ID NO. 48]	19p13.1-p12	U33053	Hs.2499	RG
98. MUC5AC	11p15	AJ001402	Hs.285899	RG
99. MAS1	6q25.3-q26	M13150	Hs.99900	CT
100. Chl a/b binding protein	Arabidopsis	AF325049		IN
101. Glycerol Kinase [SEQ ID NO. 49]		NM_000167	Hs.1466	
102. Phosphatidylserine decarboxylase [SEQ ID NO. 50]		NM_014388	Hs.8128	
103. CDP diacylglycerol inositol 3 phosphatidyl transferase [SEQ ID NO. 51]		NM_006319	Hs.227107	
104. Triacylglycerol lipase (pancreatic lipase, PNLIP) [SEQ ID NO. 52]		M93285	Hs.102876	
*IN- Incyte; RG-Research Genetics				
CT- Clontech; ST- Stratagene				

**TABLE 5: CHROMOSOMAL DELETION/ADDITION CORRELATIONS WITH LIPID ASSOCIATED AND INFLUENCED GENES**

LIPID ASSOCIATED	GENE	Chromosome	Ov Ca Chr abnormality CGAP	Deletion (Collective from Literature)
1.	Phosphatidylinositol-3-Kinase, catalytic, alpha polypeptide	3q26.3	Over	
2.	Phospholipase D1 phosphatidylcholine specific	3q26	Over	
3.	Sphingosine Kinase (also named as SphK1)	17q25.2		del(17)q(11.2-32)
4.	Sphingosine Kinase type 2	19q13.2		del(19)q
5.	Aldehyde dehydrogenase 5 family, member A1	6		del(6)q(16-qter)
6.	Phospholipase D1 Glycosylphosphatidylinositol specific	6p22.3-6p22.2		
7.	1-acylglycerol-3-phosphate O acyltransferase	6p21.3	Del(6)p(21)	
8.	Sphingosine-1-phosphate lyase 1	10q21		del(10)q(11-qter)
9.	Phosphatase and tensin homolog (PTEN)	10q23.3	Del(10)q(23)	del(10)q(11-qter)
10.	Phosphatidic Acid Phosphate type 2a	5		del(5)q(12-23)
11.	Sphingomyelin phosphodiesterase 1 (acid sphingomyelinase)	11p15.4-p15.1		
12.	Phosphate cytidylyltransferase 1, choline, alpha isoform	3q		
13.	dihydroxyacetone phosphate acyltransferase	1q42.11-42.3	Del(1)q(42)	
14.	Phosphate cytidylyltransferase 2, ethanolamine	17		del17p;del(17)q(11.2-32)
15.	Phosphatidic Acid Phosphatase type 2c	19p13	Del(19)p(13); der(19)t(17;19)q21;p13	del(19)p
16.	Prostate differentiation factor PLAB (associated with Edg 3)	19p13.1-p13.2	Del(19)p(13); der(19)t(17;19)q21;p13	del(19)p;del(19)q
17.	Phospholipase A2 Group IB			
18.	Phospholipase C, beta 3 (phosphatidylinositol specific)	11q13		
19.	Choline/ethanolamine phosphotransferase	1		del(1)p(21-31);del(1)p(34.1-34.3);del(1)p(36.1-pter)
20.	Lysophospholipase I	6		del(6)q(16-qter)
21.	Phosphatidic Acid Phosphatase type 2b	1		del(1)p(21-31);del(1)p(34.1-34.3);del(1)p(36.1-pter)

GENE	Chromosome	Ov Ca Chr abnormality CGAP	Deletion (Collective from Literature)
22. EDG 1	1p21	Del(1)p(21)	del(1)p(21-31)
23. N-acylsphingosine amidohydrolase (acid ceramidase)	8p22-p21.3	Del(8)p(21)	del(8)p(21-qter)
24. EDG 2	9q31.3-34.11		del(9)q
25. Edg 3	9q22.1-q22.2		del(9)p, del(9)q
26. Edg 4	19p12	Del(19)p(13); der(19)t(17;19)q(21;p13)	del(19)p;del(19)q
27. Edg 5	19pter-19p13.3	Del(19)p(13)	del(19)p;del(19)q
28. Edg 6	19p13.3	Del(19)p(13)	del(19)p;del(19)q
29. Edg 7	1p22.3-p31.1	Del(1)p(22)	del(1)p(21-31)
31. MAPK1 (ERK2)	22q11.2		del(22)q
56. LYPLA2	1p36.12-p35.1		del(1)p(36.1-pter)
57. Map kinase phosphatase like	Chr. 7		
62. LPAP (LPA phosphatase)	11q13.3		
69. Phospholipid scramblase 4	3		
70. Phosphatidylinositol-3-Kinase gamma polypeptide	7q22.1-q31.33	Del(7)q(22)	
72. Glycerol-3- phosphate dehydrogenase	2q24.1		
73. Diacylglycerol Kinase (gamma)	3q27-q28		
74. Human Lysophospholipase homolog			
75. Akt1 (Protein Kinase B)	14q32.3		
88. IL6 (Interferon beta 2)	7p21		
89. IL8	4q13-q21		
90. ROCK1	18		
91. uPA	10q24-qter		del(18)q(12-qter)
92. IPA	8p12-q11.2		del(10)q(11-qter)
93. gro1	4q21	Del(4)q(21)	del(4)q(21-32)
94. VEGF	6p12		
96. hb EGF	5q23		del(5)q(12-23)
97. Lipid Activated Protein Kinase	19p12		del(19)p; del(19)q
101. Glycerol Kinase			

GENE	Chromosome	Ov Ca Chr abnormality CGAP	Deletion (Collective from Literature)
102. Phosphatidylserine decarboxylase			
103. CDP diacylglycerol Inositol 3 phosphatidyltransferase			
104. Triacylglycerol lipase		M93285	Hs.102876
POSSIBLY LIPID INFLUENCED			
71. Id3	1p36.13-p36.12		del(1)p(36.1-pter)
36. Aclin B	7p15-p12	Del(7)p(15)	
32. ERK1 (p44ERK1/MAPK)-MAPK3	16p11.2	Del(16)p(11)	del(16)q; del(16)q
33. JNK1 (MAPK8)	10		del(10)q(11-qter)
38. LH receptor	2p21	Del(2)p(21)	
39. FSH receptor	2p21-p16	Del(2)p(21)	
40. GnRH receptor	4q21.2	Del(4)q(21)	del(4)q(21-32)
41. LRP	16p13.1-p11.2		del(16)q; del(16)q
42. SPARC	5q31.3-q32.		
43. Ras inhibitor (RIN1)	11		
44. IGF binding protein-4	17q12-q21.1		del(17)q(11.2-32)
45. SERPINA8	1q42-q43	Del(1)q(42)	
46. TIMP1	Xp11.3-p11.23		del(X)p
47. PIP5K2B	17		del(17)q(11.2-32); del(17)p
48. Secretory leukocyte protease Inhibitor	20pter-p12.3		
49. FLJ20258	19		del(19)p; del(19)q
50. Id4	6p22-p21.3		
51. GNA14	9q21		del(9)q
52. SYK	9q22		del(9)q
53. MAP2K4	17p11.24		del(17)p
54. Profilin 1	17p13.3	Del(17)(6;17)(q11;p13)	del(17)p
55. G protein coupled receptor 39	2q21-22		
58. SIR2	19q		del(19)q
59. Prostate epithelium specific Ets transcription factor	6p21.2-21.3	Del(6)p(21)	
60. Cathepsin D	11p15.5		

GENE	Chromosome	Ov Ca Chr abnormality CGAP	Deletion (Collective from Literature)
61. RAB13, member RAS oncogene family	12q13		
63. FCGRT (Fc fragment of IgG, receptor, transporter, alpha)	19q13.3		del(19)p; del(19)q
64. RPS9 (ribosomal protein S9)	19q13.4		del(19)p; del(19)q
65. LATS1 (large tumor suppressor)	6q24-q25.1	Del(6)q(24)	del(6)q(16-qter)
66. JunD	19p13.2-p12	Del(19)p(13)	del(19)p
67. FGFR4	5q35.1-qter		
68. p66shc (SHC)	1q21	Del(1)q(21)	
76. Human polo-like Kinase (PLK)	16		del(16)p; del(16)q
77. MDM2	12q14.3-q15		
78. CA125	17q21.1	Der(19)t(17;19)(q21;p13)	del(17)q(11.2-32)
79. Hras	11p15.5		
80. CTNNB1	3p21	Del(3)p(21)	
81. CDKN1B	12p13.1-p12		
82. CDKN1A	6p21.2	Del(6)p(21)	
83. AKT2	19q13.1-19q13.2		del(19)q
84. MGMT	10q26		del(10)q(11-qter)
85. Actin bundling Protein (Fascin)	7p22		
86. MMP7	11q21-q22		
87. MMP2	16q13-q21		del(16)p; del(16)q
95. Mesothelin	16		del(16)p; del(16)q
98. MUC5AC	11p15		
99. MAS1	6q25.3-q26		del(6)q(16-qter)

**WE CLAIM:**

1. A method for identifying tumor characteristics comprising measuring a copy number of at least two genes associated with lipid metabolism, synthesis, or action in cells from a patient tissue sample and comparing the results with a copy number of the genes in a normal cell.
2. The method of claim 1, wherein at least two of the genes associated with lipid metabolism, synthesis, or action are selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidylyltransferase 1 (choline specific, alpha form), Phosphate cytidylyltransferase 2 (ethanolamine specific), Sphingosine kinase, Phosphatidic Acid Phosphatase type 2c, Human Lysophospholipase Homolog, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lysophospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Glycerol-3-phosphate Acyltransferase, Triacylglycerol lipase, Phosphatidylserine decarboxylase, CDP Diacylglycerol inositol-3-phosphatidyltransferase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, EDG 7, Sphingosine Kinase Type 2, MAP kinase1, LYPLA2, MAP kinase phosphatase like, LPA phosphatase, Phospholipid scramblase 4, Protein kinase B and Lipid activated protein kinase, IL6, IL8, ROCK1, uPA, tPA, gro1 VEGF and hbEGF.
3. The method of claim 1, wherein at least two of the genes associated with lipid metabolism, synthesis, or action are selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidylyltransferase 1 (choline specific, alpha form), Phosphate cytidylyltransferase 2 (ethanolamine specific), Sphingosine kinase, Phosphatidic Acid Phosphatase type 2c, Human Lysophospholipase Homolog, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3



(phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lyosphospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Glycerol-3-phosphate Acyltransferase, Triacylglycerol lipase, Phosphatidylserine decarboxylase, CDP Diacylglycerol inositol-3-phosphatidyltransferase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.

4. The method of claim 1, wherein at least two of the genes associated with lipid metabolism, synthesis, or action are selected from the group consisting of: Sphingosine Kinase Type 2, MAP kinase1, LYPLA2, MAP kinase phosphatase like, LPA phosphatase, Phospholipid scramblase 4, Protein kinase B and Lipid activated protein kinase, IL6, IL8, ROCK1, uPA, tPA, gro1 VEGF and hbEGF
5. The method of claim 1, wherein at least one of the genes associated with lipid metabolism, synthesis, or action is selected from the group consisting of Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, Edg 1, Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.
6. The method of claim 1, further comprising measuring a copy number of at least two lipid influenced genes in cells from a patient tissue sample and comparing the results with a copy number of the genes in a normal cell, wherein the lipid influenced genes are selected from the group consisting of: ERK1, JNK1, Actin B, LH receptor, FSH receptor, LRP, SPARC, Ras inhibitor (RIN1), IGF binding protein 4, SERPINA8, TIMP1, PIP5K2B, Secretory leukocyte protease inhibitor, FLJ20258, Id4, GNA14, SYK, MAP2K4, G protein coupled receptor 39, SIR2, Prostate epithelium specific Ets transcription factor, Cathepsin D, GnRH receptor, Profilin, CA 125, CDKN1A, RAB13, FCGRT, RPS9, LATS1, JunD, FGFR4, p66shc, Id3, human polo like kinase, MDM2, Hras, CTNNB1, CDKN1B, AKT2, MGMT, Actin bundling protein, MMP7, MMP2, Mesothelin, MUC5AC, and MAS1.

7. The method of any one of claims 1 through 6, wherein the determination of the copy number of the genes associated with lipid metabolism, synthesis, or action is made by:
  - isolating sample nucleic acid polymers from cells of the patient tissue sample;
  - hybridizing the sample nucleic acid polymers with nucleic acid polymers specific for the selected genes to quantify the extent of hybridization; and
  - comparing the hybridization data thus obtained with data obtained from the hybridization of reference nucleic acid polymers isolated from a normal cell of the same tissue type as the patient tissue sample.
8. The method of claim 7, wherein the sample nucleic acid polymer is amplified in the isolating step.
9. The method of claim 7, wherein the step of hybridizing the sample nucleic acid polymers uses a nucleic acid polymer comprising at least about 19 nucleotides to hybridize to a coding region of one of the selected genes.
10. The method of claim 7, wherein the step of hybridizing the sample nucleic acid polymers uses a nucleic acid polymer comprising at least about 19 nucleotides to hybridize to a non-coding sequence functionally linked to the coding region of one of the selected genes, and wherein the non-coding functionally linked sequence is unique to that gene.
11. The method of claim 7, wherein the hybridizing step uses nucleic acid polymers specific for the selected genes that are immobilized on a solid support wherein a nucleic acid polymer specific for each selected gene is located at a predetermined position on the solid support.
12. A method for identifying tumor characteristics comprising measuring the expression level of at least two genes associated with lipid metabolism, synthesis, or action in cells from a patient tissue sample and comparing the results with an expression level in normal cells.
13. The method of claim 12, wherein at least two of the genes associated with lipid metabolism, synthesis, or action are selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidyltransferase 1 (choline specific, alpha form), Phosphate cytidyltransferase 2 (ethanolamine specific), Sphingosine kinase, Phosphatidic Acid Phosphatase type 2c, Human Lysophospholipase Homolog, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3

(phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lysophospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Glycerol-3-phosphate Acyltransferase, Triacylglycerol lipase, Phosphatidylserine decarboxylase, CDP Diacylglycerol inositol-3-phosphatidyltransferase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, EDG 7, Sphingosine Kinase Type 2, MAP kinase1, LYPLA2, MAP kinase phosphatase like, LPA phosphatase, Phospholipid scramblase 4, Protein kinase B and Lipid activated protein kinase, IL6, IL8, ROCK1, uPA, tPA, gro1 VEGF and hbEGF.

14. The method of claim 12, wherein at least two of the genes associated with lipid metabolism, synthesis, or action are selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidyltransferase 1 (choline specific, alpha form), Phosphate cytidyltransferase 2 (ethanolamine specific), Sphingosine kinase, Phosphatidic Acid Phosphatase type 2c, Human Lysophospholipase Homolog, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lysophospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Glycerol-3-phosphate Acyltransferase, Triacylglycerol lipase, Phosphatidylserine decarboxylase, CDP Diacylglycerol inositol-3-phosphatidyltransferase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.
15. The method of claim 12, wherein at least two of the genes associated with lipid metabolism, synthesis, or action are selected from the group consisting of: Sphingosine Kinase Type 2,

MAP kinase1, LYPLA2, MAP kinase phosphatase like, LPA phosphatase, Phospholipid scramblase 4, Protein kinase B and Lipid activated protein kinase, IL6, IL8, ROCK1, uPA, tPA, gro1 VEGF and hbEGF

16. The method of claim 12, wherein at least one of the genes associated with lipid metabolism, synthesis, or action is selected from the group consisting of Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, Edg 1, Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.
17. The method of claim 12 further comprising measuring the expression level of at least two lipid influenced genes in cells from a patient tissue sample and comparing the results with an expression level in normal cells, wherein the lipid influenced genes are selected from the group consisting of: ERK1, JNK1, Actin B, LH receptor, FSH receptor, LRP, SPARC, Ras inhibitor (RIN1), IGF binding protein 4, SERPINA8, TIMP1, PIP5K2B, Secretory leukocyte protease inhibitor, FLJ20258, Id4, GNA14, SYK, MAP2K4, G protein coupled receptor 39, SIR2, Prostate epithelium specific Ets transcription factor, Cathepsin D, GnRH receptor, Profilin, CA 125, CDKN1A, RAB13, FCGRT, RPS9, LATS1, JunD, FGFR4, p66shc, Id3, human polo like kinase, MDM2, Hras, CTNNB1, CDKN1B, AKT2, MGMT, Actin bundling protein, MMP7, MMP2, Mesothelin, MUC5AC, and MAS1.
18. The method of any one of claims 12 through 17, wherein the determination of the expression level of the genes associated with lipid metabolism, synthesis, or action is made by:
  - isolating sample ribonucleic acid polymers from the cells of the patient tissue sample;
  - hybridizing the sample ribonucleic acid polymers with nucleic acid polymers specific for the selected genes to quantify the extent of hybridization; and
  - comparing the hybridization data thus obtained with data obtained from the hybridization of reference nucleic acid polymers isolated from a normal cell of the same tissue type as the patient tissue sample.
19. The method of claim 18, wherein the sample ribonucleic acid polymer is amplified in the isolating step.

20. The method of claim 18, wherein the step of hybridizing the sample ribonucleic acid polymers uses a nucleic acid polymer comprising at least about 19 nucleotides to hybridize to a coding region of one of the selected genes.
21. The method of claim 18, wherein the hybridizing step uses nucleic acid polymers specific for the selected genes that are immobilized on a solid support wherein a nucleic acid polymer specific for each selected gene is located at a predetermined position on the solid support.
22. An array of nucleic acid polymers immobilized on a solid support, comprising:
- a solid support;
  - at least two different nucleic acid polymers which are each specific for a different gene associated with lipid metabolism, synthesis, or action;
  - wherein each nucleic acid polymer is located at a predetermined position on the solid support, and wherein the array comprises nucleic acid polymers which are specific for less than 100 genes other than the selected genes.
23. The array of claim 22, wherein at least two of the nucleic acid polymers are specific for genes selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidyltransferase 1 (choline specific, alpha form), Phosphate cytidyltransferase 2 (ethanolamine specific), Sphingosine kinase, Phosphatidic Acid Phosphatase type 2c, Human Lysophospholipase Homolog, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lyosphospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Glycerol-3-phosphate Acyltransferase, Triacylglycerol lipase, Phosphatidylserine decarboxylase, CDP Diacylglycerol inositol-3-phosphatidyltransferase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7, Sphingosine Kinase Type 2, MAP kinase1, LYPLA2, MAP kinase phosphatase

like, LPA phosphatase, Phospholipid scramblase 4, Protein kinase B and Lipid activated protein kinase, IL6, IL8, ROCK1, uPA, tPA, gro1 VEGF and hbEGF.

24. The array of claim 22, wherein at least two of the nucleic acid polymers are specific for genes selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Dihydroxyacetone phosphate acyltransferase, Phosphate cytidyltransferase 1 (choline specific, alpha form), Phosphate cytidyltransferase 2 (ethanolamine specific), Sphingosine kinase, Phosphatidic Acid Phosphatase type 2c, Human Lysophospholipase Homolog, Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase C beta 3 (phosphatidylinositol specific), Phosphatidylinositol-3-Kinase (class2, gamma polypeptide), Choline/ethanolamine phosphotransferase, Lysophospholipase, Aldehyde dehydrogenase (5 family, member A1), Phospholipase D1 glycosylphosphatidylinositol specific, 1-acylglycerol-3-phosphate acyltransferase, Phosphatidic Acid Phosphate type 2b, EDG 1, Glycerol-3-phosphate dehydrogenase, Sphingosine-1-phosphate lyase 1, Phosphatase and Tenson Homolog (PTEN), Phosphatidic Acid Phosphatase type 2a, Sphingomyelin phosphodiesterase 1, N-acylsphingosine amidohydrolase, Glycerol Kinase, Diacylglycerol Kinase gamma, Glycerol-3-phosphate Acyltransferase, Triacylglycerol lipase, Phosphatidylserine decarboxylase, CDP Diacylglycerol inositol-3-phosphatidyltransferase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.
25. Sphingosine Kinase Type 2, MAP kinase1, LYPLA2, MAP kinase phosphatase like, LPA phosphatase, Phospholipid scramblase 4, Protein kinase B and Lipid activated protein kinase, IL6, IL8, ROCK1, uPA, tPA, gro1 VEGF and hbEGF
26. The array of claim 22, wherein at least one of the nucleic acid polymers is specific for a gene selected from the group consisting of: Phosphatidylinositol-3-kinase (catalytic, alpha polypeptide), Phospholipase D1 (phosphatidylcholine specific), Prostate Differentiation Factor PLAB, Phospholipase A2, Phospholipase D1 glycosylphosphatidylinositol specific, Edg 1, Glycerol-3-phosphate dehydrogenase, EDG 2, EDG 3, EDG 4, EDG 5, EDG 6, and EDG 7.
27. The array of claim 22, further comprising at least two different nucleic acid polymers which are each specific for a different lipid influenced gene, wherein the lipid influenced genes are selected from the group consisting of: ERK1, JNK1, Actin B, LH receptor, FSH receptor, LRP, SPARC, Ras inhibitor (RIN1), IGF binding protein 4, SERPINA8, TIMP1, PIP5K2B,

Secretory leukocyte protease inhibitor, FLJ20258, Id4, GNA14, SYK, MAP2K4, G protein coupled receptor 39, SIR2, Prostate epithelium specific Ets transcription factor, Cathepsin D, GnRH receptor, Profilin, CA 125, CDKN1A, RAB13, FCGRT, RPS9, LATS1, JunD, FGFR4, p66shc, Id3, human polo like kinase, MDM2, Hras, CTNNB1, CDKN1B, AKT2, MGMT, Actin bundling protein, MMP7, MMP2, Mesothelin, MUC5AC, and MAS1.

28. The array of any one of claims 22 through 27, wherein at least one of the nucleic acid polymers specific for the selected genes is a nucleic acid polymer comprising at least about 19 nucleotides which hybridize to a coding region of one of the selected genes.
29. The array of any one of claims 22 through 27, wherein at least one of the nucleic acid polymers specific for the selected genes is a nucleic acid polymer comprising at least about 19 nucleotides which hybridize under the conditions to a non-coding sequence functionally linked to the coding region of one of the selected genes, wherein the functionally linked sequence is unique to that gene.

# Pathways for Phospholipid Metabolism




FIGURE 1



# Pathways for Sphingolipid Metabolism




FIGURE 2

## Key Enzymes Involved

1. Ceramide cholinephosphotransferase
2. Sphingomyelin phosphodiesterase
3. N-Acylsphingosine glucosyltransferase
4. Ceramidase
5. Sphingosine N-Acyltransferase
6. Sphingosine Kinase
7. S-1-P Lyase

## SEQUENCE LISTING

<110> Atairgin Technologies, Inc.

Skinner, Michael K.

Patton, Jodi L.

Chaudhary, Jaideep

<120> A METHOD OF DETERMINING TUMOR CHARACTERISTICS BY DETERMINING ABNORMAL COPY NUMBER OR EXPRESSION LEVEL OF LIPID-ASSOCIATED GENES

<130> PATRICK EAGLEMAN: ATAIRGIN 252/124 US

<160> 52

<170> PatentIn version 3.1

<210> 1

<211> 2045

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(2045)

<223> The sequence of the cDNA coding for 1-acylglycerol-3-phosphate acyltransferase

```

<400> 1
cgacaccccg acagagacag agacacagcc atccgccacc accgctgccg cagcctggct      60
ggggaggggg ccagccccc agggccccta cccctctgag gtggccagaa tggatttggt      120
gccaggggca tggatgctgc tgctgctgct ctctctgctg ctgctcttcc tgctgcccac      180
cctgtgggtc tgcagcccca gtgccaagta cttcttcaag atggccttct acaatggctg      240
gatectcttc ctggctgtgc tcgccatccc tgtgtgtgcc gtgcgaggac gcaacgtcga      300
gaacatgaag atcttgctgc taatgctgct ccacatcaaa tacctgtacg ggatccgagt      360
ggaggtgcga ggggctcacc acttccctcc ctgcgagccc tatgttggtg tctccaacca      420
ccagagctct ctcgatctgc ttgggatgat ggaggtactg ccaggccgct gtgtgcccac      480
tgccaagcgc gagctactgt gggctggctc tgccgggctg gcctgctggc tggcaggagt      540
catcttcacg gaccggaagc gcacggggga tgccatcagt gtcagtgtctg aggtcgccca      600
gaccctgctc acccaggacg tgaggggtctg ggtgtttcct gagggaaacga gaaaccacaa      660
tggtctcatg ctgcccttca aacgtggcgc ctcccatctt gcagtgcagg cccaggttcc      720
cattgtcccc atagtcatgt cctcctacca agacttctac tgcaagaagg agcgtcgctt      780
cacctcggga caatgtcagg tgcgggtgct gccccagtg cccacggaag ggctgacacc      840
agatgacgtc ccagctctgg ctgacagagt ccggcactcc atgctcactg ttttccggga      900
aatctccact gatggccggg gtggtggtga ctatctgaag aagcctgggg gcggtgggtg      960
aaccctggct ctgagctctc ctcccatctg tcccatctt cctccccaca cctaccacc      1020
cagtgggccc tgaagcaggg ccaaaccctc ttccttgtct cccctctccc cacttattct      1080

```

```

cctcttttga atcttcaact tctgaagtga atgtggatac agcgccactc ctgccccctc 1140
ttggcccat ccattgactc ttgcctcggg gcagtttcca ctcttgacct ccacctccta 1200
ctgtcttggt tgtgggacag ttgcctcccc ctcatctcca gtgactcagc ctacacaagg 1260
gaggggaaca ttccatcccc agtggagtct ctctctatgt ggtcttctct acccctctac 1320
cccacattgg ccagtggact catccattct ttggaacaaa tccccccac tccaaagtcc 1380
atggattcaa tggactcatc catttgtgag gaggacttct cgccctctgg ctggaagtgc 1440
atacctgaag cactcccagg ctcatcctgg gagctttcct cagcaccttc accttccctc 1500
ccagtgtagc ctctgtcag tgggggctgg acccttctaa ttcagagggtc tcatgcctgc 1560
ccttgcccag atggcccagg tcgtgcactc tctgggatac cagttcagtc tccacatttc 1620
tggttttctg tccccatagt acagttcttc agtggacatg accccacca gccccctgca 1680
gcctgtgc accatctcac cagacacaag gggaagaagc agacatcagg tgcctgactc 1740
acttctgccc cctggggagt tggggaagg aacgaacct ggctggaggg gataggaggg 1800
cttttaattt atttcttttt ctgttgaggc ttccccctct ctgagccagt tttcatttct 1860
tcctggtggc attagccact ccctgcctct cactccagac ctgttcccac aactggggag 1920
gtaggctggg agcaaaaagg gaggggtggg cccagttttg cgtggttggg ttttattaat 1980
tatctggata acagcaaaaa aactgaaaaa aaagagagag agagaaaaaa aaaaaaaaaa 2040
aaaaa 2045

```

&lt;210&gt; 2

&lt;211&gt; 1554

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1554)

&lt;223&gt; The sequence of the cDNA coding for Aldehyde dehydrogenase (5 family, member A1)

&lt;400&gt; 2

```

atgctgcgct tcctggcacc ccggtgctt agcctccagg gcaggaccgc cctctactcc 60
tcggcagcag ccctcccaag ccccatcttg aaccagaca tccctacaa ccagctgttc 120
atcaacaatg aatggcaaga tgcagtcagc aagaagacct tcccgacggt caacctacc 180
accggggagg tcatcgggca cgtggctgaa ggtgaccggg ctgatgtgga tcgggccgtg 240
aaagcagccc gggaagcctt ccgcctgggg tccccatggc gccggatgga tgcctctgag 300
cggggcccgc tgcgaacct cctggcagac ctagtggagc gggatcgagt ctacttggcc 360
tactcagaga ccttggacaa tgggaagcct ttccaagagt cttacgcctt ggacttggat 420
gaggtcatca aggtgtatcg gtactttgct ggctgggctg acaagtggca tggcaagacc 480
atccccatgc atggccagca tttctgcttc acccggcatt agcccggttg tgtctgtggc 540
cagatcatcc cgtggaactt ccccttggtc atgcagggtt ggaaacttgc cccggcactc 600
gccacaggca acactgtggt tatgaagggt gcagagcaga cccccctctc tgccctgtat 660
ttggcctccc tcatcaagga ggaggtttt cccctggggg tggatgaacat catcacgggg 720
tatggcccaa cagcaggtgc ggccatcgcc cagcacatgg atgttgacaa agttgccttc 780
accggttcca ccgaggtggg ccacctgatc cagaaagcag ctggcgattc caacctcaag 840
agagtcaccc tggagctggg tggtaagagc cccagcatcg tgctggccga tgctgacatg 900
gagcatgccg tggagcagtg ccacgaagcc ctgttcttca acatgggcca gtgctgctgt 960
gctggctccc ggaccttcgt ggaagaatcc atctacaatg agtttctcga gagaaccgtg 1020
gagaaggcaa agcagaggaa agtggggaac ccctttgagc tggacacca gcaggggctt 1080
caggtggaca agagcagtt tgaaagagtc ctaggctaca tccagcttgg ccagaaggag 1140
ggcgcaaaac tcctctgttg cggagagcgt ttccggggagc gtggtttctt catcaagcct 1200
actgtctttg gtggcgtgca ggatgacatg agaattgcca aagaggagat ctttgggctt 1260
gtgcagcccc tgttcaagtt caagaagatt gagaggtgg ttgagagggc caacaacacc 1320
aggtatggcc tggctgcggc tgtgttcacc cgggatctgg acaaggccat gtacttcacc 1380
caggcactcc aggcggggac cgtgtgggta aacacctaca acatcgtcac ctgccacacg 1440

```

ccatttggag ggtttaagga atctggaaac gggagggagc tgggtgagga tgggcttaag 1500  
gcctacacag aggtaaagac ggtcaccatc aaggttcctc agaagaactc gtaa 1554

<210> 3

<211> 2051

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(2051)

<223> The sequence of the cDNA coding for Choline/ethanolamine phosphotransferase

<400> 3

ggcacgagct ggagtcggag gcgatatttc taggggtgta cttgttgggg tcagggttaag 60  
caccagccac aaaaacctac aaaagaaggg aaattactgt ctttaaatat taaaaaaaaa 120  
caagatccat gagtgggcat cgatcaacaa ggaaaagatg tggagattct caccgggagt 180  
ccccagtggg cttcgggcat atgagtacta caggatgtgt attaaataaa ttgtttcagt 240  
taccaacacc accattgtca agacaccaac taaagcggct agaagaacac agatatcaaa 300  
gtgctggacg gtccctgctt gagcccttaa tgcaagggtg ttgggaatgg ctcgtagtaa 360  
gagttccctc ctggattgcc ccaaactcctc tcaccatcat tggactgtca ataaacatct 420  
gtacaactat tttattagtc ttctactgcc ctacagctac agagcaggca cctctgtggg 480  
catatattgc ttgtgcctgt ggccttttca tttaccagtc tttggatgct attgatggga 540  
aacaggcaag aagaaccaat agtagttctc ctctgggaga actttttgat catggctgtg 600  
attcactatc aacagttttt gtggttcttg gaacttgtat tgcagtgcag ctggggacaa 660  
accctgattg gatgtttttt tgttgttttg cggggacatt tatgttctat tgtgcgcact 720  
ggcaaacgta gttttctgga acattgcgat ttggaataat tgatgtgact gaagtgcata 780  
tcttcataat aatcatgcat ttgctggcag tgattggagg accacctttt tggcaatcta 840  
tgattccagt gctgaatatt caaatgaaaa tttttcctgc actttgtact gtagcaggga 900  
ccatattttc ctgtacaaat tacttccgtg taatcttcac agtggtgtgt ggcaaaaatg 960  
gatcaacaat agcaggaaca agtgtccttt ctctttttct ccatattgga tcagtgatta 1020  
cattagctgc aatgatctac aagaaatctg cagttcagct ttttgaaaag catccctgtc 1080  
tttatatact gacatttggg tttgtgtctg ctaaaatcac taataagctt gtggttgac 1140  
acatgacgaa aagtgaatg catttgcatt acacagcatt cataggcccg gcacttttgt 1200  
ttctggacca gtattttaac agctttattg atgaatatat tgtactttgg attgccctgg 1260  
ttttctcttt ctttgatttg atccgtact gtgtcagtg ttgcaatcag attgcgtctc 1320  
acctgcacat acatgtcttc agaatacagg tctctacagc tcattctaatt catcattaat 1380  
gatgtaattg gtatatagga acatcatgtt ttctgcagga aagaaagtaa catattaagg 1440  
agaatggggg tggataagaa caaatataat ttataataat caatgttgta taacttttat 1500  
tctttattat tggtaacacg ccctaactat cctgtgtgag aatgggaatt tcaagccca 1560  
tcttgtaaat tgtatatgtt gtcattgcagg gtttgggcca agaaagcatg cagaaaaaaa 1620  
tgccatgtga ttgtaattat cctggattca gaataatact gtgatgggga gccagatccg 1680  
cagtggtgga gagttctaatt gttgactgtt tgcaggccaa aagatgattg ctttataatt 1740  
ttaacaaatc attgtctttt agtaacatcc ttgttttagt tcttctcaag ctttctttac 1800  
tgagggaattc agcttgtgac acagatacat ccactagct tgtgaggtgg aactagtaat 1860  
aaagaccttg aatttggatt gaaaagtttc ctatctttac attgttgagg aagtcctttt 1920  
tttttttttt ttttaattgct caagaaatga ttctctcaca ggcttgggaa atcctgtag 1980  
catgcagaat aatgtggtta ctttgtcaat ttcccatatt atttttttaa ataaatatat 2040  
gatctaaacg g 2051

<210> 4

&lt;211&gt; 3758

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(3758)

&lt;223&gt; The sequence of the cDNA coding for Diacylglycerol kinase, gamma

&lt;400&gt; 4

cacggagata	gacagctttg	gagctgctga	actccgagca	caggggtgaag	acccccggcgc	60
taccaaccac	agcctggcag	cctgggtctcc	gcggcaccga	ctggggctgc	atccccctcc	120
cccagagagg	ctgcgccaggc	gggaagacgc	cagaggccag	cttcgggtccc	ccttctgtct	180
ctcgggttcc	ctttcctccc	aagtaaggga	ataaacccgc	aagaaggagc	gccccgggcc	240
accgcgcaac	caagtgttgc	ctgggtgagga	agagccagga	cttctgaatt	taccttgaat	300
acagacagga	ggatgttgcc	taaggaatag	cagagatctt	gtctcatctt	ctgagagggtg	360
cctgctgctg	ctgtatacac	ttgagtgtct	ccagaagtct	cctgaaaggc	ttacatcgca	420
aacctgcaat	gagccaggcc	ctgggctggg	cctccacttc	agcctagtga	acaaaactcc	480
atcactgccc	tttagccact	cacataaagt	ttaaaaatgg	gtgaagaacg	gtgggtctcc	540
ctcactccag	aagaatttga	ccaactccag	aaatattcag	aatatctctc	caagaagata	600
aaagatgcct	tgactgaatt	taatgagggt	gggagcctca	aacaatatga	cccacatgag	660
ccgattagct	atgatgtctt	caagctgttc	atgagggcgt	acctggagggt	ggaccttccc	720
cagccactga	gcactcacct	cttctctggc	ttcagccaga	agcccagaca	cgagacctct	780
gaccacccga	cggaggggagc	cagcaacagt	gaggccaaca	gcgcagatac	taatatacag	840
aatgcagata	atgccaccaa	agcagacgag	gcctgtgccc	ctgatactga	atcaaatatg	900
gctgagaagc	aagcaccagc	tgaagaccaa	gtggctgcga	ccccctgga	acccccgctc	960
cctcgggtctt	caagctcgga	atccccagtg	gtgtacctga	aggatgttgt	gtgctacctg	1020
tccctgctgg	agacggggag	gcctcaggat	aagctggagt	tcattgtttcg	cctctatgat	1080
tcagatgaga	acggtctcct	ggaccaagcg	gagatggatt	gcattgtcaa	ccaaatgtgt	1140
catattgccc	agtacctgga	gtgggatccc	acagagctga	ggcctatatt	gaaggagatg	1200
ctgcaaggga	tggactacga	ccgggacggc	tttgtgtctc	tacaggaatg	ggtccatgga	1260
gggatgacca	ccatccatt	gctgggtgtc	ctggggatgg	atgactctgg	ctccaagggg	1320
gatggggggc	acgcctggac	catgaagcac	ttcaagaaac	caacctactg	caacttctgc	1380
catatcatgc	tcattggcgt	ccgcaagcaa	ggcctgtgct	gcacttactg	taaatacact	1440
gtccacgaac	gctgtgtgtc	caaaaacatt	cctggttgtg	tcaaaacgta	ctcaaaagcc	1500
aaaaggagtg	gtgagggtgat	gcagcacgca	tgggtggaag	ggaactcctc	cgtcaagtgt	1560
gaccgggtgc	acaaaagtat	caagtgtcac	cagatgttca	ccgcgcggca	ctgcgtgtgg	1620
tgccggatga	cgtttcaccg	caaatgtgaa	ttatcaacgt	tgtgtgacgg	tggggaaactc	1680
agagaccaca	tcttactgcc	cacctccata	tgccccatca	cccgggacag	gccagggtgag	1740
aagtctgatg	gctgcgtgtc	cgccaagggc	gaacttgtca	tgaggtataa	gatcatcccc	1800
acccccggta	cccacccccct	gctgggtcttg	gtgaacccca	agagtggagg	gagacaagga	1860
gaaagaattc	ttcggaaatt	ccactatctg	ctcaacccca	aacaagtttt	caacctggac	1920
aatggggggc	ctactccagg	gttgaacttt	ttccgtgata	ctccagactt	ccgtgttttg	1980
gcctgtgggtg	gagatgggac	agttggctgg	attttggatt	gcattgataa	ggccaacttt	2040
gcaaagcatc	caccagtggc	tgtcctgcct	cttggaaacag	gaaatgacct	tgcccgttgt	2100
ctccgctggg	gaggaggtta	tgaagggggc	agcttgacaa	aaatcctgaa	agacattgag	2160
cagagcccct	tggatgatgct	ggaccgctgg	catctggaag	tcattccccag	agaggaagtg	2220
gaaaacgggg	accaggtccc	atacagcatc	atgaacaact	atttctccat	tgggtgtggac	2280
gcttccattg	cacacagatt	ccatgtgatg	agagagaaac	atcctgaaaa	attcaacagc	2340
aggatgaaga	acaagctgtg	gtactttgaa	tttggcacct	cggagacttt	tgcagcgacc	2400
tgcaagaaac	tccacgacca	cattgagttg	gagtgtgatg	gggttggggg	ggacctgagc	2460
aacatcttcc	tggaaaggcat	tgccattctc	aacattccca	gcattgtacg	aggcaccatc	2520
ctctggggag	aaaacaagaa	gaaccgggct	gtgatccggg	aaagcaggaa	gggtgtcact	2580
gaccccaaag	aactgaaatt	ctgcgttcaa	gacctcagtg	accagctcct	tgaagtgggtg	2640
gggctagaag	gagccatgga	gatggggcag	atctacaccg	gcctgaagag	tgcaggcagg	2700
aggctggccc	agtgcgcctc	tgtcaccatc	aggacaaaca	agctgctgcc	aatgcaagtg	2760

gatggagaac	cctggatgca	gccatgttgc	acgattaaaa	ttactcacia	gaaccaagcg	2820
cccattgatga	tggggcctcc	ccagaagagc	agcttcttct	cgttgagaag	gaagagccgt	2880
tcaaaagact	aaacagtgtg	ccaaacacca	gctaaacca	gagagaaagc	aagaaactat	2940
aatgcacact	cacacacaat	ttatgtgcac	actcacacat	gcacacacac	acacacatac	3000
acactcttct	ctaaccagt	gaagcaaagc	cacccttcgg	gaagaaaacg	tcaccttgcc	3060
atacattctg	tttcaacagt	gggtacaccc	ctaacagagc	cagtgccaac	aaaacatttt	3120
gaatggactt	agggcccatg	aggttgtggc	tggcttaggc	agcaacctcc	acattcccac	3180
aggccttgag	cagaattttc	tgagactgaa	gggaaatccc	cctttcttct	taccagccct	3240
gcaagtttcc	tcatggacgc	tcgcgaggag	caggctgcag	gtttcctgcc	tatggtgaga	3300
tcagatgtgg	ccaagggaag	gagctctggt	tccagagaat	ttgcacaaag	ttccctctgt	3360
acagagacaa	aacggcctcc	ggctctcaga	gcataatcct	tggcagggct	cagcaggcgc	3420
acgttgggtt	cttggtcgtc	ctttgagtga	caacttctcc	gtgaacctgc	tgaagaggca	3480
gaaaggctgt	ggaaagctgt	atttccattc	ttgggtttct	gcgccgtcgg	tgggcacttg	3540
ttattttcca	ggaaccttct	cctggtgtct	acatgtttgc	ttagaggcgg	ctccaagagc	3600
cccagagctg	cctgcatagc	acaccttaga	tgtggtatct	attttcttag	ttctgtgaac	3660
acctggggag	gagagcggag	aaactgggat	ttatttttca	aattggtgtc	ataatattgt	3720
gtaaaaaggg	aaggaaaaaa	aaaaccaccc	ccagcttc			3758

&lt;210&gt; 5

&lt;211&gt; 2470

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(2470)

&lt;223&gt; The sequence of the cDNA coding for Dihydroxyacetone phosphate acyltransferase

&lt;400&gt; 5

gaattcggca	cgagccggga	tccgtgtgtg	cggctgcaga	gggtgccgcc	gccctaggcg	60
aagtagggcc	gtcctgagcg	aaagaaccgc	cccagcagg	agcaccacca	cggcttagca	120
aagaatccca	gaccccgccc	gggaaggcag	ccgcaccatg	gagcttcca	gttcatctaa	180
ctcttatttc	tccgttgccc	caaccagtc	cagcgtgtc	gtgctcctct	actcgaagga	240
gctcaaaaag	tgggatgagt	ttgaagatat	tttagaagag	aggaggcatg	tcagtactt	300
gaaatttgca	atgaaatgct	acacacctct	tgtctataag	ggaattactc	catgtaaaac	360
aattgatatt	aaatgtagt	ttctcaattc	tgaggagatt	cattatgtca	ttaaacagct	420
ttccaaggaa	tcccttcaat	ctgtggatgt	cctccgagag	gaagtgtgtg	agatcttaga	480
tgaaatgagt	cacaaactgc	gtcttgagc	cattcgggtt	tgtgccttca	ccctgagcaa	540
agtattttaa	caaattttct	cgaagggtgt	tgtaaatgaa	gaaggatttc	agaaactaca	600
aagagccatc	caggagcatc	ctgttgttct	gtgcctagt	catcgaagtt	acattgactt	660
cctcatgttg	tcttttcttc	tatacaatta	tgatttgctt	gtgccagtta	tagcagcagg	720
aatggacttc	ctgggaatga	aaatggtttg	tgagctgcta	cgaatgtcgg	gtgccttttt	780
catgcggcgt	acctttggtg	gcaataaaact	ctactgggct	gtattctctg	aatatgtaaa	840
aactatgtta	cggaatgggt	atgctcctgt	tgaatttttc	ctcgaaggga	caagaagccg	900
ctctgccaa	acattgactc	ctaaatttgg	tcttctgaat	attgtgatgg	agccattttt	960
taaaagagaa	gtttttgata	cctaccttgt	ccaattagt	atcagttatg	ataagatctt	1020
ggaagaaaact	ctttatgtgt	atgagcttct	aggggttctt	aaacaaaaag	agtctacaac	1080
tgggttgctg	aaagccagaa	agattctctc	tgaataattt	ggaagcatcc	atgtgtactt	1140
tggagatcct	gtgtcacttc	gatctttggc	agctgggagg	atgagtcgga	gctcatataa	1200
cttggttcca	agatacattc	ctcagaaaca	gtctgaggac	atgcatgcct	ttgtcactga	1260
agttgcctac	aaaatggagc	ttctgcaaat	tgaataacatg	gttttgagcc	cctggacctt	1320
aatagttgct	gttctgcttc	agaaccggcc	atccatggac	tttgatgtct	tgggtgaaaa	1380
gactttatgg	ctaaaaggct	taaccagggc	atttgagggg	tttctcattt	ggcctgataa	1440
taaacctgct	gaagaagttg	tcccggccag	cattcttctg	cattccaaca	ttgccagcct	1500

tgtcaaagac	caggtgattc	tgaaagtgga	ctcggagagac	tcggaagtgg	tcgatgggct	1560
tatgtctccag	cacatcactc	tcctcatgtg	ctcagcttat	aggaaccagc	tgctcaacat	1620
ttttgtgcg	ccatccttag	tagcagtagc	attgcagatg	acaccagggg	tcaggaaaga	1680
ggatgtctac	agttgctttc	gcttcctacg	tgatgttttt	gcagatgagt	tcattcttct	1740
tccaggaaac	acactaaagg	actttgaaga	aggctgttac	ctgctttgta	aaagtgaagc	1800
catacaagtg	actacgaaag	acatcctagt	tacagagaaa	ggaaatactg	tgtagaatt	1860
tttagtagga	ctctttaaac	cttttgtgga	aagctatcag	ataatttgca	agtacctttt	1920
gagtgaagaa	gaggaccact	tcagttagga	acagtacttg	gctgcagtca	gaaaattcac	1980
aagtcagctt	ctcgatcaag	gtacctctca	atgttatgat	gtattatctt	ctgatgtgca	2040
gaaaaacgcc	ttagcagcct	gtgtgaggct	cggagtagtg	gagaagaaga	agataaataa	2100
taactgtata	tttaattgtga	atgaacctgc	cacaaccaa	ttagaagaaa	tgcttggttg	2160
taagacacca	ataggaaaac	cagccactgc	aaaactttta	taatcaacaa	atagttatgg	2220
aaaattcggg	cacgtaatta	ctctcatcga	aggactcatt	acaacaaaca	gggaagttaa	2280
ggaagagaca	catcctctca	tactccctga	gactctgaga	acagtggacg	cagagggaag	2340
agatgatcat	tggaagcaat	cagtttactc	ttccccacca	cagtggttta	aaggcgtttg	2400
tatctgacac	tatgtgtgtg	ttttaaaata	aacttttgga	aacatgaaaa	aaaaaaaaaa	2460
aaaactcgag						2470

&lt;210&gt; 6

&lt;211&gt; 2757

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(2757)

&lt;223&gt; The sequence of the cDNA coding for EDG-1

&lt;400&gt; 6

tctaaagggtc	gggggcagca	gcaagatgcg	aagcgagccg	tacagatccc	gggctctccg	60
aacgcaactt	cgccctgctt	gagcgaggct	gcggtttccg	aggccctctc	cagccaagga	120
aaagctacac	aaaaagcctg	gatcactcat	cgaaccaccc	ctgaagccag	tgaaggctct	180
ctcgccctcg	cctctagcgt	tcgtctggag	tagcgccacc	ccggcttcc	ggggacacag	240
ggttggcacc	atggggccca	ccagcgctcc	gctgggtcaag	gcccaccgca	gctcggctct	300
tgactacgtc	aactatgata	tcactgctcc	gcattacaac	tacacgggaa	agctgaatat	360
cagcgcgagc	aaggagaaca	gcattaaaat	gacctcgggtg	gtgttcattc	tcactgctg	420
ctttatcatc	tgaggagaaca	tctttgtctt	gctgaccatt	tggaacacca	agaaattcca	480
ccgacccatg	tactatttta	ttggcaatct	ggccctctca	gacctgttgg	caggagtagc	540
ctacacagct	aacctgctct	tgtctggggc	caccacctac	aagctcactc	ccgcccagtg	600
gtttctgctg	gaagggagta	tgtttgtggc	cctgtcagcc	tccgtgttca	gtctcctcgc	660
catcgccatt	gagcgctata	tcacaatgct	gaaaatgaaa	ctccacaacg	ggagcaataa	720
cttcgcctc	ttcctgctaa	tcagcgctg	ctgggtcacc	tcctcatcc	tggttgccct	780
gcctatcatg	ggctggaact	gcacagtg	gctgtccagc	tgctccaccg	tgctgcgct	840
ctaccacaag	cactatatcc	tcttctgcac	cacggtcttc	actctgtctc	tgctctccat	900
cgtcattctg	tactgcagaa	tctactcctt	ggtcaggact	cggagccgcc	gcctgacgtt	960
ccgcaagaac	atttccaagg	ccagccgcag	ctctgagaat	gtggcgctgc	tcaagaccgt	1020
aattatcgtc	ctgagcgtct	tcacgcctg	ctgggcaccg	ctcttcatcc	tgctcctgct	1080
ggatgtgggc	tgcaaggtga	agacctgtga	catcctcttc	agagcggagt	acttcctggt	1140
gtagctgtg	ctcaactccg	gcaccaaccc	catcatttac	actctgacca	acaaggagat	1200
gcgtcggggc	ttcatccgga	tcattgtcctg	ctgcaagtgc	ccgagcggag	actctgctgg	1260
caaattcaag	cgacccatca	tcgcccggcat	ggaattcagc	cgcagcaaat	cggacaattc	1320
ctcccacccc	cagaaagacg	aaggggacaa	cccagagacc	attatgtctt	ctggaaacgt	1380
caactcttct	tcctagaact	ggaagctgtc	caccacccg	aagcgctctt	tacttggctg	1440
ctggccaccc	cagtgttttg	aaaaaaatct	ctgggcttcg	actgctgcca	gggaggagct	1500
gctgcaagcc	agagggagga	agggggagaa	tacgaacagc	ctggtggtgt	cgggtggttg	1560

tgggtagagt	tagttcctgt	gaacaatgca	ctgggaaggg	tggagatcag	gtccccgcct	1620
ggaatatata	ttctaccccc	ctggagcttt	gattttgcac	tgagccaaag	gtctagcatt	1680
gtcaagctcc	taaagggttc	atttggcccc	tcctcaaaga	ctaagtcccc	catgtgaaag	1740
cgtctctttg	tctggagctt	tgaggagatg	tttcccttca	ctttagtttc	aaacccaagt	1800
gagtgtgtgc	acttctgctt	ctttagggat	gccctgtaca	tcccacaccc	caccctccct	1860
tcccttcata	ccccctctca	acgttctttt	actttatact	ttaactacct	gagagtattc	1920
agagctgggg	ttgtggaatg	atcgatcatc	tatagcaaat	aggctatgtt	gagtacgtag	1980
gctgtgggaa	gatgaagatg	gtttggagggt	gtaaaacaat	gtccttcgct	gaggccaaag	2040
tttccatgta	agcgggatcc	gttttttgga	atttggttga	agtcactttg	atttctttaa	2100
aaaacatctt	ttcaatgaaa	tgtgttacca	tttcatatcc	attgaagccg	aaatctgcat	2160
aaggaagccc	actttatcta	aatgatatta	gccaggatcc	ttggtgtcct	aggagaaaca	2220
gacaagcaaa	acaaagtga	aaccgaatgg	attaactttt	gcaaaccaag	ggagatttct	2280
tagcaaatga	gtctaacaaa	tatgacatcc	gtctttccca	cttttgttga	tgtttatttc	2340
agaatcttgt	gtgattcatt	tcaagcaaca	acatgttgta	ttttgttggt	ttaaaagtac	2400
ttttcttgat	ttttgaatgt	atttgtttca	ggaagaagtc	attttatgga	tttttctaac	2460
ccgtgttaac	ttttctagaa	tccacctctt	tgtgccctta	agcattactt	taactggtag	2520
ggaacgccag	aactttttaag	tccagctatt	cattagatag	taattgaaga	tatgtataaa	2580
tattacaaag	aataaaaaata	tattactgtc	tcttttagtat	ggttttcagt	gcaattaaac	2640
cgagagatgt	cttggtttttt	taaaaagaat	agtatttaat	aggtttctga	cttttgtgga	2700
tcattttgca	catagcttta	tcaactttta	aacattaata	aactgatttt	tttaaag	2757

&lt;210&gt; 7

&lt;211&gt; 1217

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1) .. (1217)

&lt;223&gt; The sequence of the cDNA coding for EDG-2

&lt;400&gt; 7

ctgacaccta	cagcatcagg	tacacagctt	ctcctagcat	gacttcgata	tgatcagcaa	60
acaagaaaat	ttgtctcccg	tagttctggg	gcgtgttcac	cacctacaac	cacagagctg	120
tcatggctgc	catctctact	tccatccctg	taatttcaca	gccccagttc	acagccatga	180
atgaaccaca	gtgcttctac	aacgagtcca	tgcccttctt	ttataaccga	agtggaaagc	240
atcttgccac	agaatggaac	acagtcagca	agctgggtgat	gggacttgga	atcactgttt	300
gtatcttcat	catgttggcc	aacctattgg	tcatgggtggc	aatctatgtc	aaccgcccgt	360
tccattttcc	tatttattac	ctaattggcta	atctggctgc	tgcagacttc	tttgtctgggt	420
tggcctactt	ctatctcatg	ttcaacacag	gacccaatac	tcggagactg	actgtcagca	480
catggctcct	tcgtcagggc	ctcattgaca	ccagcctgac	ggcatctgtg	gccaacttac	540
tggctattgc	aatcgagagg	cacattacgg	ttttccgcat	gcagctccac	acacggatga	600
gcaaccggcg	ggtagtgggtg	gtcattgtgg	tcatctggac	tatggccatc	gttatgggtg	660
ctatacccg	tgtgggctgg	aactgtatct	gtgatattga	aaattgttcc	aacatggcac	720
ccctctacag	tgactcttac	ttagtcttct	gggccatttt	caacttggtg	acctttgtgg	780
taatgggtgt	tctctatgct	cacatctttg	gctatgttcg	ccagaggact	atgagaatgt	840
ctcggcatag	ttctggaccc	cggcggaatc	gggataccat	gatgagtctt	ctgaagactg	900
tggctattgt	gcttggggcc	tttatcatct	gctggactcc	tggattgggt	ttgttacttc	960
tagacgtgtg	ctgtccacag	tgcgacgtgc	tggcctatga	gaaattcttc	cttctccttg	1020
ctgaattcaa	ctctgccatg	aaccccatca	tttactccta	ccgcgacaaa	gaaatgagcg	1080
ccacctttag	gcagatcctc	tgctgccagc	gcagtgagaa	ccccaccggc	cccacagaag	1140
gtcagaccg	ctcggcttcc	tccctcaacc	acaccatctt	ggctggagtt	cacagcaatg	1200
atcactctgt	ggttttag					1217



&lt;210&gt; 8

&lt;211&gt; 1137

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1137)

&lt;223&gt; The sequence of the cDNA coding for EDG-3

&lt;400&gt; 8

atggcaactg	ccctcccgcc	gcgtctccag	cgggtgcggg	ggaacgagac	cctgcgggag	60
cattaccagt	acgtggggaa	ggtggcgggc	aggctgaagg	aggcctccga	gggcagcacg	120
ctcaccaccg	tgctcttctt	ggcatctgc	agcttcacg	tcttgagaa	cctgatgggt	180
ttgattgcc	tctggaaaaa	caataaat	cacaaccgca	tgtactttt	cattggcaac	240
ctggctctct	gcgacctgt	ggccggcatc	gcttacaagg	tcaacattct	gatgtctggc	300
aagaagacgt	tcagcctgtc	tcccacggtc	tggttctca	gggagggcag	tatgttcgtg	360
gcccttgggg	cgtccacctg	cagcttactg	gccatcgcca	tcgagcggca	cttgacaatg	420
atcaaaatga	ggccttacga	cgccaacaag	aggcaccgcg	tcttcctcct	gatcgggatg	480
tgctggctca	ttgccttcac	gctgggcgcc	ctgcccattc	tgggctggaa	ctgcctgcac	540
aatctccctg	actgctctac	catcctgccc	ctctactcca	agaagtacat	tgcttctgc	600
atcagcatct	tcacggccat	cctggtgacc	atcgtgatcc	tctacgcacg	catctacttc	660
ctgggtgaagt	ccagcagccg	taaggtggcc	aaccacaaca	actcggagcg	gtccatggca	720
ctgctgcgga	ccgtgggtgat	tgtggtgagc	gtgttcacg	cctgctggtc	cccactcttc	780
atcctcttcc	tcattgatgt	ggcctgcagg	gtgcaggcgt	gccccatcct	cttcaaggct	840
cagtggttca	tcgtgttggt	tgtgtcaaac	tccgccatga	acccggtcac	ctacacgctg	900
gccagcaagg	agatgcggcg	ggccttcttc	cgtctggctc	gcaactgect	ggtcagggga	960
cggggggccc	gcgcctcacc	catccagcct	gcgctcgacc	caagcagaag	taaataaagc	1020
agcagcaaca	atagcagcca	ctctccgaag	gtcaagggaag	acctgcccc	cacagacccc	1080
tcacctctga	tcattggacaa	gaacgcagca	cttcagaatg	ggatcttctg	caactga	1137

&lt;210&gt; 9

&lt;211&gt; 1056

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1056)

&lt;223&gt; The sequence of the cDNA coding for EDG-4

&lt;400&gt; 9

atgggtcatca	tgggccagtg	ctactacaac	gagaccatcg	gcttcttcta	taacaacagt	60
ggcaaagagc	tcagctccca	ctggcgccc	aaggatgtgg	tcgtgggtggc	actggggctg	120
accgtcagcg	tgctgggtgct	gctgaccaat	ctgctgggtca	tagcagccat	cgctccaac	180
cgcgcttcc	accagcccat	ctactacctg	ctcggaatc	tggccgcggc	tgacctcttc	240
gcgggcgtgg	cctacctctt	cctcatgttc	cacactggtc	cccgcacage	cgaactttca	300

cttgagggt	ggttcctg	gcagggctg	ctggacacaa	gcctcactgc	gtcgggtggc	360
acactgctg	ccatcgccg	ggagcggcac	cgcagtgtga	tggccgtgca	gctgcacagc	420
cgctgcccc	gtggcgcgt	ggcatgctc	atttgggcg	tgtgggtggc	tgccctgggc	480
ctggggctgc	tgctgcccc	ctcctggcac	tgctctgtg	ccctggaccg	ctgctcacgc	540
atggcacc	tgctcagccg	ctcctatttg	gccgtctggg	ctctgtcgag	cctgcttg	600
ttcctgctca	tgggtgctgt	gtacacccgc	attttcttct	acgtgcggcg	gcgagtgcag	660
cgcatggcag	agcatgtcag	ctgccacccc	cgctaccgag	agaccacgct	cagcctggtc	720
aagactgttg	tcatcatcct	gggggcggtc	gtggtctgct	ggacaccagg	ccagggtggt	780
ctgctcctgg	atggttttag	ctgtgagtc	tgcaatgtcc	tggctgtaga	aaagtacttc	840
ctactgttgg	ccgaggccaa	ctcactggtc	aatgctgctg	tgtactcttg	ccgagatgct	900
gagatgcgcc	gcaccttcgc	ccgccttctc	tgtgcgcg	gcctccgcca	gtccacccgc	960
gagtcctgtc	actatacatc	ctctgccag	ggaggtgcc	gcactcgcat	catgcttccc	1020
gagaacggcc	accactgat	ggactccacc	ctttag			1056

&lt;210&gt; 10

&lt;211&gt; 1062

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1062)

&lt;223&gt; The sequence of the cDNA coding for EDG-5

&lt;400&gt; 10

atgggagct	tgtactcgga	gtacctgaac	cccaacaagg	tccaggaaca	ctataattat	60
accaaggaga	cgctggaac	gcaggagacg	acctcccgcc	aggtggcctc	ggccttcac	120
gtcatcctct	gttgcccat	tgtggtggaa	aaccttcttg	tgctcattgc	ggtggcccca	180
aacagcaagt	tccactcggc	aatgtacctg	tttctgggca	acctggccgc	ctccgatcta	240
ctggcaggcg	tggccttcgt	agccaatacc	ttgtctctg	gctctgtcac	gctgaggctg	300
acgcctgtgc	agtggtttgc	ccgggagggc	tctgctcca	tcacgctctc	ggcctctgtc	360
ttcagcctcc	tggccatcgc	cattgagcgc	cacgtggcca	ttgccaaggt	caagctgtat	420
ggcagcgaca	agagctgccg	catgcttctg	ctcatcgggg	cctcgaggct	catctcgctg	480
gtcctcggtg	gcctgccc	ccttggtctg	aactgcctgg	gccacctcga	ggcctgctcc	540
actgtcctgc	ctctctacgc	caagcattat	gtgctgtgcg	tggtagccat	cttctccatc	600
atcctgttgg	ccatcgtggc	cctgtacgtg	cgcactact	gcgtggctcg	ctcaagccac	660
gctgacatgg	ccgcccgcga	gacgctagcc	ctgctcaaga	cggtcaccat	cgtgctaggc	720
gtctttatcg	tctgtgggt	gcccgccttc	agcctcctcc	ttctggacta	tgctgtcccc	780
gtccactcct	gcccgatcct	ctacaaagcc	cactactttt	tcgccgtctc	caccctgaat	840
tccctgctca	accccgatc	ctacacgtgg	cgcagccggg	acctgcggcg	ggaggtgctt	900
cggccgctgc	agtgtggcg	gccgggggtg	ggggtgcaag	gacggaggcg	ggtcgggacc	960
ccgggccacc	acctcctgcc	actccgcagc	tccagctccc	tggagagggg	catgcacatg	1020
cccacgtcac	ccacgtttct	ggagggaac	acggtggtct	ga		1062

&lt;210&gt; 11

&lt;211&gt; 1566

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1566)

&lt;223&gt; The sequence of the cDNA coding for EDG-6

&lt;400&gt; 11

```

gagtcagccc ccgsggggagg ccatgaacgc cacgggggacc ccggtggccc ccgagtcctg      60
ccaacagctg gcggccggcg ggcacagccg gctcattgtt ctgcactaca accactcggg      120
ccggctggcc gggcgcgggg ggccggagga tggcggcctg ggggcccctg gggggctgtc      180
ggtggccgcc agctgcctgg tgggtgctga gaacttgctg gtgctggcgg ccatcaccag      240
ccacatgcgg tcgcgacgct ggggtctacta ttgcctggtg aacatcacgc tgagtgaacct      300
gctcacgggc gcggcctacc tggccaacgt gctgctgtcg ggggcccga ccttcctct      360
ggcgcccgcc cagtggttcc tacgggaggg cctgctcttc accgccctgg ccgctccac      420
cttcagcctg ctcttctactg caggggagcg ctttgccacc atggtgcggc cgggtggcca      480
gagcggggcc accaagacca gccgcgtcta cggtctcatc ggctctgct ggctgctggc      540
cgcgctgctg gggatgctgc ctttgctggg ctggaactgc ctgtgcgcct ttgaccgctg      600
ctccagcctt ctgcccctct actccaagcg ctacatcctc ttctgcctgg tgatcttcgc      660
cggcgctcctg gccaccatca tgggcctcta tggggccatc ttccgcctgg tgcaggccag      720
cgggcagaag gccccacgcc cagcgggccc cgcaaggcc cgccgcctgc tgaagacggg      780
gctgatgate ctgctggcct tectgggtgt ctggggccca ctcttcgggc tgctgctggc      840
cgacgtcttt ggctccaacc tctgggcccc ggagtacctg cggggcatgg actggatcct      900
ggccctggcc gtctcaact cggcggtcaa ccccatcatc tactcttcc gcagcaggga      960
ggtgtgcaga gccgtgctca gcttctctg ctgcggtgt ctccggctgg gcagtcgagg      1020
gcccggggac tgcctggccc gggccgtcga ggctcactcc ggagcttcca ccaccgacag      1080
ctctctgagg ccaagggaca gctttcgcgg ctcccgcctc ctccagcttcc ggatgcggga      1140
gccctgtcc agcatctcca gcgtgcggag catctgaagt tgcagtcttg cgtgtggatg      1200
gtgcagccac cgggtgcgtg ccaggcaggc cctctctggg tacaggaagc tgtgtgcagc      1260
cagcctcgcc tgtatggga gcagggaacg ggacaggccc ccatggtctt cccggtggcc      1320
tctcggggct tctgaccca aatgggcttc ccatggtcac cctggacaag gaggtaacca      1380
ccccacctcc ccgtaggagc agagagcacc ctggtgtggg ggcgagtggg tccccacaac      1440
cccgttctg tgtgattctg gggaagtccc ggcccctctc tgggcctcag tagggctccc      1500
aggctgcaag ggggtggactg tgggatgcat gccctggcaa cattgaagtt cgatcatggt      1560
aaaaaa                                           1566

```

&lt;210&gt; 12

&lt;211&gt; 1148

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1148)

&lt;223&gt; The sequence of the cDNA coding for EDG-7

&lt;400&gt; 12

```

cttcttttaa tttctttcta ggatgttcac ttcttctcca caatgaatga gtgtcactat      60
gacaagcaca tggacttttt ttataatagg agcaacactg atactgtcga tgactggaca      120
ggaacaaagc ttgtgattgt tttgtgtgtt gggacgtttt tctgcctgtt tatttttttt      180
tctaattctc tggatcatgc gccagtgatc aaaaacagaa aatttcattt ccccttctac      240
tacctgtttg ctaatttagc tgctgcccga ttcttcgctg gaattgccta tgtattcctg      300
atgtttaaca caggccagc ttcaaaaact ttgactgtca accgctggtt tctccgtcag      360
ggccttctgg acagtgcctt gactgcttcc ctcaaccaact tgctggttat cgcctggag      420
aggcacatgt caatcatgag gatgcgggtc catagcaacc tgaccaaaaa gagggtgaca      480

```

ctgctcattt	tgcttgtctg	ggccatcgcc	atttttatgg	gggcgggtccc	cacactgggc	540
tggaaattgcc	tctgcaacat	ctctgcctgc	tcttccttgg	ccccattta	cagcaggagt	600
taccttgttt	tctggacagt	gtccaaacctc	atggccttec	tcatcatggg	tgtgggtgtac	660
ctgcggtatct	acgtgtacgt	caagaggaaa	accaacgtct	tgtctccgca	tacaagtggg	720
tccatcagcc	gccggaggac	acccatgaag	ctaatagaaga	cgggtgatgac	tgtcttaggg	780
gcgtttgtgg	tatgctggac	cccgggcctg	gtggttctgc	tcttcgacgg	cctgaactgc	840
aggcagtgtg	gcgtgcagca	tgtgaaaagg	tggttcctgc	tgctggcgct	gctcaactcc	900
gtcgtgaacc	ccatcatcta	ctcctacaag	gacgaggaca	tgtatggcac	catgaagaag	960
atgatctgct	gcttctctca	ggagaaccca	gagaggcgct	cctctcgcat	cccctccaca	1020
gtcctcagca	ggagtgcac	aggcagccag	tacatagagg	atagtattag	ccaaggtgca	1080
gtctgcaata	aaagcacttc	ctaaactctg	gatgcctctc	ggcccaccca	ggtgatgact	1140
gtcttagg						1148

&lt;210&gt; 13

&lt;211&gt; 1606

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1606)

&lt;223&gt; The sequence of the cDNA coding for Glycerol-3-phosphate dehydrogenase

&lt;400&gt; 13

tttttttttt	tttttttttt	ttgggtggcg	gggggttgca	agtgggaagc	ctgctgttca	60
gtgcccgggg	ctctccgcct	ccccccacct	gtatgaggct	gggtctgggg	aacctgtgct	120
cagcattcca	ccccctggag	cttgggcttg	gtcttccttg	cgggtccctg	cgctgacatt	180
caggcgggga	gccaggaggc	ctggcgcgcc	tccagagccc	gccgggggag	ccgggcgagg	240
gttctgggct	ctgacggcgg	ggtcgcaggg	tgcgccgcct	cctggacacg	tctgtaggcc	300
taggggaagcc	tgccggccgg	gaggtacaga	gtaggagaag	ccagatccca	ggcgggacaa	360
cgagaagtcg	tcaggctaag	aaatggcatt	tcaaaaggca	gtgaaaggga	cgattcttgt	420
tggaggaggt	gctcttgcaa	ctgttttagg	actttctcag	tttgctcatt	acagaaggaa	480
acaaatgaac	ctggcctatg	ttaaagcagc	agactgcatt	tcagaaccag	ttaacaggga	540
gcctccttcc	agagaagctc	agctactgac	tttgcaaaat	acatctgaat	ttgatatact	600
tgttattgga	ggaggagcaa	caggaagtgg	ctgtgcgcta	gatgctgtca	ccagaggact	660
aaaaacagcc	cttgtagaaa	gagatgattt	ctcatcaggg	accagcagca	gaagcactaa	720
attgatccat	ggtggtgtga	gatatactga	gaaggccatc	atgaagttgg	atattgagca	780
gtataggatg	gtaaaagaag	cccttcatga	gcgtgccaac	ctgctagaaa	ttgctcccca	840
tttatcagct	ccattgccta	taatgcttcc	agtttacaag	tggtggcagt	taccttacta	900
ctgggtagga	atcaagctgt	atgatttggg	tgcaggaagc	aattgcctaa	aaagcagtta	960
tgtcctcagc	aaatcaagag	cccttgaaca	tttcccaatg	ctccagaagg	acaaactggg	1020
aggagcaatt	gtctactatg	acggacaaca	taacgatgca	cggatgaacc	ttgccattgc	1080
tctgactgct	gccaggtatg	gggctgccac	agccaattac	atggaggtag	tgagcttgct	1140
caagaagaca	gaccccagca	cagggaaagt	gcatgtgagc	ggcgacgggt	gcaaggatgt	1200
cctcacaggg	caggaatttg	acgtgagagc	caaattgtgt	atcaatgcc	cgggaccttt	1260
cacggactct	gtgcgcaaaa	tggatgataa	agacgcagca	gctatctgcc	agccaagtgc	1320
tggtgtccat	attgtgatgc	ctggttatta	cagcccagag	agcatgggac	ttcttgaccc	1380
agcgaccagt	gatggcgag	ttattttctt	cttaccctgg	caaaagatga	cgatcgctgg	1440
cactactgat	actccaaactg	atgttacaca	ccatccaatt	ccttcagaag	aagatatcaa	1500
cttcattttg	aatgaagtgc	gtaattacct	gagttgtgat	gttgaagtga	gaagagggga	1560
tgtcctggca	gcatggagtg	gaatccgtcc	tcttgttaca	gacccc		1606

&lt;210&gt; 14

&lt;211&gt; 2417

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(2417)

&lt;223&gt; The sequence of the cDNA coding for Lyosphospholipase I

&lt;400&gt; 14

cttccttccg	cttgcgctgt	gagctgagggc	gggtgatgtg	cggcaataac	atgtcaaccc	60
cgctgcccgc	catcgtgcc	gccgcccga	aggccaccgc	tgcggtgatt	ttcctgcatg	120
gattgggaga	tactgggcac	ggatgggcag	aagcctttgc	aggtatcaga	agttcacata	180
tcaaataat	ctgcccgc	gcgcctgtta	ggcctgttac	attaaatatg	aacgtggcta	240
tgccttcatg	gtttgatatt	attgggcttt	caccagattc	acaggaggat	gaatctggga	300
ttaaacaggc	agcagaaaat	ataaaagctt	tgattgatca	agaagtgaag	aatggcattc	360
cttctaacag	aattattttg	ggagggtttt	ctcaggagg	agctttatct	ttatatactg	420
cccttaccac	acagcagaaa	ctggcagggtg	tcactgcact	cagttgctgg	cttccacttc	480
gggcttcctt	tccacagggt	cctatcggtg	gtgctaatag	agatatttct	attctccagt	540
gccacgggga	ttgtgaccct	ttggttcccc	tgatgtttgg	ttctcttacg	gtggaaaaac	600
taaaaacatt	ggtgaatcca	gccaatgtga	cctttaaaac	ctatgaaggt	atgatgcaca	660
gttcgtgtca	acaggaaatg	atggatgtca	agcaattcat	tgataaactc	ctacctccaa	720
ttgattgacg	tcactaagag	gccttgtgta	gaagtacacc	agcatcattg	tagtagagtg	780
taaacctttt	cccatgccca	gtcttcaaat	ttctaattgt	ttgcagtgtt	aaaatgtttt	840
gcaaatacat	gccgataaca	cagatcaaat	aatatctcct	catgagaaat	ttatgatcct	900
ttaagtttct	attcatgtat	tcttataaga	cgaccaggga	tctactatat	tagaatagat	960
gaagcaggta	gcttcttttt	tctcaaatgt	aattcagcaa	aataatacag	tactgccacc	1020
agatttttta	ttacatcatt	tgaaaattag	cagtatgctt	aatgaaaatt	tgttcaggta	1080
taaatgagca	gttaagatat	aaacaattta	tgcatgctgt	gacttagtct	atggatttat	1140
tccaaaattg	cttagtcacc	atgcagtgtc	tgtattttta	tatatgtgtt	catatataca	1200
taatgattat	aatacataat	aagaatgagg	tggtattaca	ttattcctaa	taatagggat	1260
aatgctgttt	attgtcaaga	aaaagtaaaa	tcgttctctt	caattaatgg	cccttttatt	1320
ttgggaccag	gctttttatt	tccctgatat	tatttctatt	taatactctt	ttctctcaag	1380
aaaaaaaaaa	aagtttggtt	tttctttatt	gtccttcata	gcaggccaag	tattgcctct	1440
ctgcaataga	cagctactgt	caatacatgc	tgtaatttga	cattctgggt	cacagatata	1500
aggtatttta	aatctattta	tgctttatag	agaaaccaga	cattaaaact	tcatgcacta	1560
cttatttcga	attactgtac	cttatccaaa	tttacaccta	gctattagga	tcttcaaccc	1620
aggtaacagg	aataattctg	tggtttcatt	tttctgtaaa	caactgaaag	aataattaga	1680
tcatattcta	gtatgttctg	aaatatcttt	aagactgata	ttaaaaacta	acttctaaga	1740
tgatttcatc	ttctcatagt	atagagttaa	ctttgtacac	ggtgaaacca	actactgtag	1800
aagatgagga	atctattgta	attttttgct	ttattttcat	ctgccagtgg	acttatttga	1860
attttcactt	tagtcaaatt	attttttgta	ttagtttttg	atgcagacat	aaaaatagca	1920
atcattttta	attgtcaaaa	ttccagatt	actggtaaaa	attatttgaa	aacaaaacta	1980
tggtgaataa	aggctagtca	gaaccctata	ccataaagtg	tagttaccat	acagattaat	2040
atgtagcaaa	aatgtatgct	tgatatttct	caactgtgtt	aatttttctg	ctgtattcca	2100
gctgaccaa	acaatattaa	gaatgcatct	ttataaatgg	gtgctaattg	ataatggaaa	2160
taatttagta	atggactata	caggatgtta	ataatgaagc	catatgttta	tgtctggatt	2220
taaaaatttt	aaacaatcat	ttactatgtc	atttttcttt	accttgaaga	acataaactg	2280
ttatttcact	tctacaaatc	agcaagatat	tattttatgg	aagaaatatt	ccattgaaat	2340
attgtgctgt	aactatggga	agtgtaaatg	ttttcatgg	tttctatcaa	tgtgaaataa	2400
aatttaattc	tgaaaaa					2417

&lt;210&gt; 15

&lt;211&gt; 1192

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1) .. (1192)

&lt;223&gt; The sequence of the cDNA coding for Human Lysophospholipase Homolog

&lt;400&gt; 15

ccagcccgaa	aggcagggtc	tgggtgcggg	aagagggctc	ggagctgcct	tcctgctgcc	60
ttggggccgc	ccagatgagg	gaacagcccg	atttgcctgg	ttctgattct	ccaggctgtc	120
gtggttgtgg	aatgcaaacg	ccagcacata	atggaaacag	gacctgaaga	cccttccagc	180
atgccagagg	aaagttcccc	caggcggacc	ccgcagagca	ttccctacca	ggacctccct	240
cacctgggtca	atgcagacgg	acagtacctc	ttctgcaggt	actggaaacc	cacaggcaca	300
cccaaggccc	tcatctttgt	gtcccatgga	gccggagagc	acagtggccg	ctatgaagag	360
ctggctcgga	tgctgatggg	gctggacctg	ctgggtttcg	cccacgacca	tggtggccac	420
ggacagagcg	aaggggagag	gatggtagtg	tctgacttcc	acgttttcgt	cagggatgtg	480
ttgcagcatg	tggattccat	gcagaaagac	taccctgggc	ttcctgtctt	ccttctgggc	540
cactccatgg	gaggcgccat	cgccatcctc	acggccgcag	agaggccggg	ccacttcgcc	600
ggcatggtac	tcatttcgcc	tctggttctt	gccaatcctg	aatctgcaac	aactttcaag	660
gtccttgctg	cgaaagtgtc	caaccttggt	ctgccaaaact	tgccctcggg	gcccacgcac	720
tccagcgtgc	tctctcgga	taagacagag	gtcgacattt	ataactcaga	ccccctgatc	780
tgccgggcag	ggctgaaggt	gtgcttcggc	atccaaactgc	tgaatgccgt	ctcacgggtg	840
gagcgcgccc	tccccaaagct	gactgtgccc	ttcctgctgc	tccagggctc	tgccgatcgc	900
ctatgtgaca	gcaaaggggc	ctacctgtc	atggagttag	ccaagagcca	ggacaagact	960
ctcaagattt	atgaaggtgc	ctaccatgtt	ctccacaagg	agcttcctga	agtcaccaac	1020
tccgtcttcc	atgaaataaa	catgtgggtc	tctcaaagga	cagccacggc	aggaactgcg	1080
tccccaccct	gaatgcattg	gccggtgccc	ggctcatggg	ctgggggatg	caggcagggg	1140
aagggcagag	atggcttctc	agatatggct	tgcaaaaaaa	aaaaaaaaaa	aa	1192

&lt;210&gt; 16

&lt;211&gt; 2333

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1) .. (2333)

&lt;223&gt; The sequence of the cDNA coding for N-acylsphingosine amidohydrolase

&lt;400&gt; 16

ggcacgaggc	tagagcgatg	ccggggccgga	gttgcgtcgc	cttagtcctc	ctggctgccg	60
ccgtcagctg	tgccgtcgcg	cagcacgcgc	cgccgtggac	agaggactgc	agaaaaatcaa	120
cctatcctcc	ttcaggacca	acgtacagag	gtgcagttcc	atggtacacc	ataaatcttg	180
acttaccacc	ctacaaaaga	tggcatgaat	tgatgcttga	caaggcacca	atgctaaagg	240

ttatagtga	ttctctgaag	aatatgataa	atacattcgt	gccaaagtga	aaagttatgc	300
aggtgggtga	tgaaaaattg	cctggcctac	ttggcgaactt	tcctggccct	tttgaagagg	360
aaatgaagg	tattgcccgt	gttactgata	tacctttagg	agagattatt	tcattcaata	420
ttttttatga	attatttacc	atttgtactt	caatagtagc	agaagacaaa	aaagggtcatc	480
taatacatgg	gagaaacatg	gattttggag	tatttcttgg	gtggaacata	aataatgata	540
cctgggtcat	aactgagcaa	ctaaaacctt	taacagtga	tttggatttc	caaagaaaca	600
acaaaactgt	cttcaaggct	tcaagctttg	ctggctatgt	gggcatgtta	acaggattca	660
aaccaggact	gttcagtcct	acactgaatg	aacgtttcag	tataaatggg	ggttatctgg	720
gtattctaga	atggattctg	ggaaagaaag	atgccatgtg	gatagggttc	ctcactagaa	780
cagttctgga	aaatagcaca	agttatgaag	aagccaagaa	tttattgacc	aagaccaaga	840
tattggcccc	agcctacttt	atcctgggag	gcaaccagtc	tggggaaggt	tgtgtgatta	900
cacgagacag	aaaggaatca	ttggatgtat	atgaactcga	tgctaagcag	ggtagatggt	960
atgtggtaca	aacaaattat	gaccgttgga	aacatccctt	cttccttgat	gatcgagaa	1020
cgctgcaaaa	gatgtgtctg	aaccgcacca	gccaaagaga	tatctcattt	gaaaccatgt	1080
atgatgtcct	gtcaacaaaa	cctgtcctca	acaagctgac	cgtatacaca	accttgatag	1140
atgttaccac	aggccaattc	gaaacttacc	tgccgggactg	ccctgaccct	tgtatagggt	1200
ggtagagaca	cgtctggcct	acagaatgag	gcctctgaga	catgaagaca	ccatctccat	1260
gtgaccgaac	actgcagctg	tctgaccttc	caaagactaa	gactcgcggc	aggttctctt	1320
tgagtcaata	gcttgtcttc	gtccatctgt	tgacaaatga	cagatctttt	tttttttccc	1380
cctatcagtt	gatttttctt	atttacagat	aacttcttta	ggggaagtaa	aacagtcac	1440
tagaattcac	tgagttttgt	ttcactttga	catttgggga	tctggtgggc	agtcgaacca	1500
tggtgaactc	cacctccgtg	gaataaatgg	agattcagcg	tgggtgttga	atccagcacg	1560
tctgtgtgag	taacgggaca	gtaaacactc	cacattcttc	agtttttcac	ttctacctac	1620
atatttgtat	gtttttctgt	ataacagcct	tttccttctg	gttctaactg	ctgttaaaat	1680
taatatatca	ttatctttgc	tgttattgac	agcgatatta	ttttattaca	tatcattaga	1740
gggatgagac	agacattcac	ctgtatatatt	cttttaatgg	gcacaaaatg	ggcccttgcc	1800
tctaaatagc	actttttggg	gttcaagaag	taatcagtat	gcaaagcaat	cttttataca	1860
ataattgaag	tgttcccttt	ttcataatta	ctctacttcc	cagtaaccct	aagggaagtg	1920
ctaacttaaa	aaactgcac	ccacgttctg	ttaatttagt	aaataaaca	gtcaaagact	1980
tgtggaaaat	aggaagtga	cccatatttt	aaattctcat	aagtagcatt	gatgtaataa	2040
acagggtttt	agtttgttct	tcagattgat	agggagtttt	aaagaaattt	tagtagttac	2100
taaaattatg	ttactgtatt	tttcagaaat	caaactgctt	atgaaaagta	ctaatagaac	2160
ttgttaacct	ttctaacctt	cacgattaac	tgtgaaatgt	acgtcatttg	tgcaagaccg	2220
tttgtccact	tcattttgta	taatcacagt	tgtgttcctg	acactcaata	aacagtcact	2280
ggaaagagtg	ccagtcagca	gtcatgcacg	ctgataaaaa	aaaaaaaaaa	aaa	2333

&lt;210&gt; 17

&lt;211&gt; 1016

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1016)

&lt;223&gt; The sequence of the cDNA coding for Phospholipase A2

&lt;400&gt; 17

atggatacca	atgttccgac	tggagacggg	gagccccgga	gacccgggtc	tccaggggtct	60
gcccaggaa	gttgctcatg	ggagcagacc	cctagagcag	gatttgaggc	caggccaaag	120
agaaccccag	agatgaaagg	cctcctccca	ctggcttggg	tcctggcttg	tagtgtgcct	180
gctgtgcaag	gaggcttgct	ggacctaaaa	tcaatgatcg	agaagggtgac	agggaagaac	240
gccctgacaa	actacggctt	ctacggctgt	tactgcccgt	ggggcgcccg	aggaaacccc	300
aaggatggca	ccgattgggtg	ctgttggggc	catgaccact	gctatggggc	gctggaggag	360
aagggtcgca	acattcgcac	acagtcctac	aaatacagat	tcgcgtgggg	cgtggtcacc	420

tgcgagcccc	ggcccttctg	ccatgtgaac	ctctgtgcct	gtgaccggaa	gctcgtctac	480
tgccctcaaga	gaaacctacg	gagctacaac	ccacagtacc	aatactttcc	caacatcctc	540
tgctcctagg	cctccccagc	gagctcctcc	cagaccaaga	cttttggtct	gtttttctac	600
aacacagagt	actgactctg	cctggttcct	gagagaggct	cctaagtcac	agacctcagt	660
ctttctcgaa	gcttggcgga	ccccagggc	cacactgtac	cctccagcga	gtcccaggag	720
agtgactctg	gtcataggac	ttggtagggt	cccagggtcc	ctaggcctcc	acttctgagg	780
gcagccccctc	tggtgccaa	agctctcctc	caactcaggg	ttggctgtgt	ctcttttctt	840
ctctgaagac	agcgtcctgg	ctccagttgg	aacactttcc	tgagatgcac	ttactttctca	900
gcttctgcga	tcagattatc	atcaccacca	ccctccagag	aattttacgc	aagaagagcc	960
aaattgactc	tctaaatctg	gtgtatgggt	attaaataaa	attcattctc	aagget	1016

&lt;210&gt; 18

&lt;211&gt; 3609

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(3609)

&lt;223&gt; The sequence of the cDNA coding for Phospholipase D1 (phosphatidylcholine specific)

&lt;400&gt; 18

ggcagcagga	gccctgagag	tccgccgcca	acgcgcaggt	gctagcggcc	ccttcgcctt	60
gcagcccctt	tgcttttact	ctgtccaaag	ttaacatgtc	actgaaaaac	gagccacggg	120
taaaatacctc	tgactgagag	aaaattgctg	ctgacatgag	taatatcata	gaaaatctgg	180
acacgcggga	actccacttt	gagggagagg	aggtagacta	cgacgtgtct	cccagcgatc	240
ccaagataca	agaagtgtat	atccctttct	ctgctattta	taacactcaa	ggattttaagg	300
agcctaatat	acagacgtat	ctctccggtc	gtccaataaa	agcacaagtt	ctggaagtgg	360
aacgcttcac	atctacaaca	agggtaccaa	gtattaatct	ttacactatt	gaattaacac	420
atgggggaatt	taaatggcaa	gttaagagga	aattcaagca	ttttcaagaa	tttcacagag	480
agctgctcaa	gtacaaagcc	tttatccgca	tccccattcc	cactagaaga	cacacgttta	540
ggaggcaaaa	cgtcagagag	gagcctcgag	agatgccccag	tttgccccgt	tcatctgaaa	600
acatgataag	agaagaacaa	ttccttggtg	gaagaaaaca	actggaagat	tacttgacaa	660
agatactaaa	aatgcccatg	tatagaaact	atcatgccac	aacagagttt	cttgatataa	720
gccagctgtc	tttcatccat	gatttgggac	caaagggcat	agaaggtatg	ataatgaaaa	780
gatctggagg	acacagaata	ccaggcttga	attgctgtgg	tcagggaaga	gcctgtctaca	840
gatggtcaaa	aagatggtta	atagtgaag	attccttttt	attgtatatg	aaaccagaca	900
gcggtgccat	tgcttcgctc	ctgctggtag	acaaagaatt	caaaattaag	gtggggaaga	960
aggagacaga	aacgaaatat	ggaatccgaa	ttgataatct	ttcaaggaca	cttattttta	1020
aatgcaacag	ctatagacat	gctcggtggt	ggggaggggc	tatagaagaa	ttcatccaga	1080
aacatggcac	caactttctc	aaagatcatc	gatttgggtc	atatgctgct	atccaagaga	1140
atgcttttagc	taaatggtat	gttaatgcca	aaggatattt	tgaagatgtg	gcaaatgcaa	1200
tggaagaggc	aaatgaagag	atttttatca	cagactgggtg	gctgagtcca	gaaatcttcc	1260
tgaaacgccc	agtggttgag	ggaaatcggt	ggagggttga	ctgcattctt	aaacgaaaag	1320
cacaacaagg	agtgaggatc	ttcataatgc	tctacaaaga	ggtggaactc	gctcttgcca	1380
tcaatagtga	atacaccaag	aggactttga	tgcgtctaca	tcccaacata	aaggtgatga	1440
gacacccgga	tcatgtgtca	tccaccgtct	atttgtgggc	tcaccatgag	aagcttgtca	1500
tcattgacca	atcggtggcc	tttgtgggag	ggattgacct	ggcctatgga	aggtgggacg	1560
acaatgagca	cagactcaca	gacgtgggca	gtgtgaagcg	ggtcacttca	ggaccgtctc	1620
tgggttcctc	cccactgccc	gcaatggagt	ctatggaatc	cttaagactc	aaagataaaa	1680
atgagcctgt	tcaaaaacct	ccatccaga	agagtattga	tgatgtggat	tcaaaactga	1740
aaggaatagg	aaagccaaga	aagttctcca	aatttagtct	ctacaagcag	ctccacaggc	1800
accacctgca	cgacgcagat	agcatcagca	gcattgacag	cacctccagt	tatttttaac	1860



actatagaag	tcatcacaat	ttaatccatg	gtttaaaacc	ccacttcaaa	ctctttcacc	1920
cgccagtgga	gtctgagcaa	ggactcacta	gacctcatgc	tgataccggg	tccatccgta	1980
gtttacagac	aggtgtggga	gagctgcatg	gggaaaccag	attctggcat	ggaaaggact	2040
actgcaattt	cgtcttcaaa	gactgggttc	aacttgataa	accttttgct	gatttcattg	2100
acaggtactc	cacgcccggg	atgccctggc	atgacattgc	ctctgcagtc	cacgggaagg	2160
cggctcgtga	tgtggcacgt	cacttcatcc	agcgctggaa	cttcacaaaa	attatgaaat	2220
caaaatatcg	gtccctttct	tatccttttc	tgcttccaaa	gtctcaaaaca	acagcccatg	2280
agttgagata	tcaagtgcct	gggtctgtcc	atgctaacgt	acagttgctc	cgctctgctg	2340
ctgattggtc	tgctggtata	aagtaccatg	aagagtccat	ccacgccgct	tacgtccatg	2400
tgatagagaa	cagcaggcac	tatatctata	tcgaaaacca	gtttttcata	agctgtgctg	2460
atgacaaaag	tgtgttcaac	aagataggcg	atgccattgc	ccagaggatc	ctgaaagctc	2520
acagggaaaa	ccagaaatac	cgggtatatg	tcgatgatac	acttctgcca	gggttcgaag	2580
gagacatttc	aaccggcgga	ggaaatgctc	tacaggcaat	catgcacttc	aactacagaa	2640
ccatgtgcag	aggagaaaaat	tccatccttg	gacagttaaa	agcagagctt	ggtaatcagt	2700
ggataaatta	catatcattc	tgtggtctta	gaacacatgc	agagctcgaa	ggaaacctag	2760
taactgagct	tatctatgtc	cacagcaagt	tgtaattgct	tgatgataac	actgttatta	2820
ttggctctgc	caacataaat	gaccgcagca	tgctgggaaa	gcgtgacagt	gaaatggctg	2880
tcatgttgca	agatacagag	actgttcctt	cagtaatgga	tggaaaagag	taccaagctg	2940
gccggtttgc	ccgaggactt	cggctacagt	gctttagggt	tgtccttggc	tatcttgatg	3000
acccaagtga	ggacattcag	gatccagtga	gtgacaaatt	cttcaaggag	gtgtgggttt	3060
caacagcagc	tcgaaatgct	acaatttatg	acaagggttt	ccggtgcctt	cccaatgatg	3120
aagtacacaa	tttaattcag	ctgagagact	ttataaacia	gccgtatta	gctaagggaag	3180
atcccattcg	agctgaggag	gaactgaaga	agatccgtgg	atttttgggtg	caattcccct	3240
tttattttct	gtctgaagaa	agcctactgc	cttctgttgg	gaccaaagag	gccatagtgc	3300
ccatggagggt	ttggacttaa	gagatattca	ttggcagctc	aaagacttcc	accctggaga	3360
ccacactgca	cacagtgact	tcctggggat	gtcatagcca	aagccaggcc	tgacgcattc	3420
tcgtatccaa	cccaaggacc	ttttggaatg	actggggagg	gctgcagtca	cattgatgta	3480
aggactgtaa	acatcagcaa	gactttataa	ttccttctgc	ctaacttgta	aaaagggggc	3540
tgcatctctg	ttggtagcat	gtactctgtt	gagtaaaaca	catattcaaa	ttccgctcgt	3600
gccgaattc						3609

&lt;210&gt; 19

&lt;211&gt; 2893

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(2893)

&lt;223&gt; The sequence of the cDNA coding for Phospholipase D1 glycosylphosphatidylinositol specific

&lt;400&gt; 19

cgctcattaga	ggagccgggtg	gggaatgaga	gcatgtctgc	tttcaggttg	tggccccggcc	60
tgctgatgat	cgtgatggct	tctctctgcc	atagagggtc	atcgtgtggc	ctttcaacgc	120
acatagaaat	cggacacaga	gctctggagt	ttcttcatct	tcacaatggg	catgttaact	180
acaagagagt	gttactagaa	caccaggatg	catatcaggc	tggaaaccgtg	tttcctgatt	240
gtttttaccc	tagcctctgc	aaaggaggaa	aattccatga	tgtgtctgag	agcactcact	300
ggactccggt	tcttaacgca	agcggttcatt	atatccgaga	gaactatccc	cttcctggg	360
agaaggacac	agagaaactg	gtagctttct	tgtttggaat	tacttctcat	atggtagcag	420
atgtcagctg	gcatagtctg	ggcattgaac	aaggattcct	taggaccatg	ggagctattg	480
attttcacgg	ctcctattct	gaggctcatt	cagctgggtga	ttttggagga	gatgtgttga	540
gccagtttga	atttaatttt	aattaccttg	cacgacgctg	gtatgtgcca	gtcaaagatc	600
tgctgggaat	ttatgagaaa	ctctatggtc	gagaagtcac	cactgaaaat	gtaattgttg	660

attgttcaca	tatccagttc	ttagaaatgt	atggtgagat	gctagctggt	tccaagttat	720
atccctctta	ctctacaaag	tccccgtttt	tgggtggaaca	attccaagag	tattttcttg	780
gaggactgga	tgatatggcg	ttttggtcca	ctaataattta	ccatctaacg	agcttcatgt	840
tggagaatgg	gaccagtgac	tgcagcctac	ctgagaaccc	tctgttcatt	gcatgtggtg	900
gccagcaaaa	ccacaccag	ggctcgaaaa	tgcagaaaaa	tgattttcac	agaaatttga	960
cttcatccct	aactgaaaac	attgacagga	atataaaacta	taccgaaaga	ggagtgttct	1020
tcagtgtaaa	ttcctggacc	ccggattcca	tgctctttat	ctacaaggct	ttggaaagga	1080
acgtaaggac	aatgttcata	ggtggctctc	agtgtgcaca	gaagcacatc	tctagcccct	1140
tagcatctta	cttcttgta	tttcttatg	caaggcttgg	ctgggcaatg	acctcagctg	1200
acctcaacca	ggatgggtac	ggcgacctcg	tgggtggcgc	accaggctac	agccgcccgtg	1260
gccgcatcca	catcgggcgc	gtgtacctca	tctacggcaa	tgaactgggt	ctgccgcccg	1320
ttgacctgga	cctggacaag	gaggcccacg	ggatccttga	aggtttccag	ccctcaggtc	1380
ggtttggctc	ggccttggct	atgttggact	ttaacatgga	tggcgtgcct	gacctggccg	1440
tgggagctcc	ctcgttgggc	tctgagcagc	tcacctacaa	aggtgctgtg	tatgtctact	1500
ttggttccaa	acaaggaaaga	atgtcttctt	cccctaacat	caccatctct	tgccaggaca	1560
tctactgtaa	cttgggctgg	actctcttgg	ctgcagatgt	gaatggagac	agtgagcccg	1620
atctgggtcat	tggctcccct	tttgcaccag	gtggagggaa	gcagaaggga	attgtggctg	1680
cgtttttattc	tggccccagc	ctgagcaaca	aagagaaact	gaacgtggag	gcggccaact	1740
ggacggtgag	aggcgaggaa	gactttgcct	ggtttggata	ctcccttcac	ggtgtcactg	1800
tggacaacag	aaccttgctg	ctggttggga	gcccgcacctg	gaagaatgcc	agcaggettg	1860
gccgtttgtt	acacatccga	gatgagaaaa	agagccttgg	gaggggtgat	ggctacttcc	1920
caccaaacag	ccaaagctgg	tttaccattg	ttggagacaa	ggcaatgggg	aaactgggta	1980
cttccctgtc	cagtggccac	gtgctgatga	atggaactct	gacccagggtg	ctgctgggtg	2040
gagccccgac	acgtgatgat	gtgtctaaga	tggcattcct	gacctgacc	ctgcaccaag	2100
gcggagccac	tcggatgtac	gcgctcacat	ccgacctgca	gccaccgctg	ctcagcacct	2160
tcagcggaga	ccgccgcttc	tctcgatttg	gtggcgttct	gcacttgagt	gacctggatg	2220
atgatggcgt	agatgaaatc	atcgtggcag	ccccctgag	gatagcagat	gtaacctctg	2280
ggctgattgg	gggagaagat	ggccgagttt	atgtatataa	tggcaaagag	accacccttg	2340
gtgacatgac	tggcaaatgc	aaatcgtgga	tgactccatg	tccagaagaa	aaggccaat	2400
atgtattgat	ttctcctgaa	gccagctcaa	ggtttgggag	ctccctgatc	accgtgaggt	2460
ccaaggcaaa	gaatcaagtc	gtcattgccg	ctggaaggag	ctctttggga	gcccgactct	2520
ccggggcact	tcacgtctat	agctttggct	cagattgaag	atttcaactgc	gtttccccac	2580
tctgcccacc	tctctcatgc	tgaatcacat	ccatggtgag	cattttgatg	gacaaaatgg	2640
cacatccagt	ggagctgtgg	cagatcctaa	tagatgtggg	gctcctggga	gtagagacac	2700
acaccaacag	ccaccctttc	tggaaatctg	atatagtata	tatatgactg	caccaggagt	2760
atgtgaaata	tcagacacac	tctgtctatt	catgtctcct	tccacagttt	atttctctgc	2820
ttcctttgca	tctaaacctt	tcttctttcc	gaactttttg	cctatagtca	gacctgctgt	2880
accacctatt	tcc					2893

&lt;210&gt; 20

&lt;211&gt; 1362

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1) .. (1362)

&lt;223&gt; The sequence of the cDNA coding for Phosphatidic Acid Phosphatase type 2B

&lt;400&gt; 20

ggcgagctc	tgcaaaagtt	tctgctcggg	atctggctct	cttccccctg	gactttagaa	60
cgatttaggg	ttgacagagg	aaagcagagg	cgcgaggagg	gagcagaaaa	caccaccttc	120
tgcagttgga	ggcaggcagc	cccggctgca	ctctagccgc	cgcgcccggg	gccggggccg	180
accgcgcact	atccgcagca	gcctcggcca	ggaggcgacc	cgggcgcctg	ggtgtgtggc	240

```

tgctgttgcg ggacgtcttc gggggcggg aggctcgcgc cgcagccagc gccatgcaaa 300
actacaagta cgacaaagcg atcgtcccgg agagcaagaa cggcggcagc ccggcgctca 360
acaacaaccc gaggaggagc ggcagcaagc ggggtgctgt catctgcctc gacctcttct 420
gcctcttcat ggcgggcctc cccttcctca tcatcgagac aagcaccatc aagccttacc 480
accgagggtt ttactgcaat gatgagagca tcaagtaccc actgaaaact ggtgagacaa 540
taaagtacgc tgtgctctgt gccgtgggga tcgtcattgc catcctcgcg atcatcacgg 600
gggaattcta ccgatctat tacctgaaga agtcgcggtc gacgattcag aaccctacg 660
tggcagcact ctataagcaa gtgggctgct tcctctttgg ctgtgccatc agccagtctt 720
tcacagacat tgccaaagtg tccatagggc gcctgcgtcc tcacttcttg agtgtctgca 780
accctgattt cagccagatc aactgctctg aaggetacat tcagaactac agatgcagag 840
gtgatgacag caaagtcag gaagccagga agtccttctt ctctggccat gcctccttct 900
ccatgtacac tatgctgtat ttggtgctat acctgcaggc ccgcttcact tggcgaggag 960
cccgctgct ccggcccctc ctgcagttca ccttgatcat gatggccttc tacacgggac 1020
tgtctcgcgt atcagaccac aagcaccatc ccagtgatgt tctggcagga tttgctcaag 1080
gagccctggt ggcctgctgc atagttttct tcgtgtctga cctcttcaag actaagacga 1140
cgctctccct gcctgcccct gctatccgga aggaaatcct ttcacctgtg gacattattg 1200
acaggaaaca tcaccacaac atgatgtagg tgccaccac ctctgagct gtttttgtaa 1260
aatgactgct gacagcaagt tcttgctgct ctccaatctc atcagacagt agaattgtagg 1320
gaaaaacttt tgcccagctg atttttaaaa aaaaaaaaaa aa 1362

```

&lt;210&gt; 21

&lt;211&gt; 1043

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1043)

&lt;223&gt; The sequence of the cDNA coding for Phosphatidic Acid Phosphatase type 2a

&lt;400&gt; 21

```

cccggcccgg gctcgagaat caagggcctc ggccgcgcgc ccgcagctca gtccatcgcc 60
cttgccgggc agcccgggca gagaccatgt ttgacaagac gcggtgccc tacgtggccc 120
tcgatgtgct ctgctgtgtg ctggctggat tgccttttgc aatttttact tcaaggcata 180
ttacttcaag gcatacccc ttccaacgag gagtattctg taatgatgag tccatcaagt 240
acccttaca aagaagacacc ataccttatg cgttattagg tggataatc attccattca 300
gtattatcgt tattattctt ggagaaaccc tgtctgttta ctgtaacctt ttgactcaa 360
attcctttat caggaataac tacatagcca ctatttaca agccattgga acctttttat 420
ttggtgcagc tgctagtcag tccctgactg acattgccaa gtattcaata ggcagactgc 480
ggcctcactt cttggatgtt tgtgatccag attgggtcaa aatcaactgc agcgatgggt 540
acattgaata ctacatatgt cgagggaatg cagaaagagt taaggaaggc aggttgtcct 600
tctattcagg ccactcttcg ttttccatgt actgcatgct gtttgtggca ctttatcttc 660
aagccaggat gaagggagac tgggcaagac tcttacgccc cacttgcaa tttggtcttg 720
ttgccgtatc ctttatgtg ggcctttctc gagtttctga ttataaacac cactggagcg 780
atgtgttgac tggactcatt cagggagctc tgggtgcaat attagttgct gtatatgtat 840
cggatttctt caaagaaaga acttctttta aagaaagaaa agaggaggac tctcatacaa 900
ctctgcatga aacaccaaca actgggaatc actatccgag caatcaccag ccttgaaagg 960
cagcagggtg ccaggtgaa gctggcctgt tttctaaagg aaaatgattg ccacaaggca 1020
agaggatgca tctttcttcc tgg 1043

```

&lt;210&gt; 22

&lt;211&gt; 5397

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(5397)

<223> The sequence of the cDNA coding for Phosphatidylinositol-3-Kinase  
(class 2, gamma polypeptide)

&lt;400&gt; 22

gaattcggca	cgagcacttc	cttctcggct	agattatctg	aaactgttgt	cggttcttga	60
gatgatacta	ccaccgaatg	tctgtgtttc	attgtctagt	ccaacctgta	ttgtggatat	120
ctacaacggt	ccggcaatag	ttttgcaggt	gcatcacatt	tttgtttttg	ttttgggagg	180
aaaagggagg	gcacggcagc	caggcttcat	attcctacaa	gtgcatgctt	caagattact	240
gtacttacag	tgtttccaac	atcttctcat	aaaaggggaa	agcttcatag	cctcaaccat	300
gaaggaaacc	agtcgcatag	ggcatggagc	tggagaacta	taaacagccc	gtggtgctga	360
gagaggacaa	ctgccgaagg	cgccggagga	tgaagccgcg	cagtgtgtcc	agcctgtcct	420
ccatggagct	catcccatc	gagttcgtgc	tgcccaccag	ccagcgcaaa	tgcaagagcc	480
ccgaaacggc	gctgtgcac	gtggccggcc	acggcaacgt	ggagcagatg	aaggcccagg	540
tgtggctgcg	agcgtggag	accagcgtgg	cgccggactt	ctaccaccgg	ctgggaccgc	600
atcacttcct	ctgtctctat	cagaagaagg	ggcagtggtg	cgagatctac	gacaagtacc	660
agggtgtgca	gactctggac	tgcttgcgtc	actggaaggc	cacgcaccgg	agcccgggcc	720
agatccacct	ggtgcagcgg	caccgcctct	ccgaggagtc	ccaagccttc	cagcggcagc	780
tcacggcgct	gattggctat	gacgtcactg	acgtcagcaa	cgtgcacgac	gatgagctgg	840
agttcacgcg	ccgtggcttg	gtgaccccg	gcatggcgga	ggtggccagc	cgcgacccca	900
agctctacgc	catgcacccg	tgggtgacgt	ccaagcccct	cccggagtag	ctgtggaaga	960
agattgcca	aatgcgcatc	ttcatcgta	ttcacgcgag	caccaccagc	cagaccatta	1020
aggtctcacc	cgacgcacac	cccgccgcca	tcctgcagag	cttcttcacc	aagatggcca	1080
agaagaaatc	tctgatggat	attcccga	gccaaagcga	acaggatttt	gtgctgcgcg	1140
tctgtggccg	ggatgagtac	ctggtggg	aaacgccc	caaaaacttc	cagtgggtga	1200
ggcactgcct	caagaacgga	gaagagattc	acgtggtact	ggacacgcct	ccagaccggg	1260
ccctagacga	ggtgaggaag	gaagagtggc	cgctgggtga	cgactgcacg	ggagtaccgg	1320
gctaccatga	gcagcttacc	atccacggca	aggaccacga	gagtgtgttc	accgtgtccc	1380
tgtgggactg	cgaccgcaag	ttcagggtca	agatcagagg	cattgatata	cccgtcctgc	1440
ctcggaacac	cgacctcaca	gtttttgtag	aggcaaacat	ccagcatggg	caacaagtcc	1500
tttgccaaag	gagaaccagc	cccaaaccct	tcacagagga	ggtgtgtgtg	aatgtgtggc	1560
ttgagttcag	tatcaaaatc	aaagacttgc	ccaaaggggc	tctactgaac	ctccagatct	1620
actgcggtaa	agctccagca	ctgtccagca	aggcctctgc	agagtcccc	agttctgagt	1680
ccaagggcaa	agttcggctt	ctctattatg	tgaacctgct	gctgatagac	caccgtttcc	1740
tcttgcgccc	tggagaatac	gtcctccaca	tgtggcagat	atctgggaag	ggagaagacc	1800
aaggaagctt	caatgctgac	aaactcacgt	ctgcaactaa	cccagacaag	gagaactcaa	1860
tgtccatctc	cattcttctg	gacaattact	gccacccgat	agccctgcct	aagcatcagc	1920
ccacccctga	cccgggaagg	gaccgggttc	gagcagaaat	gcccaccagg	cttcgcaagc	1980
aattggaggc	gatcatagcc	actgatccac	ttaaccctct	cacagcagag	gacaaagaat	2040
tgctctggca	ttttagatac	gaaagcctta	agcaccqaaa	agcatatact	aagctattta	2100
gttcagtga	atggggacag	caagaaattg	tggccaaaac	ataccaattg	ttggccagaa	2160
gggaagtctg	ggatcaaagt	gctttggatg	ttgggttaac	aatgcagctc	ctggactgca	2220
acttctcaga	tgaatgtgta	agagccattg	cagttcagaa	actggagagc	ttggaggacg	2280
atgatgttct	gcattacctt	ctacaattgg	tccaggctgt	gaaatttgaa	ccataccatg	2340
atagcgcctt	tgccagattt	ctgctgaagc	gtgggtttaag	aaacaaaaga	attggtcact	2400
ttttgttttg	tctcttgaga	agtgagatag	cccgatccag	acactatcag	cagaggttcg	2460
ctgtgattct	ggaagcctat	ctgaggggct	gtggcacagc	catgctgcac	gactttaccc	2520
aacaagtcca	agtaatcgag	atgttacaaa	aagtcaccct	tgatattaaa	tcgctctctg	2580
ctgaaaagta	tgacgtcagt	tcccaagtta	tttcacaact	taaacaaaag	cttgaaaacc	2640
tgagaatttc	tcaactcccc	gaaagcttta	gagttccata	tgatcctgga	ctgaaagcag	2700

gagcgcctggc	aattgaaaaa	tgtaaagtaa	tggcctccaa	gaaaaaacca	ctatggcttg	2760
agtttaaatg	tgccgatcct	acagccctat	caaatagaac	aattggaatt	atctttaaac	2820
atgggtgatga	tctgcgcca	gacatgctta	ttttacagat	tctacgaatc	atggagtcta	2880
tttgggagac	tgaatctttg	gatctatgcc	tccctgccata	tggttgcat	tcaactggtg	2940
acaaaatagg	aatgatcgag	attgtgaaag	acgccacgac	aattgccaaa	attcagcaaa	3000
gcacagtggg	caacacggga	gcatttaaa	atgaagtcct	gaatcactgg	ctcaaagaaa	3060
aatcccctac	tgaagaaaag	tttcaggcag	cagtggagag	atttggttat	tcctgtgcag	3120
gtactgtgt	ggcaaccttt	gttcttgga	taggcgacag	acacaatgac	aatattatga	3180
tcaccgagac	aggaaaacct	tttcataattg	acttcgggca	cattcttggg	aattacaaaa	3240
gtttcctggg	cattaataaa	gagagagtgc	catttggtgc	aacccctgac	ttcctctttg	3300
tgatgggaac	ttctggaaa	aagacaagcc	cacacttcca	gaaatttcag	gacatctgtg	3360
ttaaggtcta	tctagccctt	cgtcatcaca	caaacctact	gatcatcctg	ttctccatga	3420
tgctgatgac	aggaaatgcc	cagttaacaa	gcaaagaaga	cattgaatat	atccgggatg	3480
ccctcacagt	ggggaaaaat	gaggaggatg	ctaaaaagta	ttttcttgat	cagatcgaag	3540
tttgacagaga	caaaggatgg	actgtgcagt	tttaattggt	tctacatctt	gttcttgga	3600
tcaacaagg	agagaaacat	tcagccta	actttaggct	agaatcaaaa	acaagttagt	3660
gttctatggt	ttaaatttagc	atagcaatca	tcgaacttgg	atttcaaatg	caatagacat	3720
tgtgaaagct	ggcatttcag	aagtatagct	cttttcctac	ctgaactctt	ccctggagaa	3780
aagatgttgg	cattgctgat	tggttggtta	agcaatgtcc	agtgttagga	ttatttgag	3840
gtttgggttt	ttctcatttg	tctgtggcag	tggagaatat	tctcggttta	aacagactaa	3900
tgacttcctt	attgtccctg	atattttgac	tatcttacta	ttgagtgcct	ctgggaaattc	3960
tttggaataa	ttgatgacat	ctattttcat	ctgggtttag	tctcaatttt	ggttatcttt	4020
gtgttcctca	agctctttaa	agaaaaagat	gtaatcgttg	taacctttgt	ctcattcctt	4080
aaatgatgct	tccaaacatc	tccttagtgt	ctgcaggtgt	tagtggtgtg	ctaaaagcaa	4140
ggaaagcgag	ttagtctttt	cagtgtcttt	tgcaattcaa	ttcttttgct	atgtataact	4200
gagacacaca	aacacagcag	gagaaatcta	aaccgttgtg	ccttgacctt	cctctgctgg	4260
tcttggtcca	gggttatgaa	tatgaaaaaa	tagagatgag	actttttgtg	tcaactctgt	4320
ccacaagagt	gagttatcta	gtatgattag	tatagctttc	tccagcatgg	cagcaggaag	4380
taactacagg	gcctctttta	tgctgacat	ttcttccctt	cctttttccc	tgctccctt	4440
tttcatcaat	tgcaatgctc	ccacaactct	ttacagactt	gtgaaatctt	caagaacacc	4500
tttactctat	aactcaaaaa	ttagttgaaa	aataattact	tctcaaggat	tattagaatc	4560
ttaggtactt	atttgtaaa	atgttttagtg	actttttttt	caagtatcta	taaaggaggc	4620
agattctaga	aaatatgaat	tagtttccaa	atgccttaat	tttaaaacttt	ggcctgaaca	4680
gttttttctt	tttcttaatg	gaagaagata	tttaatatct	taaaaatatt	ccaagttagg	4740
aagaacacta	cttgccctat	ccatttccca	tttaaaggac	ttttaaaactt	tgacacagtc	4800
cttcagattt	cctgaaaaatc	cttgaaatat	cttactttta	aaataattttc	atctctgaaa	4860
tatctcgtaa	tttattggag	gtattgttta	accttagata	gaccattaaa	ttattttataa	4920
aatattttgt	aattactgta	gctaatacat	tacatagaaa	aaactatgtt	aacagtgtct	4980
ctgtttaagt	ataatcagat	ataaatatat	aacttaattt	tttaatttta	aaaaatagat	5040
acctgtttga	ctttgaggta	gtccaggcct	ttttcttttt	tttttttttt	aatgtgtgca	5100
aaagcccaaa	ggttcctaag	cctggctgca	aagaagaatc	aacagggaca	ctttttaaaa	5160
acactcttat	cagcctgggg	caacacagtg	agactccatc	tcttaaaaaa	aaaattagct	5220
gggtatagt	gtatgtgcct	gtagtcccag	gtactcagga	ggctgaggca	ggaggattgc	5280
ctgagcccag	gaggtggaaa	ctgcagagag	tcgatgatcat	gtccttacac	tccagcctgg	5340
ataacagagc	gagaccctgt	ctcaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	actcgag	5397

&lt;210&gt; 23

&lt;211&gt; 3424

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1) .. (3424)

<223> The sequence of the cDNA coding for Phosphatidylinositol-3-kinase  
(catalytic, alpha polypeptide)

<400> 23

```

aggatcagaa caatgcctcc aagaccatca tcaggtgaac tgtggggcat ccacttgatg      60
cccccaagaa tcctagtggg atgtttacta ccaaattggaa tgatagtga c tttagaatgc      120
ctccgtgagg ctacattagt aactataaag catgaactat ttaaagaagc aagaaaatac      180
cctctccatc aacttcttca agatgaatct tcttacattt tcgtaagtgt tacccaagaa      240
gcagaaaggg aagaattttt tgatgaaaca agacgacttt gtgatcttcg gctttttcaa      300
ccatttttaa aagtaattga accagtaggc aaccgtgaag aaaagatcct caatcgagaa      360
attggttttg ctatcgggcat gccagtgtgc gaatttgata tggttaaaga tcctgaagta      420
caggacttcc gaagaaatat tcttaatgtt tgtaaagaag ctgtggatct tagggatctt      480
aattcacctc atagtagagc aatgtatgtc tatccgccac atgtagaatc ttcaccagag      540
ctgccaaagc acatatataa taaattggat agaggccaaa taatagtggg gatttgggta      600
atagtttctc caaataatga caagcagaag tatactctga aaatcaacca tgactgtgtg      660
ccagaacaag taattgtctg agcaatcagg aaaaaaacta gaagtatgtt gctatcatct      720
gaacaattaa aactctgtgt tttagaatat cagggcaagt acattttaaa agtgtgtgga      780
tgtgatgaat acttcctaga aaaatcctct ctgagtcagt ataagtatat aagaagctgt      840
ataatgcttg ggaggatgcc caatttgaag atgatggcta aagaaagcct ttattctcaa      900
ctgccaatgg actgttttac aatgccatct tattccagac gcatttccac agctacacca      960
tatatgaatg gagaacatc tacaaaaatc ctttgggtta taaatagagc actcagaata     1020
aaaattcttt gtgcaaccta cgtgaatcta aatattcgag acattgacaa gatttatgtt     1080
cgaacaggta tctaccatgg aggagaacct ttatgtgaca atgtgaacac tcaaagagta     1140
ccttgttcca atcccagggt gaatgaatgg ctgaattatg atatatacat tcctgatctt     1200
cctcgtgctg ctgcactttg cctttccatt tgctctgtta aaggccgaaa ggggtgctaaa     1260
gaggaacact gtccattggc atggggaaat ataaacttgt ttgattacac agacactcta     1320
gtatctggaa aaatggcttt gaatcctttg ccagtacctc atggattaga agatttgctg     1380
aaccctattg tgtttactgg atcaaatcca aataaagaaa ctccatgctt agagtggag     1440
tttgacttgt tcagcagtg ggtaaaagtt ccagatagt cagtattga agagcatgcc     1500
aattggctg tatcccgaga agcaggattt agctattccc acgcaggact gagtaacaga     1560
ctagctagag acaatgaatt aagggaaaat gacaaagaac agctcaaagc aatttctaca     1620
cgagatcctc tctctgaaat cactgagcag gagaaagatt ttctatggag tcacagacac     1680
tattgtgtaa ctatccccga aattctaccc aaattgcttc tgtctgttaa atggaattct     1740
agagatgaag tagccagat gtattgcttg gtaaaagatt ggcctccaat caaacctgaa     1800
caggctatgg aacttctgga ctgtaattac ccagatccta tggttcgagg ttttgctgtt     1860
cgggtcttgg aaaaaatatt aacagatgac aaactttctc agtatttaat tcagctagta     1920
caggctcctaa aatatgaaca atatttgat aacttgcttg tgagattttt actgaagaaa     1980
gcattgacta atcaaaggat tgggcacttt ttcttttggc atttaaaatc tgagatgcac     2040
aataaaacag ttagccagag gtttggcctg cttttggagt cctattgtcg tgcagtggg     2100
atgtatttga agcacctgaa taggcaagtc gaggcaatgg aaaagctcat taacttaact     2160
gacattctca aacaggagag gaaggatgaa acacaaaagg tacagatgaa gtttttagtt     2220
gagcaaatga ggcgaccaga tttcatggat gccctacagg gcttgctgtc tcctctaaac     2280
cctgctcatc aactaggaaa cctcaggctt aaagagtgtc gaattatgtc ttctgcaaaa     2340
aggccactgt ggttgaattg ggagaacca gacatcatgt cagagttact gtttcagaac     2400
aatgagatca tctttaaaaa tggggatgat ttacggcaag atatgctaac acttcaaatt     2460
attcgtatta tggaaaatat ctggcaaaat caaggtcttg atcttcgaat gttaccttat     2520
ggttgctctg caatcggtga ctgtgtggga cttattgagg tgggtcgaaa ttctcacact     2580
attatgcaaa ttcagtgcaa aggcggcttg aaaggtgcac tgcagttcaa cagccacaca     2640
ctacatcagt ggtcaaaga caagaacaaa ggagaaatat atgatgcagc cattgacctg     2700
tttacacgtt catgtgctgg atactgtgta gctaccttca ttttgggaat tggagatcgt     2760
cacaatagta acatcatggt gaaagacgat ggacaactgt ttcatataga ttttggacac     2820
tttttggatc acaagaagaa aaaatttggg tataaacgag aacgtgtgcc atttcttttg     2880
acacaggatt tcttaatagt gattagttaa ggagcccaag aatgcacaaa gacaagagaa     2940
tttgagaggt ttcaggagat gtgttacaag gcttatctag ctattcgaca gcatgccaat     3000
ctcttcataa atcttttctc aatgatgctt ggctctggaa tgccagaact acaatctttt     3060
gatgacattg catacattcg aaagacccta gccttagata aaactgagca agaggctttg     3120
gagtatttca tgaacaaaat gaatgatgca catcatggtg gctggacaac aaaaatggat     3180
tggactcttc acacaattaa acagcatgca ttgaactgaa agataactga gaaaatgaaa     3240
gtcactctg tcttccacac tgcactgta ataacttca gcaggcaaag accgattgca     3300
taggaattgc acaatccatg aacagcatta gatttcagc aagaacagaa ataaaatact     3360
atataattta aataatgtaa acgcaaacag ggtttgatag cacttaact agttcatttc     3420

```

aaaa

3424

&lt;210&gt; 24

&lt;211&gt; 1201

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1201)

&lt;223&gt; The sequence of the cDNA coding for Prostate Differentiation Factor PLAB

&lt;400&gt; 24

```

agtcccagct cagagccgca acctgcacag ccatgcccg gcaagaactc aggacgtga      60
atggctctca gatgctcctg gtgttgctgg tgctctogtg gctgccgat gggggcgccc      120
tgtctctggc cgaggcgagc cgcgcaagtt tcccgggacc ctgagagttg cacaccgaag      180
actccagatt ccgagagttg cggaaacgct acgaggacct gctaaccagg ctgcgggcca      240
accagagctg ggaagattcg aacaccgacc tcgtcccggc ccctgcagtc cggatactca      300
cgccagaagt gcggtggga tccggcgccc acctgcacct gcgtatctct cgggcccggc      360
ttcccgaggg gctccccgag gcctcccgcc ttcaccgggc tctgttccgg ctgtccccga      420
cggcgtaag gtctgtgggac gtgacacgac ctctgcggcg tcagctcagc cttgcaagac      480
cccaggcgcc cgcgctgcac ctgcgactgt cgccgcggcc gtcgcagtcg gaccaactgc      540
tggcagaatc ttcgtccgca cggccccagc tggagttgca cttgcggccg caagccgcca      600
gggggcgccg cagagcgcggt gcgcgcaacg gggaccactg tccgctcggg cccgggcggt      660
gctgcggtct gcacacggtc cgcgctgcgc tgggaagacct gggctggggc gattgggtgc      720
tgtgccacg ggaggtgcaa gtgacctatg gcacggcggc gtgcccagac cagttccggg      780
cggcaaacat gcacgcgcag atcaagacga gctgcaccg cctgaagccc gacacgggtg      840
cagcgccctg ctgctgccc gccagctaca atcccatggt gctcattcaa aagaccgaca      900
ccggggtgtc gctccagacc tatgatgact tgtagccaa agactgccac tgcataatgag      960
cagtcctggt ccttccactg tgcacctgcg cgggggaggg gacctcagtt gtcctgccct      1020
gtggaatggg ctcaaggttc ctgagacacc cgattcctgc ccaaacagct gtatttatat      1080
aagtctgtta tttattatta atttattggg gtgaccttct tggggactcg ggggctggtc      1140
tgatggaaact gtgtatttat ttaaaactct ggtgataaaa ataaagctgt ctgaactgtt      1200
c                                                                1201

```

&lt;210&gt; 25

&lt;211&gt; 1269

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1269)

&lt;223&gt; The sequence of the cDNA coding for Phosphatidic Acid Phosphatase type 2c

<400> 25  
 gcgacgggac ggcgtgggac cggcgtcggg ggtcgcgggg accatgcagc ggaggtgggt 60  
 cttcgtgctg ctcgacgtgc tgtgcttact ggtcgccctc ctgcccttcg ctatcctgac 120  
 gctggtgaac gccccgtaca agcagaggatt ttactgcggg gatgactcca tccggtaccc 180  
 ctaccgtcca gataccatca cccacgggct catggctggg gtcaccatca cggccaccgt 240  
 catccttgte tcggccgggg aagcctacct ggtgtacaca gaccggctct attctcgctc 300  
 ggacttcaac aactacgtgg ctgctgtata caaggtgctg gggaccttcc tgtttggggc 360  
 tgccgtgagc cagtctctga cagacctggc caagtaecat attgggcgctc tgaggcccaa 420  
 cttcctagcc gtctgcgacc ccgactggag ccgggtcaac tgctcggtct atgtgcagct 480  
 ggagaagggtg tgcaggggaa accctgctga tgtcaccgag gccaggttgt ctttctactc 540  
 gggacactct tcctttggga tgtactgcat ggtgttcttg gcgctgtatg tgcaggcacg 600  
 actctgttgg aagtgggcac ggctgctgag acccacagtc cagttcttcc tgggtggcctt 660  
 tgccctctac gtgggctaca cccgcgtgct tgattacaaa caccactgga gcgatgtcct 720  
 tgttggcctc ctgcaggggg cactggtggc tgccctcact gtctgctaca tctcagactt 780  
 cttcaaagcc cgacccccac agcactgtct gaaggaggag gagctggaac ggaagcccag 840  
 cctgtcactg acgttgaccc tgggcgaggc tgaccacaac cactatggat acccgactc 900  
 ctcctcctga ggcgggaccc cgcccaggca gggagctgct gtgagtccag ctgatgccc 960  
 cccaggtggt cctccagcc tggttaggca ctgaggggtc tggacgggct ccaggaaccc 1020  
 tgggctgatg ggcagctga gcggttcgc tgccccctgc cctgcactgg accaggagtc 1080  
 tggagatgcc tgggtagccc tcagcatttg gaggggaacc tgttcccgtc ggtccccaaa 1140  
 tatccccctt tttttatggg gttaaggaag ggaccgagag atcagatagt tgctgttttg 1200  
 taaaaatgtaa tgtatatgtg gtttttagta aaatagggca cctgtttcac aaaaaaaaaa 1260  
 aaaaaaaaaa 1269

<210> 26

<211> 1286

<212> DNA

<213> Homo sapiens

<220>

<221> gene

<222> (1)..(1286)

<223> The sequence of the cDNA coding for Phosphocholine cytidyltransfe  
 rase

<400> 26  
 cgaccggacc gggctcgggg gagcgtgagt tgcagttaaa agaagatgga tgcacagtgt 60  
 tcagccaagg tcaatgcaag gaagaggaga aaagaggcgc ccggacccaa cggggcaaca 120  
 gaagaagatg ggggttccttc caaagtgcag cgctgtgcag tgggcttacg gcaaccagct 180  
 cctttttctg atgaaattga agttgacttt agtaagccct atgtcagggt aactatggaa 240  
 gaagccagca gaggaactcc ttgtgagcga cctgtgagag tttatgccga tgggaatattt 300  
 gacttatctc actctggtca cgcccgagct ctgatgcaag cgaagaacct tttccctaatt 360  
 acgtacctca ttgtgggagt ttgcagtgat gagctcacac acaacttcaa aggcttcacg 420  
 gtgatgaacg agaatgagcg ctatgacgca gtccagcact gccgctacgt ggatgagggtg 480  
 gtgaggaatg cgccctggac gctgacaccc gagttcctgg ccgaacaccg gattgatttt 540  
 gtagcccatg atgatattcc ttattcatct gctggcagtg atgatgttta taagcacatc 600  
 aaggaggcag gcatgtttgc tccaacacag aggacagaag gtatctccac atcagacatc 660  
 atcacccgaa ttgtgcggga ttatgatgtg tatgcgaggc ggaacctgca gaggggctac 720  
 acagcaaagg agtcaatgt cagctttatc aacgagaaga aataccactt gcaggagagg 780  
 gttgacaaa agtaaggagaa agtgaaagat gtggaggaaa agtcaaaaga atttgttcag 840  
 aagggtggagg aaaaaagcat tgacctcatt cagaagtggg aggagaagtc ccgagaattc 900  
 attggaagtt ttctggaaat gtttggtccg gaaggagcac tgaaacatat gctgaaagag 960  
 gggaagggcc ggatgctgca ggccatcagc ccgaagcaga gccccagcag cagccctact 1020  
 cgcgagcgct cccctccccc ctctttccga tggcccttct ccggcaagac ttccccacct 1080



tgctccccag	caaattctctc	caggcacaag	gctgcagcct	atgatatcag	tgaggatgaa	1140
gaagactaat	gtttctctcc	tcctttctctg	tcctcccttt	ctgtcccatt	accttcagaa	1200
gctctctgtt	gaattccgaa	ttgtgacccc	aactactaac	ctaaggacag	ctacaaagga	1260
aagacaactg	gggaaagaag	acctag				1286

&lt;210&gt; 27

&lt;211&gt; 1856

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1856)

&lt;223&gt; The sequence of the cDNA coding for Phosphate cytidylyltransferase 2 (ethanolamine specific)

&lt;400&gt; 27

attgcgggcg	gcggcgttcg	gagtcgcccg	gagctgccag	gctgtccgcg	ccgccgctgc	60
ggggccatga	tccggaacgg	gcgcggggct	gcaggcgggc	cagagcagcc	gggcccgggg	120
ggcaggcgcg	ccgtgagggg	gtgggtcgat	ggctgctatg	acatgggtgca	ttacggccac	180
tccaaccagc	tgcgccaggc	acgggcccag	ggtgactacc	tcatcgtagg	cgtgcacacc	240
gatgaggaga	tcgccaagca	caaggggccc	ccggtgttca	ctcaggagga	gagatacaag	300
atggtgcagg	ccatcaaata	ggtggacgag	gtgggtgccag	cggctcccta	cgctactaca	360
ctagagaccc	tggacaaata	caactgtgac	ttctgtgttc	acggcaatga	catcaccctg	420
actgtagatg	gccgggacac	ctatgaggaa	gtaaagcagg	ctgggaggta	cagagaatgc	480
aagcgcacgc	aaggggtgtc	caccacagac	ctcgtgggcc	gcatgctgct	ggtaacccaa	540
gcccatacaca	gcagccagga	gatgtcctct	gagtaccggg	agtatgcaga	cagttttggc	600
aagtgccttg	gtgggcggaa	cccctggacc	ggggtatccc	agttcctgca	gacatctcag	660
aagatcatcc	agtttgcttc	tgggaaggag	ccccagccag	gggagacagt	catctatgtg	720
gctggtgcct	tcgacctgtt	ccacatcggt	catgtggact	tcctggagaa	ggtgcacagg	780
ctggcagaga	ggccctacat	catcgcgggc	ttacactttg	accaggaggt	caatcactac	840
aaggggaaga	actaccccat	catgaatctg	catgaacgga	ctctgagcgt	gctggcctgc	900
cggtacgtgt	cagaagtggg	gattggagcc	ccgtacgcgg	tcacagcaga	gctcctaagt	960
cacttcaagg	tggacctggg	gtgtcacggc	aagacagaaa	ttatccctga	cagggatggc	1020
tccgacccat	accaggagcc	caagagaagg	ggcatcttcc	gtcagattga	cagtggcagc	1080
aacctcacca	cagacctcat	cgtccagcgg	atcatcacca	acaggttgga	gtatgaggcg	1140
cgaaaccaga	agaagggaagc	caaggagctg	gccttccttg	aggctgccag	gcagcaggcg	1200
gcacagcccc	tgggggagcg	cgatggtgac	ttctaacctg	gcagaggccc	tggccggccc	1260
tccccctgct	ctgcttctgc	gccttctgcg	tttggaacata	ggactctgca	gggccgacct	1320
ctctaactgg	cctggctctg	gaagggtctg	tgaggactct	gcctccttgc	ctgcctacaa	1380
ggtgcctggg	ttgcagcagg	ctctccgctc	tttcagcaa	agctgctcag	agagggtgtc	1440
cagcacagtg	gagaggccgg	aagtgcagcg	ggcagacggc	acctgcagcc	tgaacgcac	1500
cgctcctgcg	tgcgccccca	cctgggtccc	ggatgcccc	accacctgga	cagaggccac	1560
actgactgcc	caccagctg	tggcgggagg	tcagagcag	ggggctttag	ggagcagtga	1620
ctgcggtcac	ccctttagtt	ctctgggtgt	agaccacacc	acctccact	gggcaccccc	1680
caacacggtg	tcctgccacc	cagcgcttg	ctccaggaaa	acacgcttgc	cttcttccc	1740
ggcagcttcg	ccactctct	tatggactct	gttctgtttg	tacatggctg	acggaaatct	1800
ctttggtaca	accgaataaa	gcctgggtggc	agtgtctgct	ggggctccca	gccaat	1856

&lt;210&gt; 28

&lt;211&gt; 3160

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1) .. (3160)

&lt;223&gt; The sequence of the cDNA coding for Phosphatase and Tenson Homolog (PTEN)

&lt;400&gt; 28

```

cctccccctcg cccggcgcggg tcccgtccgc ctctcgctcg cctcccgccct cccctcggtc      60
ttccgagggcg cccgggctcc cggcgcgggcg gcgagggggg cgggcaggcc ggccggcggt      120
gatgtggcag gactctttat gcgctgcggc aggatacgcg ctccggcgctg ggacgcgact      180
gcgctcagtt ctctcctctc ggaagctgca gccatgatgg aagtttgaga gttgagccgc      240
tgtgaggcga ggccgggctc aggcgaggga gatgagagac ggccggcgcc gcggcccgga      300
ccccctctca cgcctgtga gcagccgagg gggcagcgcc ctccggggagc cggccggcct      360
gcggcgggcg cagcggcgcc gtttctcgcc tctctctcgt cttttctaac cgtgcagcct      420
cttctcgggc ttctcctgaa aggaaggtg gaagcgtgg gctcggggcg gagccggctg      480
aggcgcgggcg gcggcgggcg cggcacctcc cgctcctgga gcggggggga gaagcgggcg      540
cggcgggcggc cgcggcggtc gcagctccag ggagggggtc tgagtcgcct gtcaccattt      600
ccaggggctgg gaacgcggga gagttggtct ctccccctct actgcctcca acacggcggc      660
ggcgggcgggc gcacatccag ggaccggggc cggtttttaa cctcccgctc gccgcccgcg      720
caccccccctg ggcccgggct cgggagggcg cggcgggagg cagocgttcg gaggattatt      780
cgtctttctcc ccattccgct gcgcgcgctg ccaggcctct ggctgctgag gagaagcagg      840
ccagtgctgt ccaaccatcc agcagccgcc gcagcagcca ttaccggct gcggtccaga      900
gccaagcggc ggagagcgga ggggcatcag ctaccgccaa gtccagagcc atttccatcc      960
tgcagaagaa gccccgccac cagcagcttc tgccatctct ctctccttt ttcttcagcc      1020
acaggctccc agacatgaca gccatcatca aagagatcgt tagcagaaac aaaaggagat      1080
atcaagagga tggattcgac ttagacttga cctatattta tccaaacatt attgctatgg      1140
gatttcctgc agaaagactt gaaggcgtat acaggaacaa tattgatgat gtagtaagg      1200
ttttggattc aaagcataaa aaccattaca agatatacaa tctttgtgct gaaagacatt      1260
atgacacgcg caaatttaat tgcagagttg cacaatatcc ttttgaagac cataaccac      1320
cacagctaga acttatcaaa cccttttgtg aagatcttga ccaatggcta agtgaagatg      1380
acaatcatgt tgcagcaatt cactgtaaag ctggaaaggg acgaactggg gtaatgatat      1440
gtgcatattt attacatcgg ggcaaatttt taaaggcaca agaggcccta gatttctatg      1500
gggaagtaag gaccagagac aaaaaggagg taactattcc cagtcagagg cgctatgtgt      1560
attattatag ctacctgtta aagaatcatc tggattatag accagtggca ctgttgtttc      1620
acaagatgat gtttgaactt attccaatgt tcatggcgcg aacttgcaat cctcagttt      1680
tggctgtcca gctaaagggt aagatatatt cctccaattc aggaccaca cgcagggaag      1740
acaagttcat gtactttgag ttccctcagc cgttacctgt gtgtggtgat atcaaagtag      1800
agttcttcca caaacagaac aagatgctaa aaaaggacaa aatgtttcac ttttgggtaa      1860
atacattctt cataccagga ccagaggaaa cctcagaaaa agtagaaaat ggaagtctat      1920
gtgatcaaga aatcgatagc atttgcagta tagagcgtgc agataatgac aaggaatatc      1980
tagtacttac ttaacaaaaa aatgatcttg acaaagcaaa taaagacaaa gccaacccgat      2040
acttttctcc aaattttaag gtgaagctgt acttcacaaa aacagtagag gagccgtcaa      2100
atccagaggc tagcagttca acttctgtaa caccagatgt tagtgacaat gaacctgatc      2160
attatagata ttctgacacc actgactctg atccagagaa tgaacctttt gatgaagatc      2220
agcatacaca aattacaaaa gtctgaattt ttttttatca agagggataa aacaccatga      2280
aaataaactt gaataaactg aaaatggacc tttttttttt taatggcaat aggacattgt      2340
gtcagattac cagttatagg aacaattctc ttttctgac caatcttgtt ttaccctata      2400
catccacagg gttttgacac ttgtgttcca gttgaaaaaa ggttgtgtag ctgtgtcatg      2460
tatatacctt tttgtgtcaa aaggacattt aaaattcaat taggattaat aaagatggca      2520
ctttcccggt ttattccagt ttataaaaaa gtggagacag actgatgtgt atacgtagga      2580
attttttctt ttgctgttct gtcaccaact gaagtggcta aagagctttg tgatatactg      2640
gttcacatcc taccgctttg cacttgggc aacagataag tttgcagttg gctaagagag      2700
gtttccgaaa ggttttgcta ccattctaata gcatgtattc ggggttagggc aatggagggg      2760
aatgctcaga aaggaaataa ttttatgctg gactctggac catataccat ctccagctat      2820
ttacacacac ctttctttag catgctacag ttattaatct ggacattcga ggaattggcc      2880

```

gctgtcactg	cttgttggtt	gcgcattttt	ttttaagca	tattggtgct	agaaaaggca	2940
gctaaaggaa	gtgaatctgt	attgggggtac	aggaatgaac	cttctgcaac	atcttaagat	3000
ccacaaatga	agggatataa	aaataatgtc	ataggttaaga	aacacagcaa	caatgactta	3060
accatataaa	tgtggaggct	atcaacaaag	aatgggcttg	aaacattata	aaaattgaca	3120
atgattttatt	aaatatgttt	tctcaattgt	aaaaaaaaaa			3160

&lt;210&gt; 29

&lt;211&gt; 1707

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1707)

<223> The sequence of the cDNA coding for Sphingosine-1-phosphate lyase  
1

&lt;400&gt; 29

atgcctagca	cagaccttct	gatgttgaag	gcctttgagc	cctacttaga	gattttggaa	60
gtatactcca	caaaagccaa	gaattatgta	aatggacatt	gcaccaagta	tgagccctgg	120
cagctaattg	catggagtgt	cgtgtggacc	ctgctgatat	tctggggata	tgagtttgtc	180
ttccagccag	agagtttatg	gtcaagggtt	aaaaagaaat	gttttaagct	caccaggaag	240
atgcccatta	ttggtcgtaa	gattcaagac	aagttgaaca	agaccaagga	tgatattagc	300
aagaacatgt	cattcctgaa	agtggacaaa	gagtatgtga	aagctttacc	ctcccagggt	360
ctgagctcat	ctgctgtttt	ggagaaactt	aaggagtaca	gctctatgga	cgccttctgg	420
caagagggga	gagcctctgg	aacagtgtac	agtggggagg	agaagctcac	tgagctcctt	480
gtgaaggctt	atggagattt	tgcatggagt	aaccccctgc	atccagatat	cttcccagga	540
ctacgcaaga	tagaggcaga	aattgtgagg	atagcttggt	ccctgttcaa	tgggggacca	600
gattcgtgtg	gatgtgtgac	ttctggggga	acagaaagca	tactcatggc	ctgcaaagca	660
tatcgggata	tggcctttga	gaaggggata	aaaactccag	aaattgtggc	tcccaaaagt	720
gcccattgct	catttaacaa	agcagccagt	tactttggga	tgaagattgt	gcgggtccca	780
ttgacgaaga	tgatggaggt	ggatgtgagg	gcaatgagaa	gagctatctc	caggaacact	840
gccatgctcg	tctgtttctac	cccacagttt	cctcatgggt	taatagatcc	tgtccctgaa	900
gtggccaaag	tggtgtgtaa	atacaaaata	ccccttcatg	tcgacgcttg	tctgggaggc	960
ttcctcatcg	tctttatgga	gaaagcagga	taccactggg	agcaccattt	tgatttccgg	1020
gtgaaagggt	taaccagcat	ttcagctgac	accataagt	atggctatgc	cccaaaaggc	1080
tcattcattg	tggtgtatag	tgacaagaag	tacaggaact	atcagttctt	cgtcgatata	1140
gattggcagg	gtggcatcta	tgcttcccca	accatcgag	gctcacggcc	tggtggcatt	1200
agcgcagcct	gttgggctgc	cttgatgcac	ttcgggtgaga	acggctatgt	tgaagctacc	1260
aaacagatca	tcaaaactgc	tcgcttcctc	aagtcagaac	tggaataat	caaaggcatc	1320
tttggttttg	ggaatcccca	attgtcagtc	attgctctgg	gatcccgtga	ttttgacatc	1380
taccgactat	caaacctgat	gactgctaag	gggtggaact	tgaaccagtt	gcagttccca	1440
cccagtattc	atctctgcat	cacattacta	cacgcccgga	aacgagtagc	tatacaattc	1500
ctaaaggaca	ttcgagaatc	tgctactcaa	atcatgaaga	atcctaaagc	gaagaccaca	1560
ggaatgggtg	ccatctatgg	catggcccag	acaactgttg	acaggaatat	gggtgcagaa	1620
ttgtcctcag	tcttcttggg	cagctgttac	agcaccgaca	ctgtcaccca	gggcagccag	1680
atgaatgggt	ctccaaaacc	ccactga				1707

&lt;210&gt; 30

&lt;211&gt; 1879

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1879)

&lt;223&gt; The sequence of the cDNA coding for Sphingomyelin phosphodiesterase 1

&lt;400&gt; 30

```

cctgccgtgt gccaatccat tgtccacctc tttgaggatg acatggtgga ggtgtggaga      60
cgctcagtcg tgagcccatc tgaggcctgt ggcctgctcc tgggctccac ctgtgggcac     120
tgggacattt tctcatcttg gaacatctct ttgcctactg tgccgaagcc gcccccaaa      180
ccccctagcc cccagcccc aggtgccctc gtcagccgca tcctcttcct cactgacctg     240
cactgggata atgactacct ggagggcacg gaccctgact gtgcagaccc actgtgctgc     300
cgccgggggt ctggcctgcc gcccgcatcc cggccaggtg ccggatactg gggcgaaatac     360
agcaagtgtg acctgcccct gaggaccctg gagagcctgt tgagtgggct gggccagcc     420
ggcccttttg atatggtgta ctggacagga gacatccccg cacatgatgt ctggcaccag     480
actcgtcagg accaactgcg ggccctgacc accgtcacag cacttgtgag gaagttcctg     540
gggccagtcg cagtgtaccc tgcctgtggg aaccatgaaa gcatacctgt caatagcttc     600
cctccccctt tcattgaggg caaccactcc tcccgtggc tctatgaagc gatggccaag     660
gcttgggagc cctggctgcc tgccgaagcc ctgcccaccc tcagaattgg ggggttctat     720
gctctttccc cataccccgg tctccgcctc atctctctca atatgaattt ttgttcccgt     780
gagaacttct ggctcttgat caactccacg gatcccgcag gacagctcca gtggctggtg     840
ggggagcttc aggtgctga ggatcgagga gacaaagtgc atataattgg ccacattccc     900
ccagggcact gtctgaagag ctggagctgg aattattacc gaattgtagc caggtatgag     960
aacaccctgg ctgctcagtt ctttggccac actcatgtgg atgaatttga ggtcttctat    1020
gatgaagaga ctctgagccg gccgctggct gtagccttcc tggcaccagc tgcaactacc    1080
tacatcggcc ttaatcctgg ttaccgtgtg taccaaatag atggaaacta ctccaggagc    1140
tctcagctgg tcctggacca tgagacctac atcctgaatc tgaccaggc aaacataaccg    1200
ggagccatac cgcactggca gcttctctac agggctcgag aaacctatgg gctgccaac     1260
acactgccta ccgctggca caacctgcta tatcgcatgc gggcgacat gcaacttttc     1320
cagaccttct ggtttctcta ccataagggc caccaccct cggagccctg tggcacgccc     1380
tgccgtctgg ctactctttg tgcccagctc tctgccctg ctgacagccc tgctctgtgc     1440
cgccacctga tgccagatgg gagcctccca gagggccaga gcctgtggcc aaggccactg     1500
ttttgctagg gccccagggc ccacatttgg gaaagtctt gatgtaggaa agggtgaaaa     1560
agcccaaatg ctgctgtggt tcaaccaggc aagatcatcc ggtgaaagaa ccagtccctg     1620
ggcccaagg atgccgggga aacaggacct tctcctttcc tggagctggt ttagctggat     1680
atgggagggg gtttggtgct ctgtgccag gagctagact gccttgaggc tgctgtcctt     1740
tcacagccat ggagtagagg cctaagttga cactgccctg ggcagacaag acaggagctg     1800
tcgcccagg cctgtgctgc ccagccagga accctgtact gctgctgcca cctgatgctg     1860
ccagtctgtt aaaataaag

```

&lt;210&gt; 31

&lt;211&gt; 3553

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(3553)

&lt;223&gt; The sequence of the cDNA coding for Phospholipase C beta 3 (phosphatidylinositol specific)

&lt;400&gt; 31

gaagcgggtg	gagactgcgc	tggaaatcctg	tggcctcaaa	ttcaaccgga	gtgagtccat	60
ccggcctgat	gagttttcct	tggaaatcctt	tgagcggttc	ctgaacaagc	tggtgtctgcg	120
gccggacatt	gacaagatcc	tgctggagat	aggcgccaag	ggcaagccat	acctgacgct	180
ggagcagctc	atggacttca	tcaaccagaa	gcaacgcgac	ccgagactca	acgaagtgt	240
gtaccgcgcc	ctgcggccct	cccaggcccg	gctgtctcatc	gaaaagtatg	agcccaacca	300
gcagtttctg	gagcgagacc	agatgtccat	ggagggcttt	agccgctacc	tgggaggcga	360
ggagaatggc	atcctgcccc	tggaaagccct	ggatctgagc	acggacatga	ccagccact	420
gagtgcctac	ttcatcaact	cctcgcataa	cacctatctc	actgcggggc	agctggctgg	480
gacctcgtcg	gtggagatgt	accgccaggc	actactatgg	ggctgccgct	gcgtggagct	540
ggacgtgtgg	aagggacggc	cgcctgagga	ggaacccttc	attaccacag	gcttcacat	600
gaccacagag	gtgcctctgc	gcgacgtgct	ggaggccatt	gccgagactg	ccttcaagac	660
ctcgccctac	cccgtcatcc	tctccttcga	gaaccatgtg	gactcggcaa	agcaacaggc	720
aaagatggct	gagtactgcc	gctccatctt	tggagacgcg	ctactcatcg	agcctctgga	780
caagtaccgc	ctggcccccag	gcgttccccct	gcccagcccc	caggacctga	tgggcccgtat	840
cctggtgaag	aacaagaagc	ggcaccgacc	cagcgcaggt	ggcccagaca	gcgccggggcg	900
caagcggccc	ctggagcaga	gcaattctgc	cctgagcagag	agctccgcgg	ccaccgagcc	960
ctcctccccg	cagctggggt	ctcccagctc	tgacagctgc	ccaggcctga	gcaatgggga	1020
ggaggtaggg	cttgagaagc	ccagccctgga	gcctcagaag	tctctgggtg	acgaggccct	1080
gaaccgaggg	ccctatgttc	ttggacctgc	tgacctgag	gatgaggagg	aagatgagga	1140
agaggaggaa	cagacagacc	ccaaaaagcc	aactacagat	gagggcacag	ccagcagcga	1200
ggtgaatgcc	actgaggaga	tgtccacgct	tgtcaactac	atcgaacctg	tcaagttaa	1260
gtcctttgag	gctgtctgaa	agaggaacaa	atgcttcgag	atgtcgtcct	ttgtggagac	1320
caaggccatg	gagcaactga	ccaagagccc	catggagttt	gtggaatata	acaagcagca	1380
gctcagccgc	atctacccca	agggcacccg	cgtggactcc	tccaactaca	tgccccagct	1440
cttctggaac	gtagggtgcc	agcttggtgc	gctcaacttc	cagaccctcg	atgtggcgat	1500
gcagctcaac	gcgggcgttt	ttgagtacaa	cgggcgagc	gggtacctgc	tcaagccgga	1560
gttcatgcgg	cggccggaca	agtccttcga	cccccttact	gaggtcatcg	tggatggcat	1620
cgtggccaat	gccttgccgg	tcaaggtgat	ctcagggcag	ttcctgtccg	acaggaaagg	1680
gggcactctac	gtggaggtgg	acatgtttgg	cctccctgtt	gatacgcggc	gcaagtaccg	1740
caccgcggacc	tctcagggga	actcgttcaa	ccccgtgtgg	gacgaagagc	ccttcgactt	1800
ccccaaagg	gtgctgccca	cgttggttcc	acttcgcatt	gcagcctttg	aggagggggg	1860
taaattcgta	gggcaccgga	tctgtcctgt	ctctgccatc	cgctccggat	accactacgt	1920
ctgctcgccg	aacgagccca	accaaccgct	gtgcctgccg	gccctgtcca	tctacaccga	1980
agccttgga	tacattcctg	acgaccacca	ggactatgcg	gaggccctga	tcaaccccat	2040
taagcacgtc	agcctgatgg	accagagggc	ccggcagctg	gccgccctca	ttggggagag	2100
tgaggctcag	gctggccaag	agacgtgcc	ggacaccag	tctcagcagc	tggggtctca	2160
gccgtcctca	aacccccacc	ccagcccaact	ggatgcctcc	ccccgccggc	ccccctggccc	2220
caccacctcc	cctgccagca	cctccctcag	cagcccaggg	cagcgtgatg	atctcatcgc	2280
cagcatcctc	tcagaggtgg	ccccaccccc	cctggatgag	ctccgaggtc	acaaggctct	2340
ggtaagctc	cggagccggc	aagacgcaga	cctgcgggag	ctgcgcaaga	agcatcagcg	2400
gaaggcagtc	accctcacc	gccgcctgct	ggatggcctg	gctcaggcac	aggctgaggg	2460
caggtgccgg	ctgcggccag	gtgccctagg	tggggccgct	gatgtggagg	acacgaagga	2520
gggggaggac	gaggcaaagc	ggtatcagga	gttccagaac	agacaggtgc	agagcctgct	2580
ggagctgcgg	gaggcccagg	tggacgcaga	ggcccagcgg	aggctggaac	acctgagaca	2640
ggctctgcag	cggctcaggg	aggctcgtcct	tgatgcaaac	acaactcagt	tcaagaggct	2700
gaaagagatg	aacgagaggg	agaagaagga	gctgcagaag	atcctggaca	gaaagcgcca	2760
taacagcatc	tcggaggcca	agatgaggga	caagcataag	aaggaggcgg	aactgacgga	2820
gattaaaccgt	cggcacatca	ctgagtcagt	caactccatc	cgtcggctgg	aggaggccca	2880
gaagcagcgg	catgaccgtc	ttgtggctgg	gcagcagcag	gtcctgcaac	agctggcaga	2940
agaggagccc	aagctgctgg	cccagctggc	ccaggagtgt	caggagcagc	gggcgaggct	3000
ccccaggag	atccgcggga	gcctgctggg	cgagatgccg	gaggggctgg	gggacgggccc	3060
tctggtggcc	tgtgccagca	acggtcacgc	acccgggagc	agcgggcacc	tgtcgggccc	3120
tgactcggag	agccaggagg	agaacacgca	gctctgaact	ggctgagcga	ggtggccaca	3180
ggggcagggg	ggggcgtggg	tggagggcag	gaggcaatga	cactaatgct	tttttttttt	3240
gttttaact	tttttttag	aaattttatt	tttttaaac	cggggcaagt	acctcagcta	3300
actcccttca	tcctcctggg	gcccctcctt	cctgcctcca	gtcttaggtt	agggccttgg	3360
tcagggtttt	gctccctgtg	acacccacac	cctcgagcta	gcagcgtctc	ctcccttccc	3420
cgggagagct	ggctggagac	ttggagctcc	gggaagtagg	agtcacattt	ttttctctat	3480
tctttgggga	ttttttttac	atgaataaaa	gtggatttca	gggaaaaaaa	aaaaaaaaaa	3540

aaaaaaaaaa aaa

3553

&lt;210&gt; 32

&lt;211&gt; 1173

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1173)

&lt;223&gt; Sphingosine kinase (SPHK) mRNA, complete cds

&lt;400&gt; 32

gagccgcggg	tcgaggttat	ggatccagcg	ggcgcccccc	ggggcggtgt	cccgcggccc	60
tgccgcgtgc	tgggtgctgt	gaacccgcgc	ggcggaagg	gcaaggcctt	gcagctcttc	120
cggagtcacg	tcagcccct	tttggtgag	gctgaaatct	ccttcacgct	gatgctcaact	180
gagcggcgga	accacgcgcg	ggagctggtg	cggtcggagg	agctggggcg	ctgggacgct	240
ctggtggtca	tgtctggaga	cgggctgatg	cacgaggtgg	tgaacgggct	catggagcgg	300
cctgactggg	agaccgccat	ccagaagccc	ctgtgtagcc	tcccagcagg	ctctggcaac	360
gcgctggcag	cttccttgaa	ccattatgct	ggctatgagc	aggtcaccaa	tgaagacctc	420
ctgaccaact	gcacgtatt	gctgtgccgc	cggctgctgt	cacccatgaa	cctgctgtct	480
ctgcacacgg	cttcggggct	gcgcctcttc	tctgtgtctca	gcctggcctg	gggcttcatt	540
gctgatgtgg	acctagagag	tgagaagtat	cggcgtctgg	gggagatgcg	cttcaactctg	600
ggcacttttc	tgcgtctggc	agccttgccg	acttaccgcg	gccgactggc	ttacctccct	660
gtaggaagag	tgggttccaa	gacacctgcc	tccccggttg	tggtcagca	gggcccggta	720
gatgcacacc	ttgtgccact	ggaggagcca	gtgccctctc	actggacagt	ggtgcccagac	780
gaggactttg	tgctagtccct	ggcactgctg	cactcgcacc	tgggcagtga	gatgtttgct	840
gcacccatgg	gccgctgtgc	agctggcgctc	atgcactctgt	tctacgtgcg	ggcgggagtg	900
tctcgtgcc	tgctgtgcg	cctcttcctg	gccatggaga	agggcaggca	tatggagtat	960
gaatgccctt	acttggtata	tgtgcccgtg	gtcgcccttc	gcttggagcc	caaggatggg	1020
aaaggtatgt	ttgcagtgga	tggggaattg	atggttagcg	aggccgtgca	gggccagggtg	1080
caccctaaact	acttctggat	ggtcagcggt	tgcgtggagc	ccccgccag	ctggaagccc	1140
cagcagatgc	caccgccaga	agagccctta	tga			1173

&lt;210&gt; 33

&lt;211&gt; 2380

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(2380)

&lt;223&gt; Sphingosine kinase type 2 isoform mRNA, complete cds

&lt;400&gt; 33

gccacccatgg	ccccgcccc	accgccactg	gctgccagca	ccccgtcct	ccatggcgag	60
tttggtctct	accagcccc	aggcccaagc	tttgccctca	cccttacatc	gcaggccctg	120
cacatacagc	ggctgcgccc	caaacctgaa	gccaggcccc	ggggtggcct	ggtccccgtt	180

```

gccgaggtct caggetgctg caccctgcga agccgcagcc cctcagactc agcggcctac 240
ttctgcatct acacctaccc tcggggccgg cgcgggggccc ggcgcagagc cactcgcacc 300
ttccgggcag atggggccgc cacctacgaa gagaaccgtg ccgaggccca gcgctgggcc 360
actgccctca cctgtctgct ccgaggactg ccactgccc gggatgggga gatcacccct 420
gacctgctac ctcgcccgcc ccggttgett ctattggtca atccctttgg gggtcggggc 480
ctggcctggc agtgggtgtaa gaaccacgtg cttcccatga tctctgaagc tgggctgtcc 540
ttcaacctca tccagacaga acgacagaac cagccccggg agctggtcca ggggctgagc 600
ctgagtgagt gggatggcat cgtcacggtc tcgggagacg ggctgctcca tgagggtgctg 660
aacgggctcc tagatcgccc tgactgggag gaagctgtga agatgcctgt gggcatcctc 720
ccctgcggct cgggcaacgc gctggccgga gcagtgaacc agcacggggg atttgagcca 780
gcccctgggc tcgacctgtt gctcaactgc tcaactgtgc tgtgccgggg tggtagccac 840
ccactggacc tgtctctcgt gacgctggcc tcgggctccc gctgtttctc cttcctgtct 900
gtggcctggg gcttcgtgtc agatgtggat atccagagcg agcgttcag ggccctgggc 960
agtgcgcgct tcacactggg caggtgctg ggcctcgcca cactgcacac ctaccgcgga 1020
cgctctcct acctccccgc cactgtgga cctgcctcgc ccacccctgc ccatagcctg 1080
cctcgtgcca agtcggagct gaccctaacc ccagaccag ccccgcccat ggcccactca 1140
cccctgcac gttctgtgtc tgacctgect cttccccctg cccagcctgc cctggcctct 1200
cctggctcgc cagaacccct gccatcctg tccctcaacg gtggggggccc agagctggct 1260
ggggactggg gtggggctgg ggatgctcgc ctgtccccgg accactgct gtcttcacct 1320
cctggctctc ccaaggcagc tctacactca cccgtctccg aaggggcccc cgtaattccc 1380
ccatcctctg ggctccact tcccacccct gatgccggg taggggcctc cactgcggc 1440
ccgcccagacc acctgctgcc tccgctgggc acccgctgc cccagactg ggtgacgctg 1500
gagggggact ttgtgctcat gttggccatc tcgcccagcc acctaggcgc tgacctggtg 1560
gcagctccgc atgcgcgctt cgacgacggc ctggtgcacc tgtgctgggt gcgtagcggc 1620
atctcgcggg ctgcgctgct gcgccttttc ttggccatgg agcgtggtag ccacttcagc 1680
ctgggctgtc cgcagctggg ctacgcccgc gcccgctgct tccgcctaga gccgctcaca 1740
ccacgcggcg tgcacagt ggacggggag caggtggagt atgggcccgt acaggcacag 1800
atgcaccctg gcatcggtac actgctcact gggcctcctg gctgccggg gcgggagccc 1860
tgaaactaaa caagcttggg acccgccggg ggcggggcct acattccaat ggggaggagc 1920
ttgagctagg ggggtgtggc ttgctgctag agttgtggtg gcagggggccc tggccccgtc 1980
tcaggattgc gctcgctttc atgggaccag acgtgatgct ggaagggtgg cgctgctcacg 2040
gttaaagaga aatgggctcg tcccaggagt agtgcctgat caatgagggc ggggcctggc 2100
gtctgatctg gggccgccct tacggggcag ggctcagtc tgacgcttgc cacctgctcc 2160
taccgggcca ggtggctga gggcggagtc tattttacgc gtcgccaat gacaggacct 2220
ggaatgtact ggctggggtg ggcctcagtg agtcggccgg tcagggcccc cagcctcgcc 2280
ccatccactc cgggtgcctc atttagctgg ccaatcagcc caggaggggc aggttccccg 2340
gggcccggcg taggatttgc actaatgttc ctctccccgc 2380

```

&lt;210&gt; 34

&lt;211&gt; 1611

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1611)

&lt;223&gt; Mitogen-activated protein kinase 1 (MAPK1), mRNA

```

<400> 34
acataatttc tggagccctg taccaacgtg tggccacata ttctgtcagg aaccctgtgt 60
gatcatggtc tggatctgca acacgggcca ggccaaagtc acagatcttg agatcacagg 120
tgggtgttag cagcaggcag gcaggcaatc ggtccgagtg gctgtcggct cttcagctct 180
ccgctcggcg tcttccttcc tctcccggtc agctcggcg gctgcaccg cggcgggcag 240
tcctgcggga ggggcgacaa gagctgaggg gcggccgccc agcgtcgagc tcagcgcggc 300
ggaggcgggc gcggcccggc agccaacatg gcggcgggcg cggcgggcgg cgcgggcccg 360

```

gagatggtcc	gcgggcaggt	gttcgacgtg	gggcccgcgt	acaccaacct	ctcgtacatc	420
ggcgagggcg	cctacggcat	ggtgtgctct	gcttatgata	atgtcaacaa	agttcgagta	480
gctatcaaga	aaatcagccc	ctttgagcac	cagacctact	gccagagaac	cctgagggag	540
ataaaaatct	tactgcgctt	cagacatgag	aacatcattg	gaatcaatga	cattattcga	600
gcaccaacca	tcgagcaa	gaaagatgta	tatatagtag	aggacctcat	ggaaacagat	660
ctttacaagc	tcttgaagac	acaacacctc	agcaatgacc	atatctgcta	ttttctctac	720
cagatcctca	gagggttaaa	atatatccat	tcagctaacg	ttctgcaccg	tgacctcaag	780
ccttccaacc	tgctgctcaa	caccacctgt	gatctcaaga	tctgtgactt	tgacctggcc	840
cgtgttgacg	atccagacca	tgatcacaca	gggttccctga	cagaatatgt	ggccacacgt	900
tggtacaggg	ctccagaaat	tatgttgaat	tccaagggct	acaccaagtc	cattgatatt	960
tggtctgtag	gctgcattct	ggcagaaatg	ctttccaaca	ggcccatctt	tccagggag	1020
cattatcttg	accagctgaa	tcacattttg	ggatttcttg	gatccccatc	acaagaagac	1080
ctgaattgta	taataaattt	aaaagctagg	aactattttg	tttctcttcc	acacaaaaat	1140
aaggtgccat	ggaacaggct	gttcccaaat	gctgactcca	aagctctgga	cttattggac	1200
aaaatggtga	cattcaaccc	acacaagagg	attgaagtag	aacaggctct	ggccccacca	1260
tatctggagc	agtattacga	cccgagtgc	gagcccatcg	ccgaagcacc	attcaagttc	1320
gacatggaat	tggtgactt	gcctaaggaa	aagctaaaag	aactaatttt	tgaagagact	1380
gctagattcc	agccaggata	cagatcttaa	atttgtcagg	acaagggctc	agaggactgg	1440
acgtgctcag	acatcggtgt	tcttcttccc	agttcttgac	ccctggctct	gtctccagcc	1500
cgtcttggct	tatccacttt	gactcctttg	agccgtttgg	aggggcggtt	tctggtagtt	1560
gtggctttta	tgctttcaaa	gaatttcttc	agtcacagaa	attcactggc	c	1611

&lt;210&gt; 35

&lt;211&gt; 1647

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1647)

&lt;223&gt; Lysophospholipase II (LYPLA2), mRNA

&lt;400&gt; 35

ggaagtccg	gcgggggcgg	ccgaggggga	agagtgtgtc	tgccgggagaa	agaggagaat	60
cgcccaagcg	gcctcgggaag	tcccaggag	tggaggcccc	cgccgtggag	ccgtgtgggtg	120
tatgtgtggt	aacaccatgt	ctgtgcccct	gctcacccat	gctgccaccg	tgtctggagc	180
tgagcgggaa	acggccgcgg	ttattttttt	acatggactt	ggagacacag	ggcacagctg	240
ggctgacgcc	ctctccacca	tccggctccc	tcagctcaag	tacatctgtc	cccatgcgcc	300
taggatccct	gtgacctca	acatgaagat	ggtgatgccc	tcctggtttg	acctgatggg	360
gctgagtcca	gatgccccag	aggacgaggc	tggcatcaag	aaggcagcag	agaacatcaa	420
ggccttgatt	gagcatgaaa	tgaagaacgg	gateccctgc	aatcgaatcg	tcctggggag	480
cttttcacag	ggcggggccc	tgtccctcta	cacggccctc	acctgcccc	acctctggc	540
tggcatcggtg	gcgttgagct	gctggctgcc	tctgcaccgg	gccttcccc	aggcagctaa	600
tggcagtgcc	aaggacctgg	ccatactcca	gtgccatggg	gagctggacc	ccatgggtgcc	660
cgtacggttt	ggggccctga	cggctgagaa	gctccggtct	gttgtcacac	ctgccagggt	720
ccagttcaag	acatacccgg	gtgtcatgca	cagctcctgt	cctcaggaga	tggcagctgt	780
gaaggaattt	cttgagaagc	tgctgcctcc	tgtctaacta	gtcgtggccc	ccagtgcagt	840
acccagctc	atgggggact	cagcaagcaa	gcgtggcacc	atcttggatc	tgagccggtc	900
gagccctgt	ccccaccctt	cctgacctgt	ccttttcccc	caggcctctg	ggggcagggtg	960
gcaaggcctg	gccgggccc	ccttcctggc	cttagccacc	tggtctgtgc	tgacgagggg	1020
gcaggctgct	ttcttatact	ttccctgga	ggcgggcccc	cctggcagca	gtattggagg	1080
ggctacaggc	agctggagaa	agggggccag	ccgctgaccc	actcactcag	gacctcactc	1140
actagccccc	ctttggggcc	cctcctgtga	cctcagggtt	tggcccatgg	ggccccccca	1200
ggccccctgcc	ccaactgatt	ctgcccagat	aatcgtgtct	cctgcctcca	ctcagctgct	1260



tctcagtc	cat	gaatgtggcc	atggccccgg	ggcccccttg	ctgctgtggg	ctccctgtcc	1320
ctgggcaaga	atgctgggga	agaagtggag	ccttttgagg	ggggcttccc	tcaactgttt		1380
ccccacactg	gggggctggg	ccctgcctcc	ccgttacct	ccttccctgc	aggcctggag		1440
cctgtagggc	tggactgagg	ttcaggcttc	ccccagctg	tctaccccc	actttgtccc		1500
cactctagag	cagggaggca	gtgggggagg	agttgtgtct	cgtcttctgt	ctccatgtgg		1560
tttttggtg	tttttcttgt	tgtgtcctgg	attccgataa	aattaaagaa	attgcttcct		1620
taaaaaaaaa	aaaaaaaaaa	aaaaaaa					1647

&lt;210&gt; 36

&lt;211&gt; 1418

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(1418)

&lt;223&gt; n is a, c, t, or g

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1418)

&lt;223&gt; Map kinase phosphatase-like protein MK-STYX mRNA

&lt;400&gt; 36

gccacttccg	ggagtcggaa	aggaaagctg	tgggaccatc	ctggcaacce	cggtgtttgg	60
ctgggttcta	gcgtaccggt	ctgtgtggcc	gggtgggggac	ctgcggtcgg	agtgggaggg	120
ccagtctgca	ccaagagggt	ggaagaggac	gggcttttagg	ctggaacgcc	ttagaggagc	180
cattttttcca	ggtggggccc	cagnagaggc	tccgacagga	gctgngccat	agtcgcgcga	240
cggggagggtg	gagcgcgtcc	cagacccgan	cccccgacct	cagccaaacc	cattccttct	300
gtccttggag	gccagagggg	actctgagca	tccgaaagga	tgcctgggtt	gcttttatgt	360
gaaccgacag	agctttacaa	catcctgaat	caggccacaa	aactctccag	attaacagac	420
cccaactatc	tctgtttatt	ggatgtccgt	tccaaatggg	agtatgacga	aagccatgtg	480
atcactgccc	ttcgagtga	gaagaaaaat	aatgaatatc	ttctcccga	gtctgtggac	540
ctggagtgtg	tgaagtactg	cgtgggtgtat	gataacaaca	gcagcaccct	ggagatactc	600
ttaaagatg	atgatgatga	ttcagactct	gatgggtgatg	gcaaagatct	tgtgcctcaa	660
gcagccattg	agtatggcag	gatcctgacc	cgcctcaccc	accaccccg	ctacatcctg	720
aaaggggggt	atgagcgctt	ctcaggcacg	taccactttc	tccggaccca	gaagatcatc	780
tggatgcctc	aggaactgga	tgcatttcag	ccatacccca	ttgaaatcgt	gccaggggaag	840
gtcttcggtg	gcaatttcag	tcaagcctgt	gacccaaga	ttcagaagga	cttgaaaatc	900
aaagcccatg	tcaatgtctc	catggataca	gggccctttt	ttgcaggcga	tgtgcacaag	960
cttctgcaca	tccggataga	agattccccg	gaagcccaga	ttcttccctt	cttacgccac	1020
atgtgtcact	tcattgaaat	tcaccatcac	cttggctctg	tcattctgat	cttttccacc	1080
caggggtatca	gccgcagttg	tgcgcctatc	atagcctacc	tcattgcatag	taacgagcag	1140
accttgcaga	ggtcctgggc	ctatgtcaag	aagtgcacaa	acaacatgtg	tccaaatcgg	1200
ggattgggtga	gccagctgct	ggaatgggag	aagactatcc	ttggagattc	catcacaaac	1260
atcatggatc	cgctctactg	atcttctccg	aggcccaccg	aaggggtactg	aagagcctca	1320
cctgggggca	ttttgtgggt	ggagggccag	agtgtgtata	cccaggcttg	tctggaagga	1380
gaaggccttt	gctgcctgaa	agtctcaaaa	aaaaaaaa			1418

&lt;210&gt; 37

&lt;211&gt; 1731

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1731)

&lt;223&gt; LPAP for lysophosphatidic acid phosphatase (LOC51205), mRNA

&lt;400&gt; 37

```

ggaactcagg gccggctcct gttccttcaa gagtgcctgga ggccaaactt gaaatacaag      60
tttaatgttc ctcgtcgggc aaaagataag gatccgatct cccccggccc ggtgtgcagc      120
aggagcgacc aaccccgacc cgggttaaaa ctcccaggga ctcttcgctg ctgccacctc      180
ttgttctctc ccccggtccc actcgggggc tccctcaggg ccgggaggga cagcgggtccc      240
tgcttgctga agggctggat gtacgcattc gcagggtccc gcggacttgg gggcgccgc      300
tgagccccgg cgcgcgcaga agacttgtgt ttgcctcctg cagcctcaac ccggaggcag      360
cgagggccta ccaccatgat cactggtgtg ttcagcatgc gcttgtggac cccagtgggc      420
gtcctgacct cgctggcgta ctgcctgcac cagcggcggg tggccctggc cgagctgcag      480
gaggccgatg gccagtgctc ggtcgaccgc agcctgctga agttgaaaat ggtgcaggtc      540
gtgtttcgac acggggctcg gagtcctctc aagccgctcc cgctggagga gcaggtagag      600
tggaaccccc agctattaga ggtcccaccc caaactcagt ttgattacac agtcaccaat      660
ctagtgggtg gtcggaaacc atattctctc tacgactctc aataccatga gaccaccctg      720
aaggggggca tgtttgctgg gcagctgacc aaggtgggca tgagcaaat gtttgcttg      780
ggagagagac tgaggaagaa ctatgtggaa gacattccct ttctttcacc aaccttcaac      840
ccacaggagg tctttattcg ttccactaac atttttcgga atctggagtc caccggtgt      900
ttgctggctg ggcttttcca gtgtcagaaa gaaggacca tcatcatcca cactgatgaa      960
gcagattcag aagtcttgta tcccactac caaagctgct ggagcctgag gcagagaacc     1020
agaggccgga ggcagactgc ctctttacag ccaggaatct cagaggattt gaaaaagggtg     1080
aaggacagga tgggcattga cagtagtgat aaagtggact tcttcacctt cctggacaac     1140
gtggctggcg agcaggcaca caacctccca agctgcccc tgctgaagag atttgacgg      1200
atgatcgaac agagagctgt ggacacatcc ttgtacatac tgcccaagga agacaggga      1260
agtcttcaga tggcagtagg cccattcctc cacatcctag agagcaacct gctgaaagcc     1320
atggactctg ccactgcccc cgacaagatc agaaagctgt atctctatgc ggctcatgat     1380
gtgaccttca taccgctctt aatgacctg gggatTTTTT accacaaatg gccaccgttt     1440
gctgttgacc tgaccatgga actttaccag cacctggaat ctaaggagtg gtttgtgcag     1500
ctctattacc acgggaagga gcagggtgcc agagggtgcc ctgatgggct ctgccgctg     1560
gacatgttct tgaatgccat gtcagtttat accttaagcc cagaaaaata ccatgcactc     1620
tgctctcaaa ctcaggtgat ggaagttgga aatgaagag aactgattta taaaagcagg     1680
atgtgttgat tttaaaataa agtgccttta tacaaaaaaa aaaaaaaaaa a      1731

```

&lt;210&gt; 38

&lt;211&gt; 3206

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(3206)

## &lt;223&gt; Phospholipid scramblase 4 mRNA

&lt;400&gt; 38

gtttataact	tgaaaaatcc	tctccgtctc	ccttccctgc	ctccttttcc	ttccctttcc	60
tctgccagta	caactagacc	cggcgtctgg	cgtccccggt	gcccagcatt	ctgcggggca	120
ggcggattaa	ttggaattct	tcaaaatgtc	aggtgtggta	cccacagccc	ctgaacagcc	180
tgcaggtgaa	atggaaaatc	aaacaaaacc	accagatcca	aggcctgatg	ctcctcctga	240
atacagttct	cattttttac	caggaccccc	tggacagct	gtccctccac	ctactggcta	300
cccaggaggc	ttgcctatgg	gatactacag	tccacagcaa	cccagtacct	tccctttgta	360
ccagccagtt	ggtggtatcc	atcctgtccg	gtatcagcct	ggcaaatac	ctatgccaaa	420
tcagtctgtt	ccaataacat	ggatgccagg	gccaaactct	atggcaaact	gccctcctgg	480
tctggaatac	ttagttcagt	tggacaacat	acatgttctt	cagcattttg	agcctctgga	540
aatgatgaca	tgttttgaaa	ctaataatag	atatgatatt	aaaaacaact	cagaccagat	600
ggtttacgtt	gtaaccgaag	acacagatga	ctttaccagg	aatgcctatc	ggacactaag	660
gcccttcgtc	ctccgggtca	ctgattgtat	gggccgagaa	atcatgacaa	tgcagagacc	720
cttcagatgc	acctgctgtt	gcttctgttg	cccctctgcc	agacaagagc	tggagggtgca	780
gtgtcctcct	ggtgtcacca	ttggctttgt	tgcggaacat	tggaaacctgt	gcagggcggt	840
gtacagcatc	caaaatgaga	agaaagaaaa	tgtgatgaga	gttcgtgggc	catgctcaac	900
ctatggctgt	ggttcagatt	ctgtttttga	ggtcaaactc	cttgatggca	tatccaacat	960
cggcagttat	atccggaagt	ggaatggttt	ggtatcagca	atggcagatg	ctgaccattt	1020
tgcattcacc	ttcccactag	acctggatgt	gaagatgaaa	gccatgattt	ttggagcttg	1080
cttcctcatt	gacttcattg	attttgaaag	atctccacca	caacgttcaa	gatagagaga	1140
cacagcaagc	catcaactat	ggttaatttt	gaaaaatgga	aaagttggat	tgggcttaca	1200
gtcagcactc	agttattttg	aagtgtattt	ctttgctttg	tagagtattt	ttattgggtg	1260
ttaactttga	cagctgagag	tgggcttgca	agaacacaat	ctaaaagtgt	gtttcaattg	1320
agtatctctc	tagtagaata	ggagtccatc	ctgaaaagct	gtgactcatt	aaccagtaa	1380
acatatataa	agtaagctta	aaacactata	aacatgagat	aagggaaaat	gaatccagag	1440
ttctcatatt	aataggtagt	gaaacaataa	ggctttttag	agcagacttt	gttggcataa	1500
aataacctgg	cttctatccc	taaccctttc	ctacctttcc	tctccgtcaa	catgtcctca	1560
tactgaagac	aaacttggtt	caatgatagt	cttcattttt	aaaaacaaaa	aggcaggcag	1620
acagaaataa	tgatgttttc	ttgcaactaa	aaggtactac	ttgtacacat	atatcaaaac	1680
ctcattctgc	aaagtttttg	aaggtttcaa	tgggaaattt	gattttatta	caaaataaaa	1740
cattttttta	tgttaaagtt	tatatattcc	atgcttggtt	tctcattcac	tggcatggat	1800
gatcaggagc	tgcctatata	tgaaggcaga	atcagactat	caggaaagga	gctggccagg	1860
gccacagcca	gtcaagatct	ctgagcaact	tagagacatt	ggtgtcatta	tatgaagctt	1920
gcatttcata	taatacattt	gtacatttaa	ttcataacgt	ctcttggtca	ctcttggtca	1980
cagatgcctt	atatataaaa	taagttggca	gatctctaag	attgcctagt	acacctttgt	2040
atctcatttg	atgtgatacc	cagaagagat	cattgttttt	tgtttttgtt	tttgtttttt	2100
tcaagaagat	ccttcgtgat	caccatgctg	ttctcatggt	aagaactgga	gttatgtttt	2160
taaatttgaa	aatatgacat	tttatgtagc	actatataaa	aagtgaagc	gacaaattcc	2220
accgctgctt	aatactgctt	tgtctctttt	tattgacatg	atagatacat	atgtatctac	2280
acagagtaat	aataataaaa	cacagtaaac	attctatttc	tctatggctt	acagcatgcc	2340
agtaaataat	atgtaggacc	aataataaat	tatcaattac	acatttttgt	gttaactaat	2400
taaaagcata	gtgtataagt	gagtacactc	taattaaact	gcttctgttg	cacttttagtt	2460
ttctacctgc	atatggactg	catttttttt	tttaacacag	tcagtatgta	gaatgggatg	2520
tattcttctg	ctgctgctta	ttaaataaag	aaagcctgag	tgttcttaga	tgggggttatt	2580
ctgagatgag	ggtcttagcc	tacagtctct	tttgaaatga	aaggtgcttt	gttttttaat	2640
tatattcatc	ttttcagggt	aaatttggtt	ttctgagttt	ctcgtaatgc	tcattttttac	2700
atgctgctac	tagctttttt	ttttaaaaaa	agtaaaagtt	gctgctttct	aaaatatata	2760
ttgccttata	tttgaaagtg	ccattgcaat	cgtaagtaga	ctatgtattt	cctataatga	2820
tgtctgatat	ttaaattagga	aatcagacaa	acaatttca	gaaagtttaa	gcatataaac	2880
tttttatttt	taacttgcct	agatccctgt	attccaaaac	ctgctgcac	ataataaata	2940
tatctatata	tatttagcat	aagacgtgat	atttttaatt	tcttttttaa	aaaattatat	3000
ttgtctctta	gagttaaaat	tttctttata	taattattgt	atatgtcata	gttttaatac	3060
aattcacatg	atttctatgt	ttcttaatga	tattttgttg	tgtaaaattg	atcggaattga	3120
ttaaaaaaca	aattctctgg	aatttgtgcg	ttcatgcttt	tctgtattct	ttatggcttt	3180
taaataaata	tacaatggtt	aatagt				3206

&lt;210&gt; 39

&lt;211&gt; 1254

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1254)

&lt;223&gt; mRNA for protein kinase B

&lt;400&gt; 39

atgaagacgg	agcggcccg	gcccacacc	ttcatcatcc	gctgcctgca	gtggaccact	60
gtcatcgaac	gcaccttcca	tgtggagact	cctgaggagc	gggaggagtg	gacaaccgcc	120
atccagactg	tggccgacgg	cctcaagaag	caggaggagg	aggagatgga	cttccggtcg	180
ggctcaccca	gcgacaactc	aggggccgaa	gagatggagg	tgtccctggc	caagcccaag	240
caccgcgtga	ccatgaacga	gtttgagtac	ctgaagctgc	tgggcaaggg	cactttcggc	300
aagggtgatcc	tggtaagga	gaaggccaca	gcgtactacg	ccatgaagat	cctcaagaag	360
gaagtcatcg	tggccaagga	cgaggtggcc	cacacactca	ccgagaaccg	cgtccagcag	420
aactccaggc	accccttcc	cactgcctg	aagtactctt	tccagacca	cgaccgcctc	480
tgctttgtca	tggagtacgc	caacgggggc	gagctgttct	tccacctgtc	ccgggagcgt	540
gtgttcgccg	aggaccgggc	ccgcttctat	ggcgctgaga	ttgtgtcagc	cctggactac	600
ctgcaactcg	agaagaacgt	ggtgtaccgg	gacctcaagc	tggagaacct	catgctggac	660
aaggacgggc	acattaagat	cacagacttc	gggctgtgca	aggaggggat	caaggacggt	720
gccaccatga	agaccttttg	cggcacacct	gagtacctgg	cccccgaggt	gctggaggac	780
aatgactacg	gccgtgcagt	ggactggtgg	gggctgggcg	tggatcatgta	cgagatgatg	840
tgcggtcgcc	tgcccttcta	caaccaggac	catgagaagc	tttttgagct	catcctcatg	900
gaggagatcc	gcttcccgcg	cacgcttgg	cccaggcca	agtccttgct	ttcagggctg	960
ctcaagaagg	accccaagca	gaggcttggc	gggggctccg	aggacgcca	ggagatcatg	1020
cagcatcgct	tctttaccgg	tatcgtgtgg	cagcacgtgt	acgagaagaa	gctcagccca	1080
cccttcaagc	cccaggtcac	gtcggagact	gacaccaggt	atthttgatga	ggagttcacg	1140
gccagatga	tcaccatcac	accacctgac	caagatgaca	gcatggagtg	tgtggacagc	1200
gagcgcaggc	cccacttccc	ccagttctcc	tactgcacca	gcgcgacggc	ctga	1254

&lt;210&gt; 40

&lt;211&gt; 1125

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1125)

&lt;223&gt; Interleukin 6 (interferon, beta 2) (IL6), mRNA

&lt;400&gt; 40

ttctgccctc	gagcccaccg	ggaacgaaag	agaagctcta	tctgcctcc	aggagcccag	60
ctatgaactc	cttctccaca	agcgcttcg	gtccagttgc	cttctccctg	gggctgctcc	120
tgggtgttgc	tgtgccttc	cctgccccag	tacccccagg	agaagattcc	aaagatgtag	180
ccgcccaca	cagacagcca	ctcacctctt	cagaacgaat	tgacaaacaa	attcgggtaca	240
tcttcgacgg	catctcagcc	ctgagaaaag	agacatgtaa	caagagtaac	atgtgtgaaa	300
gcagcaaaga	ggcactggca	gaaaacaacc	tgaaccttcc	aaagatggct	gaaaaagatg	360
gatgcttcca	atctggattc	aatgaggaga	cttgcctgg	gaaaatcatc	actggtcttt	420

tggagtttga	ggtataccta	gagtacctcc	agaacagatt	tgagagtagt	gaggaacaag	480
ccagagctgt	gcagatgagt	acaaaagtcc	tgatccagtt	cctgcagaaa	aaggcaaaga	540
atctagatgc	aataaccacc	cctgacccaa	ccacaaatgc	cagcctgctg	acgaagctgc	600
aggcacagaa	ccagtggctg	caggacatga	caactcatct	cattctgctg	agctttaagg	660
agttcctgca	gtccagcctg	agggctcttc	ggcaaatgta	gcatgggcac	ctcagattgt	720
tgttgtaaat	gggcattcct	tcttctggtc	agaaacctgt	ccactgggca	cagaacttat	780
gttggtctct	atggagaact	aaaagtatga	gcgttaggac	actattttaa	ttatttttaa	840
tttattaata	tttaaatatg	tgaagctgag	ttaatattatg	taagtcatat	ttatattttt	900
aagaagtacc	acttgaaaca	ttttatgtat	tagttttgaa	ataataatgg	aaagtggcta	960
tgcaagttga	atatcctttg	tttcagagcc	agatcatttc	ttggaaagtg	taggcttacc	1020
tcaataaaat	ggctaactta	tacatatttt	taaagaaata	tttatattgt	atttatataa	1080
tgtataaatg	gtttttatag	caataaatgg	cattttaaaa	aattc		1125

&lt;210&gt; 41

&lt;211&gt; 7156

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(7156)

&lt;223&gt; Interleukin 8 (IL8) gene

&lt;400&gt; 41

tagcaggtat	gtttatgttt	atgactctta	acattaacaa	catcgtaagt	caaactcact	60
aatatatgtt	aagcattctg	tttatgattc	ttttaacctt	gaggattgtt	gagctgggac	120
taatttcctc	aaatgggaaa	aaaaccagg	tgagagctga	gactgctcct	gagactgaga	180
aaggcagctc	tgacgggatc	tcagatttta	gcagcaggag	ttgaacaatg	ggcatagaat	240
cagcttgccc	aagatctcct	gattaataaa	ccatggaaca	agatttaaac	ccaagttcat	300
ttcattttcaa	agctcatacc	acattttgcc	caccatattt	tgctttgtta	tatgactaca	360
acttagttca	ggcttacaaa	aaagtcctaa	ttctaaaatt	cctatggcgt	gggtgggagg	420
ggatttagat	gattttgcat	aggcaagaaa	caccagttt	catggagttt	gatggaagag	480
ttatgtacta	atatgggaaa	agtagaggcc	atctttgtct	ttgttctttc	ttttttagac	540
gggagtctcg	ctctttcacc	caggctggag	tgcaagtggc	ctatctcggc	tcactgcaag	600
ctccgctcc	tgggttcacg	ccattctcct	gcctcagcct	cctgagtagc	tgggactaca	660
ggcgcccgcc	accgctcccg	gctaattttt	tatattttca	gtagagacgg	ggtttcaccg	720
tgtagctaa	gatggtttgg	atctcctgaa	ctcgtgatcc	gcccgcctcg	gactcccaaa	780
gtgctgggat	tacaggcttg	agccaccgcg	cccggccgct	tttgttcttt	cttgaactct	840
tccttttctt	gggtgataga	cttcgtcaac	gtctaagag	gatatctagg	tgctagtctc	900
tgctcatcaa	atgattctta	tggctcagga	gccgaatggg	acgtaaataa	acagttaagt	960
ctcatgaact	cactttgcat	tcactcttag	aagatgacaa	aacatttgta	tttatgtgta	1020
gcgtggcact	ttagttaaac	tttgtacccc	actttgctct	attttaaagc	agaataatcct	1080
taaaaaggat	acttagtcct	gctttttttt	ttccgcctaa	gcccatttag	tccttctact	1140
cattatgcaa	ggactcaaat	ggttatcttt	acagaagtga	gacaagatag	aatcaatgct	1200
cttgtagtca	cttcactctt	gtccattccc	acttctgatg	gagaggggtc	taggcataaa	1260
tgcactgaag	gttacattgt	gagagatgaa	caacatttgc	aaaagaggtc	tttttgcttt	1320
ggaaaggctt	cattcttaaa	aaaaaatgtg	agcatcaagg	ttaagtagac	ctcattagct	1380
caaactttaa	ggatgatatc	aggataaagt	tgggcccattg	agaagagaat	gagagggaga	1440
tatagtgaac	tgaataaag	gaggaaaacg	aggtgtctat	gtaagttggg	ctcaccataa	1500
atacaaaggc	aaccgttagg	gaaaagcaaa	gaagtctttg	cacatcctca	gaactctgaa	1560
tgtcttagtg	atgctgtatg	agtgaagtctt	aatgatagtg	aactgaatca	gtcaagccag	1620
gttggtgcca	tcttgaagt	tgtctttgct	aaacatgcca	acatcactga	agcaaaagaa	1680
cttgagattt	tctttaagat	ataggtcttt	tttacctatc	cggcccaagc	tttctcttct	1740
tgtcactcca	tgcactgtgt	tccgtatgct	aaatagtttg	agaaacccaa	atgggccatg	1800

ttcgcttaca	tttcattgtc	ctgtacttcc	tgtcctgtac	tagcaaagca	gtccattggg	1860
tcttttcttct	cctcattaac	aataaaggta	acacttttga	tgttggttct	tcagaaaacc	1920
ttcattcatc	aaaactgcct	caaagatcat	gtttgtttga	ttccagaact	tcctgtaatt	1980
acctgttatt	gtaacactca	tcactgtatt	ttacttactt	gtgtaactaa	ttttccatat	2040
tctgcactag	acaacaaagt	cctttaagtc	aggtactata	tctattttaca	tagcattcac	2100
atctcctaca	ataagggaca	ttagcagata	aacaacacat	attaaatgaa	taatgaagtt	2160
tctgaaatac	tacagttgaa	aactatagga	gctacattat	atagaataaa	catttacttt	2220
gctatagaat	tcagtgtaac	ccaggcatta	ttttatcctc	aagtcttagg	ttgggtggag	2280
aaagataaca	aaaagaaaca	tgattgtgca	gaaacagaca	aacctttttg	gaaagcattt	2340
gaaaatggca	ttccccctcc	acagtgtgtt	cacagtgtgg	gcaaattcac	tgtctgtctg	2400
tactttctga	aaatgaagaa	ctgttacacc	aagggtgaatt	atttataaat	tatgtacttg	2460
cccagaagcg	aacagacttt	tactatcata	agaacccttc	cttggtgctc	tttatctaca	2520
gaatccaaga	cctttcaaga	aagggtcttg	attcttttct	tcaggacact	aggacataaa	2580
gccacctttt	tatgatttgg	tgaaatttct	cactccatcc	cttttgctag	tgatcatggg	2640
tcctcagagg	tcagacttgg	tgtccttgga	taaagagcat	gaagcaacag	tggtgaacc	2700
agagtgggaa	cccagatgct	ctttccacta	agcatataac	tttccattag	ataaacactc	2760
cctcccaccc	caaccaagca	gctccagtgc	accactttct	ggagcataaa	cataacctta	2820
ctttacaact	tgagtggcct	tgaatactgt	tcctatctgg	aatgtgctgt	tctctttcat	2880
cttccctctat	tgaagccctc	ctattcctca	atgccttgct	ccaactgcct	ttggaagatt	2940
ctgctcttat	gcctccactg	gaattaatgt	cttagtacca	cttgctctatt	ctgctatata	3000
gtcagtcctt	acattgcttt	cttcttctga	tagaccaaac	tctttaagga	caagtacctt	3060
gtcttatcta	tttctagatc	ccccacatta	ctcagaaagt	tactccataa	atgtttgtgg	3120
aactgatttc	tatgtgaagc	acatgtgccc	cttccactctg	ttaacatgca	ttagaaaact	3180
aaatcttttg	aaaagttgta	gtatgcccc	taagagcagt	aacagaaact	aagagttcct	3240
agaaaactctc	taaaatgctt	agaaaaagat	ttatttttaa	ttacctcccc	aataaaatga	3300
ttggctggct	tatcttcacc	atcatgatag	catctgtaat	taactgaaaa	aaaataatta	3360
tgccattaaa	agaaaatcat	ccatgatctt	gttctaacac	ctgccactct	agtactatat	3420
ctgtcacatg	gtactatgat	aaagtatatc	agaaataaaa	aagcatataa	ttgataattc	3480
accaaaattgt	ggagcttcag	tatttttaaat	gtatattaaa	attaaattat	tttaaaagatc	3540
aaagaaaact	ttcgtcatat	tccgtatttg	ataaggaaca	aataggaagt	gtgatgactc	3600
aggtttgccc	tgaggggatg	ggccatcagt	tgcaaatcgt	ggaatttcct	ctgacataat	3660
gaaaagatga	gggtgcataa	gttctctagt	agggtgatga	tataaaaagc	caccggagca	3720
ctccataagg	caaaaaactt	cagagacagc	agagcacaca	agcttctagg	acaagagcca	3780
ggaagaaaacc	accggaagga	accatctcac	tgtgtgtaaa	catgacttcc	aagctggccg	3840
tggtctctct	ggcagccttc	ctgatttctg	cagctctgtg	tgaaggtaag	cacatctttc	3900
tgacctacag	cgttttccta	tgtctaaatg	tgatccttag	atagcaaagc	tattcttgat	3960
gctttggtaa	caaacatcct	ttttattcag	aaacagaata	taatcttagc	agtcaattaa	4020
tgtaaatttg	aagatttaga	aaaaactata	tataaacactt	aggaaagtat	aaagtttgat	4080
caatatagat	attctgcttt	tataatttat	actatctagc	atgcataat	ttaacgtaaa	4140
taagtaattt	atagtatgct	ctattgagaa	ccacggttac	ctatattatg	tattaattat	4200
gagttgagca	aggtaactca	gacaattcca	ctccttgtag	tatttcattg	acaagcctca	4260
gatttgtcat	taattcctgt	ctgggtttaa	gataccctga	ttatagacca	ggcatgtata	4320
acttatttat	atatttctgt	taattctttc	tgaaggcaat	ttctatgctg	gagagtctta	4380
gcttgccctac	tataaataac	actgtggtat	cacagaggat	tatgcaatat	tgaccagata	4440
aaaataccat	gaagatgttg	atattgtaca	aaaagaactc	taactcttta	tataggaagt	4500
cgttcaatgt	tgtcagttat	gactgttttt	taaaacaaag	aactaactga	ggtcaagggc	4560
taggagaata	ttcaggaatg	agttcactag	aaacatgatg	ccttccatag	tctccaaata	4620
atcatattgg	aattagaaaag	gaagtagctg	gcagagctgt	gcctgttgat	aaaatcaatc	4680
cttaatcact	ttttcccca	acaggtgcag	ttttgccaag	gagtgtctaa	gaacttagat	4740
gtcagtgcac	aaagacatac	tccaaacctt	tccaccccaa	atttatcaaa	gaactgagag	4800
tgattgagag	tgaccacac	tgcgccaaaca	cagaaattat	gtaagtactt	taaaaaagat	4860
tagatatttt	gttttagcaa	acttaaaatt	aaggaagggtg	gaaatattta	ggaaagttcc	4920
agggtttagg	attacagtag	taaatgaaac	aaaacaaaaat	aaaaaatatt	tgtctacatg	4980
acatttaaat	atggttagctt	ccacaactac	tataaatgtt	attttggact	tagactttat	5040
gcctgactta	aggaatcatg	atttgaatgc	aaaaactaaa	tattaatctg	aaccttttct	5100
ttcttatttc	aggtgaaagc	tttctgatgg	aagagagctc	tgtctggacc	ccaaggaaaa	5160
ctgggtgcag	agggttggg	agaagttttt	gaagaggtaa	gttatatatt	ttttaattta	5220
aatttttcat	ttatcctgag	acatataatc	caaagtcagc	ctataaattt	ctttctgttg	5280
ctaaaaatcg	tcattaggtg	tctgcctttt	tggttaaaaa	aaaaaggaat	agcatcaata	5340
gtgagtttgg	tgtactcatg	accagaaaga	ccatacatag	tttgcccagg	aaattctggg	5400
tttaagcttg	tgtcctatac	tcttagtaaa	gttctttgtc	actcccagta	gtgtcctatt	5460

ttagatgata	atttctttga	tctccctatt	tatagttgag	aatatagagc	atttctaaca	5520
catgaatgtc	aaagactata	ttgacttttc	aagaacccta	ctttccttct	tattaaacat	5580
agctcatctt	tatatattta	attttatttt	agggtcgaga	attcataaaa	aaattcattc	5640
tctgtggtat	ccaagaatca	gtgaagatgc	cagtgaacct	tcaagcaaat	ctacttcaac	5700
acttcatgta	ttgtgtgggt	ctgttgtagg	gttgccagat	gcaatacaag	attcctgggt	5760
aaatttgaat	ttcagtaaac	aatgaatagt	ttttcattgt	accatgaaat	atccagaaca	5820
tacttatatg	taaagtatta	tttatttgaa	tctacaaaaa	acaacaaata	atttttaaat	5880
ataaggattt	tcctagatat	tgcacgggag	aatatacaaa	tagcaaaatt	gaggccaagg	5940
gccaaagaaa	tatccgaact	ttaatttcag	gaattgaatg	ggtttgctag	aatgtgatat	6000
ttgaagcatc	acataaaaaa	gatgggacaa	taaattttgc	cataaagtca	aatttagctg	6060
gaaatcctgg	atttttttct	gttaaatctg	gcaaccctag	tctgctagcc	aggatccaca	6120
agtccttggt	ccactgtgcc	ttggtttctc	ctttatttct	aagtggaaaa	agtattagcc	6180
accatcttac	ctcacagtga	tgttgtgagg	acatgtggaa	gcactttaag	ttttttcatc	6240
ataacataaa	ttattttcaa	gtgtaactta	ttaacctatt	tattatttat	gtatttat	6300
aagcatcaaa	tatttgtgca	agaatttgga	aaaatagaag	atgaatcatt	gattgaatag	6360
ttataaagat	gttatagtaa	atttatttta	tttttagatat	taaatgatgt	tttattagat	6420
aaatttcaat	cagggttttt	agattaaaca	aacaaacaat	tgggtaccca	gttaaatttt	6480
catttcagat	aaacaacaaa	taatttttta	gtataagtac	attattggtt	atctgaaatt	6540
ttaattgaac	taacaatcct	agtttgatac	tcccagtcct	gtcattgcca	gctgtgttgg	6600
tagtgctgtg	ttgaattacg	gaataatgag	ttagaactat	taaaacagcc	aaaactccac	6660
agtcaatatt	agtaatttct	tgctggttga	aacttgttta	ttatgtacaa	atagattcct	6720
ataatattat	ttaaatgact	gcatttttaa	atacaaggct	ttatatTTTT	aactttaaga	6780
tgTTTTatg	tgctctccaa	atTTTTtta	ctgtttctga	ttgtatggaa	atataaaaagt	6840
aaatatgaaa	cattttaaatt	ataatttggt	gtcaaagtaa	tcaagtgttt	gtctTTTTtt	6900
tagTTTTagc	ttattgggat	tctctttggt	tatatTTaaa	attatacttt	gatttagaaa	6960
acataaatgc	ttccccttag	cattttggtt	atggaaaatt	acaaaactttt	atTTTTtagaa	7020
aacagaactc	ctttccagaa	ataggttaca	aacagtagtg	tcctccacag	aatgttgga	7080
atgttttcaa	ctccccactg	tatactatct	tgctaataag	tctgtcttca	gatttcgatt	7140
aaccggtttg	tatgtc					7156

&lt;210&gt; 42

&lt;211&gt; 4065

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(4065)

&lt;223&gt; Rho-associated, coiled coil containing protein kinase 1 (ROCK1), mRNA

&lt;400&gt; 42

atgtcgactg	gggacagttt	tgagactcga	tttgaaaaaa	tggacaacct	gctgcgggat	60
cccaaatcgg	aagtgaattc	ggattgtttg	ctggatggat	tggatgcttt	ggtatatgat	120
ttggattttc	ctgccttaag	aaaaaacaaa	aatattgaca	actttttaag	cagatataaa	180
gacacaataa	ataaaatcag	agattttacga	atgaaagctg	aagattatga	agtagtgaag	240
gtgattggta	gaggtgcatt	tggagaagtt	caattggtaa	ggcataaatc	caccaggaag	300
gtatatgcta	tgaagcttct	cagcaaattt	gaaatgataa	agagatctga	ttctgctttt	360
ttctgggaag	aaagggacat	catggctttt	gccaacagtc	cttgggttgt	tcagcttttt	420
tatgcattcc	aagatgatcg	ttatctctac	atggtgatgg	aatacatgcc	tggtggagat	480
cttgtaaaact	taatgagcaa	ctatgatgtg	cctgaaaaat	gggcacgatt	ctatactgca	540
gaagtagttc	ttgcattgga	tgcaatccat	tccatgggtt	ttattcacag	agatgtgaag	600
cctgataaca	tgctgctgga	taaatctgga	catttgaagt	tagcagattt	tggtacttgt	660
atgaagatga	ataaggaagg	catggtacga	tgtgatacag	cggttggaac	acctgattat	720

atttcccctg	aagtattaaa	atcccaaggt	ggtgatgggt	attatggaag	agaatgtgac	780
tggtggtcgg	ttgggggtatt	tttatacgaa	atgcttgtag	gtgatacacc	tttttttgca	840
gattcttttgg	ttggaactta	cagtaaaatt	atgaaccata	aaaattcact	tacctttcct	900
gatgataatg	acatatcaaa	agaagcaaaa	aaccttattt	gtgccttcct	tactgacagg	960
gaagtggagt	tagggcgaaa	tggtgtagaa	gaaatcaaac	gacatctctt	cttcaaaaat	1020
gaccagtggg	cttgggaaac	gctccgagac	actgtagcac	cagttgtacc	cgatttaagt	1080
agtgcatttg	atactagtaa	ttttgatgac	ttggaagaag	ataaaggaga	ggaagaaaca	1140
ttccctattc	ctaaaagcttt	cgttggcaat	caactacctt	ttgtaggatt	tacatattat	1200
agcaatcgta	gatacttatc	ttcagcaaat	cctaagtata	acagaactag	ctccaatgca	1260
gataaaagct	tgcaaggaaa	tttgcaaaaa	acaatctata	agctggaaga	acagctgcat	1320
aatgaaatgc	agttaaaaga	tgaaatggag	cagaagtgc	gaacctcaaa	cataaaacta	1380
gacaagataa	tgaaagaatt	ggatgaagag	ggaaatcaaa	gaagaaatct	agaatctaca	1440
gtgtctcaga	ttgagaagga	gaaaatgttg	ctacagcata	gaattaatga	gtaccaagaa	1500
aaagctgaac	aggaaaaatga	gaagagaaga	aatgtagaaa	atgaagtttc	tacattaaag	1560
gatcagtttg	aagacttaaa	gaaagtcagt	cagaattcac	agcttgctaa	tgagaagctg	1620
ttccagttac	aaaagcagct	agaagaagcc	aatgacttac	ttaggacaga	atcggaacaca	1680
gctgtaagat	tgagggaagag	tcacacagag	atgagcaagt	caattagtca	gttagagtc	1740
ctgaacagag	agttgcaaga	gagaaatcga	atttttagaga	attctaagtc	acaaacagac	1800
aaagattatt	accagctgca	agctatatta	gaagctgaac	gaagagacag	aggtcatgat	1860
tctgagatga	ttggagacct	tcaagctcga	attacatctt	tacaagagga	ggtgagcat	1920
ctcaaacata	atctcgaaaa	agtggaaagga	gaaagaaaaag	aggctcaaga	catgcttaat	1980
cactcagaaa	aggaaaagaa	taatttagag	atagatttaa	actacaaact	taaatcatta	2040
caacaacggt	tagaacaaga	ggtaaatgaa	cacaaagtaa	ccaaagctcg	tttaactgac	2100
aaacatcaat	ctattgaaga	ggcaaaagtct	gtggcaatgt	gtgagatgga	aaaaaagctg	2160
aaagaagaaa	gagaagctcg	agagaaggct	gaaaatcggg	ttgttcagat	tgagaaacag	2220
tgttccatgc	tagacgttga	tctgaagcaa	tctcagcaga	aactagaaca	tttgactgga	2280
aataaagaaa	ggatggagga	tgaagttaag	aatctaacc	tgcaactgga	gcaggaatca	2340
aataagcggc	tgttgttaca	aaatgaattg	aagactcaag	catttgaggc	agacaattta	2400
aaaggtttag	aaaagcagat	gaaacaggaa	ataaatactt	tattggaagc	aaagagatta	2460
ttagaatttg	agttagctca	gcttacgaaa	cagtatagag	gaaatgaagg	acagatgcgg	2520
gagctacaag	atcagcttga	agctgagcaa	tatttctcga	cactttataa	aaccaggta	2580
aaaggaaactta	aagaagaaat	tgaagaaaaa	aacagagaaa	atttaaagaa	aatacaggaa	2640
ctacaaaatg	aaaaagaaac	tcttgctact	cagttggatc	tagcagaaac	aaaagctgag	2700
tctgagcagt	tggcgcgagg	ccttctggaa	gaacagtatt	ttgaattgac	gcaagaaagc	2760
aagaagcgtg	cttcaagaaa	tagacaagag	attacagata	aagatcacac	tgtagtcgg	2820
cttgaagaag	caaacagcat	gctaaccaaa	gatattgaaa	tattaagaag	agagaatgaa	2880
gagctaacag	agaaaatgaa	gaaggcagag	gaagaatata	aactggagaa	ggaggaggag	2940
atcagtaatc	ttaaggctgc	ctttgaaaag	aatatcaaca	ctgaacgaac	ccttaaaaca	3000
caggctgtta	acaaattggc	agaaataatg	aatcgaaaag	attttaaaat	tgatagaaag	3060
aaagctaata	cacaagattt	gagaaagaaa	gaaaaggaaa	atcgaaagct	gcaactggaa	3120
ctcaaccaag	aaagagagaa	attcaaccag	atggtagtga	aacatcagaa	ggaactgaat	3180
gacatgcaag	cgcaattggt	agaagaatgt	gcacatagga	atgagcttca	gatgcagttg	3240
gccagcaaa	agagtgatat	tgagcaattg	cgtgctaaac	ttttggacct	ctcggattct	3300
acaagtgttg	ctagttttcc	tagtgctgat	gaaactgatg	gtaacctccc	agagtcaaga	3360
attgaagggt	ggctttcagt	accaaataga	ggaaatatca	aacgatatgg	ctggaagaaa	3420
cagtatgttg	tggttaagcag	caaaaaaatt	ttgttctata	atgacgaaca	agataaggag	3480
caatccaatc	catctatggt	attggacata	gataaactgt	ttcacgttag	acctgtaacc	3540
caaggagatg	tgtatagagc	tgaaactgaa	gaaattccta	aaatattcca	gatactatat	3600
gcaaatgaag	gtgaatgtag	aaaagatgta	gagatggaac	cagtacaaca	agctgaaaaa	3660
actaatcttc	aaaatcacaa	aggccatgag	tattttccta	cactctacca	ctttcctgcc	3720
aattgtgatg	cctgtgccaa	acctctctgg	ctgtttttta	agccaccccc	tgccctagag	3780
tgctgaagat	gccatgttaa	gtgccacaga	gatcacttag	ataagaaaga	ggacttaatt	3840
tgctcatgta	aagtaagtta	tgatgtaaca	tcagcaagag	atatgctgct	gttagcatgt	3900
tctcaggatg	aacaaaaaaa	atgggtaact	catttagtaa	agaaaatccc	taagaatcca	3960
ccatctgggt	ttgttcgtgc	ttccctcga	acgctttcta	caagatccac	tgcaaatcag	4020
tctttccgga	aagtgggtcaa	aaatacatct	ggaaaaacta	gttaa		4065

&lt;210&gt; 43

&lt;211&gt; 2304



&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(2304)

&lt;223&gt; Human pro-urokinase mRNA

&lt;400&gt; 43

gtccccgcag	cgccgctcgcg	ccctcctgcc	gcaggccacc	gaggccgcgcg	ccgtctagcg	60
ccccgacctc	gccacatga	gagccctgct	ggcgcgcctg	cttctctgcg	tcctggctcgt	120
gagcgactcc	aaaggcagca	atgaacttca	tcaagttcca	tcgaactgtg	actgtctaaa	180
tggaggaaca	tgtgtgtcca	acaagtactt	ctccaacatt	cactggtgca	actgccccaa	240
gaaattcgga	gggcagcact	gtgaaataga	taagtcaaaa	acctgctatg	aggggaatgg	300
tcactttttac	cgaggaaagg	ccagcactga	caccatgggc	cggccctgcc	tgccctggaa	360
ctctgccact	gtccttcagc	aaacgtacca	tgcccacaga	tctgatgctc	ttcagctggg	420
cctggggaaa	cataattact	gcaggaaccc	agacaaccgg	aggcgaccct	ggtgctatgt	480
gcaggtgggc	ctaaaagccgc	ttgtccaaga	gtgcatggtg	catgactgcg	cagatggaaa	540
aaagccctcc	tctcctccag	aagaattaaa	atttcagtgt	ggccaaaaga	ctctgaggcc	600
ccgctttaag	attattgggg	gagaattcac	caccatcgag	aaccagccct	ggtttgcggc	660
catctacagg	aggcaccggg	ggggctctgt	cacctacgtg	tgtggaggca	gcctcatcag	720
cccttgctgg	gtgatcagcg	ccacacactg	cttcattgat	tacccaaaga	aggaggacta	780
catcgtctac	ctgggtcgct	caaggcttaa	ctccaacacg	caaggggaga	tgaagtttga	840
ggtggaaaac	ctcatcctac	acaaggacta	cagcgctgac	acgcttgctc	accacaacga	900
cattgccttg	ctgaagatcc	gttccaagga	gggcaggtgt	gcgcagccat	cccggactat	960
acagaccatc	tgcttgcctt	cgatgtataa	cgatccccag	tttggcacaa	gctgtgagat	1020
cactggcttt	gaaaagaga	attctaccga	ctatctctat	ccggagcagc	tgaaaatgac	1080
tgttgtgaag	ctgatttccc	accgggagtg	tcagcagccc	cactactacg	gctctgaagt	1140
caccacccaaa	atgctatgtg	ctgctgaccc	ccaatggaaa	acagattcct	gccaggggaga	1200
ctcaggggga	cccctcgtct	gttcctccca	aggccgcagc	actttgactg	gaattgtgag	1260
ggtggcccg	ggtcttgccc	tgaaggacaa	gccaggcgtc	tacacgagag	tctcacactt	1320
cttaccctgg	atccgcagtc	acaccaagga	agagaatggc	ctggccctct	gaggggtccc	1380
agggaggaaa	cgggcaccac	ccgctttctt	gctgggtgtc	atTTTTgcag	tagagtcatc	1440
tccatcagct	gtaagaagag	actgggaaga	taggctctgc	acagatggat	ttgcctgtgg	1500
caccaccagg	gtgaacgaca	atagctttac	cctcacggat	aggcctgggt	gctggctgcc	1560
cagaccctct	ggccaggatg	gaggggtggg	cctgactcaa	catgttactg	accagcaact	1620
tgtctttttc	tggactgaag	cctgcaggag	ttaaaaaggg	cagggcatct	cctgtgcatg	1680
ggctcgaagg	gagagccagc	tccccgacc	ggtgggcatt	tgtgaggccc	atggttgaga	1740
aatgaataat	ttcccaatta	ggaagtgtaa	gcagctgagg	tctcttgagg	gagcttagcc	1800
aatgtgggag	cagcggtttg	gggagcagag	acactaacga	cttcagggca	gggctctgat	1860
attccatgaa	tgtatcagga	aatatatatg	tgtgtgtatg	tttgcacact	tgttgtgtgg	1920
gctgtgagtg	taagtgtgag	taagagctgg	tgtctgattg	ttaagtctaa	atatttcctt	1980
aaactgtgtg	gactgtgatg	ccacacagag	tggtctttct	ggagagggtta	taggtcactc	2040
ctggggcctc	ttgggtcccc	cacgtgacag	tgccctggaa	tgtacttatt	ctgcagcatg	2100
acctgtgacc	agcactgtct	cagtttcaact	ttcacataga	tgtccctttc	ttggccagtt	2160
atcccttccct	tttagcctag	ttcatccaat	cctcactggg	tggggtgagg	accactcctt	2220
acactgaata	tttatatttc	actattttta	tttatatttt	tgtaatTTta	aataaaaagtg	2280
atcaataaaa	tgtgattttt	ctga				2304

&lt;210&gt; 44

&lt;211&gt; 2519

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1) .. (2519)

&lt;223&gt; Human tissue-type plasminogen activator (t-PA) mRNA

&lt;400&gt; 44

acagggctgg	agagaaaacc	tctgcgagga	aagggaagga	gcaagccgtg	aatttaagg	60
acgctgtgaa	gcaatcatgg	atgcaatgaa	gagagggtc	tgctgtgtgc	tgctgtgtg	120
tggagcagtc	ttcgtttcgc	ccagccagga	aatccatgcc	cgattcagaa	gaggagccag	180
atcttaccaa	gtgatctgca	gagatgaaaa	aacgcagatg	atataccagc	aacatcagtc	240
atggctgcgc	cctgtgctca	gaagcaaccg	ggtggaatat	tgctggtgca	acagtggcag	300
ggcacagtgc	cactcagtgc	ctgtcaaaa	ttgcagcgag	ccaagggtgt	tcaacggggg	360
cacctgccag	caggccctgt	acttctcaga	tttcgtgtgc	cagtgtcccc	aaggatttgc	420
tgggaagtgc	tgtgaaatag	ataccagggc	cacgtgctac	gaggaccagg	gcatcagcta	480
caggggcacg	tggagcacag	cggagagtgg	cgccgagtgc	accaactgga	acagcagcgc	540
gttggcccag	aagccctaca	gcgggcccag	gccagacgcc	atcaggctgg	gcctggggaa	600
ccacaactac	atgcagaacc	cagatcgaga	ctcaaagccc	tggtgctacg	tctttaaggc	660
ggggaagtac	agctcagagt	tctgcagcac	ccctgcctgc	tctgagggaa	acagtgactg	720
ctactttggg	aatgggtcag	cctaccgtgg	cacgcacagc	ctcaccgagt	cgggtgcctc	780
ctgcctcccg	tggaaattcca	tgatcctgat	aggcaagggt	tacacagcac	agaaccccag	840
tgcccaggca	ctgggcctgg	gcaaacataa	ttactgccgg	aatcctgatg	gggatgccaa	900
gccctggtgc	cacgtgctga	agaaccgcag	gctgacgtgg	gagtactgtg	atgtgcctc	960
ctgtccacc	tgcggcctga	gacagtacag	ccagcctcag	tttcgcatca	aaggagggtc	1020
cttcgccag	cctgcctccc	acccctggca	ggctgcctac	tttgccaagc	acaggagggtc	1080
gcccgagag	cggttcctgt	gcgggggcat	actcaccagc	tcctgctgga	ttctctctgc	1140
cgccactgc	ttccaggaga	ggtttcgcgc	ccaccacctg	acggtgatct	tgggcagaa	1200
ataccgggtg	gtccctggcg	aggaggagca	gaaatttgaa	gtcgaaaaat	acattgtcca	1260
taaggaaattc	gatgatgaca	cttacgacaa	tgacattgcg	ctgtgcagc	tgaaatcgga	1320
ttcgtcccg	tgtgcccgag	agagcagcgt	ggtccgcact	gtgtgccttc	ccccggcgga	1380
cctgcagctg	cggactgga	cggagtgtga	gctctccggc	tacggcaagc	atgaggcctt	1440
gttcctttc	tattcggagc	ggctgaagga	ggctcattgc	agactgtacc	catccagccg	1500
ctgcacatca	caacatttac	ttaacagaa	agtcaccgac	aacatgctgt	gtgctggaga	1560
cactcggagc	ggcgggcccc	aggcaaaact	gcacgacgcc	tgccagggcg	attcgggagg	1620
ccccctggtg	tgtctgaacg	atggccgcac	gactttgggtg	ggcatcatca	gctggggcct	1680
gggctgtgga	cagaaggatg	tcccgggtgt	gtacaccaag	gttaccact	acctagactg	1740
gattcgtgac	aacatgcgac	cgtgaccagg	aacacccgac	tcctcaaaa	caaagttagat	1800
cccgctctt	cttcttcaga	agacactgca	aaggcgcagt	gcttctctac	agacttctcc	1860
agaccacca	caccgcagaa	gcgggacgag	accctacagg	agagggaaga	gtgcattttc	1920
ccagatactt	ccatttttgg	aagttttcag	gacttgggtc	gatttcagga	tactctgtca	1980
gatgggaaga	catgaatgca	cactagcctc	tccaggaatg	cctcctccct	gggcagaagt	2040
ggccatgcca	ccctgttttc	agctaaagcc	caacctcctg	acctgtcacc	gtgagcagct	2100
ttggaacag	gaccacaaaa	atgaaagcat	gtctcaatag	taaaagataa	caagatcttt	2160
caggaaagac	ggattgcatt	agaaatagac	agtatatatta	tagtcacaag	agcccagcag	2220
ggetcaaagt	tggggcaggc	tggctggccc	gtcatgttcc	tcaaaagcac	ccttgacgtc	2280
aagtctcctt	cccctttccc	cactccctgg	ctctcagaag	gtattccttt	tgtgtacagt	2340
gtgtaaagt	taaattcctt	ttctttataa	acttttagagt	agcatgagag	aattgtatca	2400
tttgaacaac	taggtttcag	catatttata	gcaatccatg	ttagttttta	ctttctgttg	2460
ccacaaccct	gtttttatac	gtacttaata	aattcagata	tatttttcac	agtttttcc	2519

&lt;210&gt; 45

&lt;211&gt; 1103

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt; ?

&lt;221&gt; gene

&lt;222&gt; (1)..(1103)

&lt;223&gt; GRO1 oncogene (melanoma growth stimulating activity, alpha) (GRO1), mRNA

&lt;400&gt; 45

cacagagccc	gggcccgcagg	cacctcctcg	ccagctcttc	cgctcctctc	acagccgcca	60
gacccgcctg	ctgagcccca	tgcccgcgc	tgctctctcc	gccgccccca	gcaatccccg	120
gctcctgcga	gtggcactgc	tgctcctgct	cctggtagcc	gctggccggc	gcgcagcagg	180
agcgtccgtg	gccactgaac	tgcgctgcca	gtgcttgag	accctgcagg	gaattcaccc	240
caagaacatc	caaagtgtga	acgtgaagtc	ccccggaccc	cactgcgccc	aaaccgaagt	300
catagccaca	ctcaagaatg	ggcggaaaagc	ttgcctcaat	cctgcatccc	ccatagttaa	360
gaaaatcatc	gaaaagatgc	tgaacagtga	caaatccaac	tgaccagaag	ggaggaggaa	420
gctcactggt	ggctgttcct	gaaggaggcc	ctgcccttat	aggaacagaa	gaggaaagag	480
agacacagct	gcagaggcca	cctggattgt	gcctaattgt	tttgagcatc	gcttaggaga	540
agtcttctat	ttatttattt	attcattagt	tttgaagatt	ctatgttaat	attttagggtg	600
taaaataatt	aagggtatga	ttaactctac	ctgcacactg	tcctattata	ttcattcttt	660
ttgaaatgtc	aaccccaagt	tagttcaatc	tggattcata	tttaatttga	aggtagaatg	720
ttttcaaagt	ttctccagtc	attatgttaa	tatttctgag	gagcctgcaa	catgccagcc	780
actgtgatag	aggctggcgg	atccaagcaa	atggccaatg	agatcattgt	gaaggcaggg	840
gaatgtatgt	gcacatctgt	tttgtaactg	tttagatgaa	tgtcagttgt	tatttattga	900
aatgatttca	cagtgtgtgg	tcaacatttc	tcatgttgaa	actttaagaa	ctaaaatgtt	960
ctaaatatcc	cttgacatt	ttatgtcttt	cttgtaaggc	atactgcctt	gtttaatggt	1020
agttttacag	tgtttctggc	ttagaacaaa	ggggcttaat	tattgatgtt	ttcatagaga	1080
atataaaaaat	aaagcactta	tag				1103

&lt;210&gt; 46

&lt;211&gt; 3166

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(3166)

&lt;223&gt; Vascular endothelial growth factor mRNA

&lt;400&gt; 46

aagagctcca	gagagaagtc	gaggaagaga	gagacggggt	cagagagagc	gcgcgggcgt	60
gcgagcagcg	aaagcgacag	gggcaaagtg	agtgaacctg	ttttgggggt	gaccgcccga	120
gcgcggcggtg	agccctcccc	cttgggatcc	cgagctgac	cagtcgcgct	gacggacaga	180
cagacagaca	ccgccccag	ccccagttac	cacctcctcc	ccggccggcg	gcggacagtg	240
gacgcggcgg	cgagccgcgg	gcaggggccc	gagcccgcgc	ccggaggcgg	ggtggagggg	300
gtcggagctc	gcggcgctgc	actgaaactt	ttcgtccaac	ttctgggctg	ttctcgcttc	360
ggaggagccg	tggtccgcgc	gggggaagcc	gagccgagcg	gagccgcgag	aagtgtatgc	420
tcggggccggg	aggagccgca	gccggaggag	ggggaggagg	aagaagagaa	ggaagaggag	480
agggggccgc	agtggcgact	cggcgctcgg	aagccgggct	catggacggg	tgaggcggcg	540
gtgtgcgcag	acagtgtctc	agcgcgcgcg	ctccccagcc	ctggcccggc	ctcgggccgg	600
gaggaagagt	agctcgccga	ggcgccgagg	agagcgggcc	gccccacagc	ccgagccgga	660

```

gagggacgcg agccgcgcgc cccggtcggg cctccgaaac catgaacttt ctgctgtctt 720
gggtgcattg gagccttgcc ttgctgtctt acctccacca tgccaagtgg tcccaggctg 780
caccatggc agaaggagga gggcagaatc atcacgaagt ggtgaagttc atggatgtct 840
atcagcgcag ctactgccat ccaatcgaga ccttggtgga catcttccag gaggaccctg 900
atgagatcga gtacatcttc aagccatcct gtgtgccctt gatgcgatgc gggggctgct 960
ccaatgacga gggcctggag tgtgtgcccc ctgaggagtc caacatcacc atgcagattt 1020
tgcgatcaa acctcacaa ggccagcaca taggagagat gagcttccta cagcacaaca 1080
aatgtgaatg cagaccaaag aaagatagag caagacaaga aaatccctgt gggccttgct 1140
cagagcggag aaagcatttg tttgtacaag atccgcagac gtgtaaatgt tcctgcaaaa 1200
acacacactc gcgttgcaag gcgaggcagc ttgagttaaa cgaacgtact tgcagatgtg 1260
acaagccgag gcggtgagcc gggcaggagg aaggagcctc cctcaggggt tcgggaacca 1320
gatctctctc caggaaagac tgatacagaa cgatcgatac agaaaccacg ctgccgccac 1380
cacaccatca ccatcgacag aacagtcctt aatccagaaa cctgaaatga aggaagagga 1440
gactctgcgc agagcacttt gggtcgggag ggcgagactc cgccggaagc attcccgggc 1500
gggtgaccca gcacggtccc tcttggaatt ggattcgcca ttttattttt cttgctgcta 1560
aatcaccgag cccggaagat tagagagttt ttttctggg attcctgtag acacaccac 1620
ccacatacat acatttatat atatatatat tatatatata taaaaataaa tatctctatt 1680
ttatatatat aaaatatata tttctttttt ttaaattaac agtgctaatt ttattggtgt 1740
cttactgga tgtatttgac tgctgtggac ttgagttggg aggggaatgt tcccactcag 1800
atcctgacag ggaagaggag gagatgagag actctggcat gatctttttt ttgtcccac 1860
tggtggggcc aggttctctt cccctgccca agaattgtca aggccagggc atgggggcaa 1920
atatgaccca gttttgggaa caccgacaaa cccagccctg gcgctgagcc tctctaoccc 1980
aggtcagacg gacagaaaga caaatcacag gttccgggat gaggacaccg gctctgacca 2040
ggagtttggg gagcttcagg acattgctgt gctttgggga tccctccac atgctgcacg 2100
cgcatctcgc ccccaggggc actgcctgga agattcagga gcctgggagg ccttcgctta 2160
ctctcacctg cttctgagtt gcccaggagg cactggcag atgtcccggc gaagagaaga 2220
gacacattgt tggaagaagc agcccatgac agcggccctt cctgggactc gccctcatcc 2280
tcttctgct ccccttctct ggggtgcagcc taaaaggacc tatgtcctca caccattgaa 2340
accatagtt ctgtccccc aggaacctg gttgtgtgtg tgtgagtggt tgaccttct 2400
ccatccctg gtccttccct tcccttcccg aggcacagag agacagggca ggatccacgt 2460
gccattgtg gaggcagaga aaagagaaag tgttttatat acggtactta tttaatatcc 2520
ctttttaatt agaaattaga acagttaatt taattaaaga gtagggtttt ttttcagtat 2580
tcttggttaa tatttaattt caactattta tgagatgtat cttttgctct ctcttgctct 2640
cttatttgta cgggtttttg tatataaaat tcatgtttcc aatctctctc tccctgatcg 2700
gtgacagtca ctagcttata ttgaacagat atttaatttt gctaacactc agctctgccc 2760
tcccgcagtc cctggctccc cagcacacat tcctttgaaa gaggggttca atatacatct 2820
acatactata tatatatgg gcaacttgta tttgtgtgta tatatatata tatatgttta 2880
tgtatatatg tgatcctgaa aaaataaaca tcgctattct gttttttata tgttcaaacc 2940
aaacaagaaa aaatagagaa ttctacatac taaatctctc tcctttttta attttaatat 3000
ttgttatcat ttatttattg gtgctactgt ttatccgtaa taattgtggg gaaaagatat 3060
taacatcacg tctttgtctc tagtgagtt tttcgagata ttccgtagta catatttatt 3120
tttaacaac gacaaagaaa tacagatata tcttaaaaaa aaaaaa 3166

```

&lt;210&gt; 47

&lt;211&gt; 2360

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(2360)

&lt;223&gt; Heparin-binding EGF-like growth factor mRNA

&lt;400&gt; 47

gctacgcggg	ccacgctgct	ggctggcctg	acctaggcgc	gcggggctcg	gcggccgcgc	60
gggcgggctg	agttagcaag	acaagacact	caagaagagc	gagctgcgcc	tgggtcccgg	120
ccaggcttgc	acgcagaggc	gggcggcaga	cggtgcccgc	cggaaatctcc	tgagctccgc	180
cgcccagctc	tggtgccagc	gcccagtggc	cgccgcttcg	aaagtgactg	gtgcctcgcc	240
gcctcctctc	ggtgcgggac	catgaagctg	ctgccgtcgg	tggtgctgaa	gctctttctg	300
gctgcagttc	tctcggcact	ggtgactggc	gagagcctgg	agcggcttcg	gagagggcta	360
gctgtgggaa	ccagcaaccc	ggaccctccc	actgtatcca	cggaccagct	gctacccta	420
ggaggcggcc	gggaccggaa	agtccgtgac	ttgcaagagg	cagatctgga	ccttttgaga	480
gtcactttat	cctccaagcc	acaagcactg	gccacaccaa	acaaggagga	gcacgggaaa	540
agaaagaaga	aaggcaaggg	gctaggggaa	aagagggacc	catgtcttcg	gaaatacaag	600
gacttctgca	tccatggaga	atgcaaatat	gtgaaggagc	tccgggctcc	ctcctgcata	660
tgccaccogg	gttaccatgg	agagaggtgt	catgggctga	gcctcccagt	ggaaaatcgc	720
ttatatacct	atgaccacac	aaccatcctg	gccgtgggtg	ctgtgggtgt	gtcatctgtc	780
tgtctgctgg	tcacgtggg	gcttctcatg	tttaggtacc	ataggagagg	aggttatgat	840
gtggaaaatg	aagagaaaat	gaagttgggc	atgactaatt	ccactgaga	gagacttgtg	900
ctcaaggaat	cggctgggga	ctgctacctc	tgagaagaca	caaggtgatt	tcagactgca	960
gaggggaaag	acttccatct	agtcacaaag	actccttcgt	ccccagttgc	cgtctaggat	1020
tgggcctccc	ataattgctt	tgccaaaata	ccagagcctt	caagtgccaa	acagagtatg	1080
tccgatggta	tctgggtaag	aagaaagcaa	aagcaaggga	ccttcatgcc	cttctgattc	1140
ccctccacca	aaccccactt	cccctcataa	gtttgtttta	acacttatct	tctggattag	1200
aatgccgggt	aaattccata	tgtctcagga	tctttgactg	aaaaaaaaaa	agaagaagaa	1260
gaaggagagc	aagaaggaaa	gatttgtgaa	ctggaagaaa	gcaacaaaga	ttgagaagcc	1320
atgtactcaa	gtaccaccaa	gggatctgcc	attgggaccc	tccagtgtctg	gatttgatga	1380
gttaactgtg	aaataccaca	agcctgagaa	ctgaattttg	ggacttctac	ccagatggaa	1440
aaataacaac	tatttttgtt	gttgttgttt	gtaaatgcct	cttaaattat	atatttattt	1500
tattctatgt	atgttaattt	atttagtttt	taacaatcta	acaataatat	ttcaagtgcc	1560
tagactgtta	ctttggcaat	ttcctggccc	tccactcctc	atccccacaa	tctggcttag	1620
tgccaccac	ctttgccaca	aagctaggat	ggttctgtga	cccatctgta	gtaatttatt	1680
gtctgtctac	atctctgcag	atcttccgtg	gtcagagtgc	cactgcggga	gctctgtatg	1740
gtcaggatgt	aggggttaac	ttggtcagag	ccactctatg	agttggactt	cagtcttgcc	1800
taggcgattt	tgtctacat	ttgtgttttg	aaagcccaag	gtgctgatgt	caaagtgtaa	1860
cagatatcag	tgtctccccg	tgtcctctcc	ctgccaaagtc	tcagaagagg	ttgggcttcc	1920
atgcctgtag	ctttcctggt	ccctcaccac	catggcccca	ggccacagcg	tgggaaactca	1980
ctttcccttg	tgtcaagaca	tttctctaac	tccctgccatt	cttctgggtgc	tactccatgc	2040
aggggtcagt	gcagcagagg	acagtctgga	gaagggtatta	gcaaagcaaa	aggctgagaa	2100
ggaacaggga	acattggagc	tgactgttct	tggttaactga	ttacctgcca	attgctaccg	2160
agaagggttg	agggtgggaa	ggctttgtat	aatcccaccc	acctcaccaa	aacgatgaag	2220
gtatgtgtgc	atggtccttt	ctggaagttt	ctgggtgccat	ttctgaactg	ttacaacttg	2280
tatttccaaa	cctggttcat	atttatactt	tgcaatccaa	ataaagataa	cccttattcc	2340
ataaaaaaaaa	aaaaaaaaaa					2360

&lt;210&gt; 48

&lt;211&gt; 2988

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(2988)

&lt;223&gt; Lipid-activated protein kinase PRK1 mRNA

&lt;400&gt; 48

tgagtaaact	gatacatcat	acgcgcgctc	ctctggccgc	ccctccctcc	gacgatcggg	60
gaccctggcg	ggcggcagga	ggacatggcc	agcgacgccc	tgacagtgga	gcctcgcagc	120
tggtccctgc	tagagcagct	gggcctggcc	ggggcagacc	tggcggcccc	cggggtacag	180

cagcagctgg	agctggagcg	ggagcggctg	cggcgggaaa	tccgcaagga	gctgaagctg	240
aaggaggggtg	ctgagaacct	gcggcggggc	accactgacc	tgggccgcag	cctggggcccc	300
gtagagctgc	tgtctcgggg	ctcctcggcg	cgcctcgacc	tgtctgacca	gcagctgcag	360
gagctgcacg	cccacgtggt	gcttcccgcg	cggcgggcca	cccacgatgg	cccccagtc	420
cctggtgcgg	gtggccccac	ctgctcggcc	accaacctga	gccgcgtggc	gggcctggag	480
aagcagttgg	ccattgagct	gaaggtgaag	cagggggcgg	agaacatgat	ccagacctac	540
agcaatggca	gcaccaagga	ccggaagctg	ctgctgacag	cccagcagat	gttgaggag	600
agtaagacca	agattgacat	catccgcgat	caactccgcc	gggcgctgca	ggccgaccag	660
ctggagaacc	aggcagcccc	ggatgacacc	caaggagtc	ctgacctggg	ggctgtggag	720
ctgcgcacgc	aagagctgcg	gcaccacttc	cgagtggagc	acgcggtggc	cgagggtgcc	780
aagaacgtac	tgcgcctgct	cagcgctgcc	aaggccccgg	accgcaaggc	agtcagcgag	840
gcccaggaga	aattgacaga	atccaaccag	aagctggggc	tgtctcgggg	ggctctggag	900
cggagacttg	gggagctgcc	cgccgaccac	cccaaggggc	ggctgctgcg	agaagagctc	960
ctgctcgccct	cctccgctgc	cttcagcacc	cgcctggccg	ggccctttcc	cgccacgcac	1020
tacagcacc	tgtgcaagcc	cgcgcgctc	acagggaccc	tggaggtacg	agtggtgggc	1080
tgcagagacc	tcccagagac	catcccgtgg	aaccctaccc	cctcaatggg	gggacctggg	1140
accccagaca	gccgcccccc	cttctgagc	cgcccagccc	ggggccttta	cagccgaagc	1200
ggaagcctca	gtggccggag	cagcctcaaa	gcagaagccg	agaacaccag	tgaagtcagc	1260
actgtgctta	agctggataa	cacagtgggtg	gggcagacgt	cttggaagcc	atgtggcccc	1320
aatgcctggg	accagagctt	cactctggag	ctggaaaggg	cacgggaact	ggagtgggct	1380
gtgttctggc	gggaccagcg	gggcctgtgt	gccctcaaat	tcctgaagtt	ggaggatttc	1440
ttggacaatg	agggcatga	ggtgcagctg	gacatggaa	cccagggtcg	cctggtggct	1500
gaggtcacct	tccgcaaccc	tgtcattgag	aggattcctc	ggctccgacg	gcagaagaaa	1560
atcttctcca	agcagcaagg	gaaggcgttc	cagcgtgcta	ggcagatgaa	catcgatgtc	1620
gccacgtggg	tgcggtgct	ccggaggctc	atccccaatg	ccacgggcac	aggcaccttt	1680
agccctgggg	cttctccagg	atccgaggcc	cggaccacgg	gtgacatatc	ggtggagaag	1740
ctgaacctcg	gcactgactc	ggacagctca	cctcagaaga	gctcgcggga	tcctccttcc	1800
agcccattga	gcctgagctc	ccccatccag	gaatccactg	ctcccagagc	gccttcggag	1860
accagggaga	cccagggccc	cgcctgtgc	agccctctga	ggaagtacc	tctgacctc	1920
gaagatttca	agttcctggc	ggtgctgggc	cggggctcatt	ttgggaagg	gctcctctcc	1980
gaattccggc	ccagtgggga	gctgttcgcc	atcaaggctc	tgaagaaagg	ggacattgtg	2040
gcccagagacg	aggtggagag	cctgatgtgt	gagaagcgga	tattggcggc	agtgaccagt	2100
gcgggacacc	ccttcctggt	gaacctcttc	ggctgtttcc	agacaccgga	gcacgtgtgc	2160
ttcgtgatgg	agtactcggc	cgggtggggac	ctgatgctgc	acatccacag	cgacgtgttc	2220
tctgagcccc	gtgccatctt	ttattccgcc	tgcgtggtgc	tgggcctaca	gtttcttcac	2280
gaaccaaga	tcgtctacag	ggacctgaag	ttggacaatt	tgtccttga	caccgagggc	2340
tacgtcaaga	tcgcagactt	tggcctctgc	aaggagggga	tgggctatgg	ggaccggacc	2400
agcacattct	gtgggacccc	ggagtctctg	gcccctgagg	tgtgacgga	cacgtcgta	2460
acgcgagctg	tggactgggt	gggactgggt	gtgctgctct	acgagatgct	ggttggcgag	2520
tccccattcc	caggggatga	tgaggaggag	gtcttcgaca	gcacgtcaa	cgacgaggtt	2580
cgctaccccc	gcttcctgtc	ggccgaagcc	atcgcatca	tgagaaggct	gcttcggagg	2640
aaccagagc	ggaggctggg	atctagcgag	agagatgcag	aagatgtgaa	gaaacagccc	2700
ttcttcagga	ctctgggctg	ggaagccctg	ttggcccggc	gcctgccacc	gccctttgtg	2760
cccacgctgt	ccggccgcac	cgacgtcagc	aacttcgacg	aggagttcac	cggggaggcc	2820
cccacactga	gcccgccccg	cgacgcgcgg	ccctcacag	ccgcggagca	ggcagccttc	2880
ctggacttgc	acttcgtggc	cgggggctgc	tagccccctc	ccctgcccct	gcccctgccc	2940
ctgcccagaga	gctcttagtt	tttaaaaagg	cctttgggat	ttgccgga		2988

&lt;210&gt; 49

&lt;211&gt; 2068

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(2068)

&lt;223&gt; Glycerol kinase (GK), mRNA

&lt;400&gt; 49

ttgaactcct	ggagcccgtc	accagggaaa	ccggccgcaa	tcgcccggccg	acctgaagct	60
ggtttcatgg	cagcctcaaa	gaaggcagtt	ttggggccat	tggtgggggc	ggtggaccag	120
ggcaccagtt	cgacgcgctt	tttggttttc	aattcaaaaa	cagctgaact	acttagtcat	180
catcaagtag	aaataaaaca	agagttccca	agagaaggat	gggtggaaca	ggaccctaag	240
gaaattctac	attctgtcta	tgagtgtata	gagaaaacat	gtgagaaact	tggacagctc	300
aatattgata	tttccaacat	aaaagctatt	ggtgtcagca	accagaggga	aaccactgta	360
gtctgggaca	agataactgg	agagcctctc	tacaatgctg	tggtgtggct	tgatctaaga	420
acccagtcta	ccgttgagag	tcttagtaaa	agaattccag	gaaataataa	ctttgtcaag	480
tccaagacag	gccttccact	tagcacttac	ttcagtcgag	tgaaacttcg	ttggctcctt	540
gacaatgtga	gaaaagttca	aaaggccggt	gaagaaaaac	gagctctttt	tgggactatt	600
gattcatggc	ttatttggag	tttgacagga	ggagtcaatg	gaggtgtcca	ctgtacagat	660
gtaacaaatg	caagtaggac	tatgcttttc	aacattcatt	ctttggaatg	ggataaacia	720
ctctgcgaat	tttttgggaat	tccaatggaa	attcctccaa	atgtccggag	ttcttctgag	780
atctatggcc	taatgaaagc	tggggccttg	gaaggtgtgc	caatatctgg	gtgttttaggg	840
gaccagtctg	ctgcattggg	gggacaaatg	tgcttccaga	ttggacaagc	caaaaaatac	900
tatggaacag	gatgtttctt	actatgtaat	acaggccata	agtgtgtatt	ttctgatcat	960
ggccttctca	ccacagtggc	ttacaaaact	ggcagagaca	aaccagtata	ttatgctttg	1020
gaaggttctg	tagctatagc	tggtgctgtt	attcgtctgg	taagagacaa	tcttggaatt	1080
ataaagacct	cagaagaaat	tgaaaaactt	gctaaagaag	taggtacttc	ttatggctgc	1140
tacttcgtcc	cagcattttc	ggggttatat	gcaccttatt	gggagcccag	cgcaagaggg	1200
ataatctgtg	gactcactca	gttcaccaat	aaatgccata	ttgcttttgc	tgcatataga	1260
gctgtttgtt	tccaaaactc	agagattttg	gatgccatga	atcgagactg	tggaattcca	1320
ctcagtcatt	tgcaggtaga	tgagggaatg	accagcaaca	aaattcctat	gcagctacaa	1380
gcagacattc	tgtatatacc	agtagtgaag	ccctcaatgc	ccgaaaccac	tgactgggtg	1440
gcggctatgg	cggcaggggc	tgacagaagg	gtcggcggtat	ggagtctcga	acccgaggat	1500
ttgtctgccc	tcacgatgga	gcggtttgaa	cctcagatta	atgcggagga	aagtgaattt	1560
cgttattcta	catggaagaa	agctgtgatg	aagtcaatgg	gttgggttac	aactcaatct	1620
ccagaaagtg	gtattccata	aaacctacca	actcatggat	tcccaagatg	tgagcttttt	1680
acataatgaa	agaaccagc	aattctgtct	cttaatgcaa	tgacactatt	catagacttt	1740
gatttttatt	ataagccact	tgctgcatga	ccctccaagt	agacctgtgg	cttaaaataa	1800
agaaaatgca	gcaaaaagaa	tgctatagaa	atatttggtg	gttttttttt	ttttaaacat	1860
ccacagttaa	ggttggggcca	gctacctttg	ggggtgacct	ccccattgc	cataacatcc	1920
tgctccattc	cctctaagat	gtaggaagaa	ttcggatcct	taccattgga	atcttccatc	1980
gaacatactc	aaacactttt	gggccaggat	ttgagtctct	gcatgacata	tacttgatta	2040
aaaggttatt	actaacctgt	taaaaatc				2068

&lt;210&gt; 50

&lt;211&gt; 2472

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(2472)

&lt;223&gt; Phosphaatidylserine decarboxylase (PISD), mRNA

&lt;400&gt; 50

cggaagctgg	agccacctgc	ggccctgacc	ctctattctg	caccctgtga	gccaccgaga	60
ctgaacaaaa	cccaggaagc	ggcgccacca	accagcctcg	cagaggcaga	ggccctggag	120

cagtgcacagc	acaggagatc	tgctggctcg	ggggaagggg	aggaaagagg	aaaacaaagg	180
gagtgatcga	gtgagcctcg	ccccgccctc	cctgcgcgcg	cccatgatgt	gtcagtcaga	240
ggcgcgggcaa	ggaccagagc	tccgcgcggc	gaaatgggtg	cacttcccc	agctggccct	300
gaggcggagg	ctggggcagc	tgagctgcat	gtccagaccc	gctctgaaac	tgcgctcctg	360
gcccttgacc	gtcctctact	acctcctgcc	cttcggcgcc	ctcagaccgc	tcagccgggt	420
gggatggagg	cccgtaaagca	gggtggcttt	gtacaagtca	gtgccaacgc	gcttgctgtc	480
acgggcctgg	ggtcgcctca	atcaggtgga	gctgccacac	tggtgcgca	ggcccgtcta	540
cagcctgtac	atctggacgt	ttggggtgaa	catgaaagag	gccgctgtgg	aggacctgca	600
tcactaccgc	aacctcagcg	agttcttccg	gcgcaagctg	aagccgcagg	cccggcctgt	660
ctgtggcctg	cacagcgtga	ttagcccatc	ggatggaagg	atcctcaact	ttgggcagggt	720
gaagaactgt	gaggtggagc	aggtaaaggg	ggtcacctac	tccctggagt	cgttcctggg	780
ccgcgctatg	tgacagaggg	acctgccctt	cccaccagcc	gcgtcgtgtg	actccttcaa	840
gaaccagctg	gtcaccgggg	aagggaatga	gctctatcac	tgtgtcatct	acctggcccc	900
tggggactac	cactgcttcc	actccccac	cgactggact	gtgtcccacc	ggcgccactt	960
cccaggctcc	ctgatgtcag	tgaaccttg	catggctcgc	tgatcaaag	agctcttctg	1020
ccataacgag	cgggtggtcc	tgacggggga	ctggaaacat	ggcttcttct	cactgcacagc	1080
tgtggggggc	accaacgtgg	gctccattcg	catctacttt	gaccggggacc	tgcacacaaa	1140
cagcccaagg	cacagcaagg	gctcctacaa	tgacttcagc	ttcgtgacgc	acaccaatag	1200
agaggcgctc	cccattgcgt	agggcgagca	cctgggcgag	ttcaacctgg	gtccaccat	1260
cggtctcatc	ttcagggccc	ccaaggactt	caatttccag	ctgaaaacag	gacagaaaat	1320
ccgctttggg	gaagccctgg	gctcgtctta	gagtctcttt	cctgattatg	gctgctaagg	1380
gatcttttcc	aaacagagtg	agggctcttt	caagagggag	gccccatgag	ccatccagggt	1440
aagggcctgc	ctcagcgtgg	ttgggagtct	gaccaggtag	gacttgaatg	attcggttac	1500
cacctgttcc	agaggtgcag	acaagaggtg	gcgagagccc	ccatcatgcc	cctcaacctt	1560
tcccgttcc	tctgcctaca	aataaaaagt	gcaggctgga	atgatctcag	tcacatttgg	1620
atctttttta	acactgtata	gacggaagag	cctgcattcc	tgaccgaacc	ttcagttggg	1680
ctcggtgtgc	gttttttctt	gctgctcttc	cccccatcac	ctgagctgtt	ttctgttggc	1740
cccttttggt	ttttggcctt	aacgctcctg	ctgcaaggg	tgagggtgct	ccttggcaca	1800
gactgtggat	gcctctcccc	cagcagagcc	acacagcctt	ctgacaact	gctttccggt	1860
cccacattca	cctcatcctg	ctcttttaga	aaagcagctt	ttgtgcttgt	ggctgaacgc	1920
atcaccctgg	actctgctag	tgtcttctga	ggacactgat	gacactgatt	aatgatacag	1980
acctttgcag	gacctgatga	gtgacccttc	tggagctggc	caggctcctct	gcagcaggca	2040
agaccaatca	atcactgaac	ctgcctcatg	gcaccagagt	gaacagggca	ggcaggtagt	2100
agggccagct	ggggaaatgg	gagagttcct	gtccccctcc	acatatccct	acatgaaata	2160
tgggaaagtt	gctgctattg	attcagggtc	tgtcttggag	gcagaggacc	cttgggtgat	2220
agtgtgtcag	tgccctggaaa	acctgtccca	gtttatcagg	aacgcaggcc	tggggagccc	2280
ccagtggcgg	ggacagggcc	agatttcatg	ttgaccctgg	ggatgctgtg	aatttctcct	2340
gcaggagaga	catcattgaa	ttttttcaac	tgtatcagta	gcacagtatt	tttgtatgaa	2400
aagtgggaga	cttctgaaca	gtaattcatt	taattgcaaa	gcattttgaa	ataaaaaaaa	2460
tcaaaactaa	aa					2472

&lt;210&gt; 51

&lt;211&gt; 1833

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1833)

&lt;223&gt; CDP-diacylglycerol--inositol 3-phosphatidyltransferase (phosphatidylinositol synthase) (CDIPT), mRNA

&lt;400&gt; 51

gaattcggca cgaggcgcgaggaggaggt tcccgggaagc cacgcgcact gggagcagcg 60



gcgaccgcag	ctggaggccc	ggagcgcctg	cggggctggc	agaggcgagg	gaggttgcgg	120
gtaggaaggg	cgggactgcg	cgcgccccct	gcgtcccgcg	cacctcgggg	ccggtccatg	180
ctcccgacgg	ctgcgggcctt	cagcatctgg	ggccagggtg	gggcggcggg	gtccagggcg	240
cagtgggtgcg	gccgatgcgc	cggggcccga	gctgaaggcc	gcgctgcggg	gctgggacag	300
cactggcatc	tccagagcag	gcccggggca	gcaaggagg	cgccgcgatg	ccagacgaaa	360
atatcttccct	gttcgtgccc	aacctcatcg	gttatgcccg	gattgtcttc	gccatcattt	420
ctttctactt	catgcctgc	tgccccctca	cggcctcctc	cttctacctg	ctcagcggcc	480
tgctggacgc	tttcgatgga	cacgctgctc	gcgctcttaa	tcaaggaacc	cggtttgggg	540
ccatgctgga	catgctgacg	gaccgctgct	ccaccatgtg	cctgttggtc	aacctggccc	600
tgctgtaccc	tggagccacg	ctgttcttcc	aaatcagcat	gagtttggtg	gtggccagtc	660
actggctgca	cctccacagt	tctgtgggtc	gaggcagtga	gagtcacaag	atgatcgact	720
tgtccgggaa	tccggtgctt	cggatctact	acacctcgag	gcctgctctg	ttcaccttgt	780
gtgctgggaa	tgagctcttc	tactgcctcc	tctacctgtt	ccatttctct	gagggacctt	840
tagttggctc	tgtgggactg	ttccggatgg	gcctctgggt	cactgcccc	atcgcttgc	900
tgaagtcgct	catcagcgtc	atccacctga	tcacggccgc	ccgcaacatg	gctgccctgg	960
acgcagcaga	ccgcgccaag	aagaagtga	gctggagccc	cgggtcctgg	ctgcccacct	1020
gccctgggag	tcttgctgtg	ccacacagct	ccccaccccc	tgctaggagg	tcccagtcctc	1080
acgccttccct	catgtgttgt	tctacctgct	gggatggggg	tcagcctctc	tttggtgacg	1140
tcacgttctc	tgggatcctg	aggacccggg	cctcaaatca	gggaggatac	gcgggaggcc	1200
ccctccatcc	aggcgggtgct	cctgggggtg	cgggaccggg	cagtgtcaca	ccctgcctgc	1260
tcagtcctgg	ggtccgagat	gctagggacg	cttgagtga	ggaggtgggtg	tgagggccag	1320
gtttcctgaa	aggcgggagt	cagacctccg	ccccagcca	gagcaagctt	ggggcaccat	1380
gcccaggagg	gaagaagcca	tccacagcct	tccctgtcac	cggctcctct	gtcctgcctg	1440
accctgggtcc	tggcgggact	tactatttg	acttggtttc	ctttcagata	ttcttggtctc	1500
agggcctggg	ttgagggagc	ttaggggaag	acgtccgtct	gggtgctttt	cctccagttt	1560
gctggctggc	ttctccgtct	acccacagtg	acctcacaga	gaggccctcc	tgccacccat	1620
gctcatgtgg	tgtccccacc	gcccacttgt	ttgatgtcac	tgactgtcta	catgtattta	1680
tattcttgat	atcttctacc	ctcactagaa	tgtaaaactcc	atgaaggcac	agacttttct	1740
tgttctcttc	tctatcccta	gagtaagacc	aacttgaacc	tggcatatag	tagctgctta	1800
ataaatactc	gtctgtcaaa	aaaaaaaaaa	aaa			1833

&lt;210&gt; 52

&lt;211&gt; 1454

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; gene

&lt;222&gt; (1)..(1454)

&lt;223&gt; Human pancreatic lipase (PNLIP) mRNA

&lt;400&gt; 52

atgctgccac	tttggactct	ttcactgctg	ctgggagcag	tagcaggaaa	agaagtttgc	60
tacgaagac	tggctgctt	cagtgatgac	tccccatggt	caggaattac	ggaaagacc	120
ctccatatat	tgcttggtc	tccaaaagat	gtcaacaccc	gcttcctcct	atatacta	180
gagaacccaa	acaactttca	agaagttgcc	gcagattcat	caagcatcag	tggctccaat	240
ttcaaaacaa	atagaaaaac	tcgctttatt	attcatggat	tcatagacaa	gggagaagaa	300
aactggctgg	ccaatgtgtg	caagaatctg	ttcaaggtgg	aaagtgtgaa	ctgtatctgt	360
gtggactgga	aaggtggctc	ccgaactgga	tacacacaag	cctcgagaa	catcaggatc	420
gtgggagcag	aagtggcata	ttttgttgaa	tttcttcagt	cggcgctcgg	ttactcacct	480
tccaacgtgc	atgtcattgg	ccacagcctg	ggtgccacg	ctgctgggga	ggctggaagg	540
agaaccaatg	ggaccattgg	acgcatcaca	gggttgacc	cagcagaacc	ttgcttttcag	600
ggcacacctg	aattagtcgg	attggacccc	agcgatgcca	aatttgtgga	tgtaattcac	660
acggatggtg	cccccatagt	ccccaatgtg	gggtttggaa	tgagccaagt	cgtgggccac	720

ctagatttct	ttccaaatgg	aggagtggaa	atgcctggat	gtaaaaagaa	cattctctct	780
cagattgtgg	acatagacgg	aatctgggaa	gggactcgag	actttgcggc	ctgtaatcac	840
ttaagaagct	acaaatatta	cactgatagc	atcgtcaacc	ctgatggctt	tgctggattc	900
ccctgtgcct	cttacaacgt	cttcactgca	aacaagtgtt	tcccttgtcc	aagtggaggc	960
tgcccacaga	tggtgacta	tgctgataga	tatcctggga	aaacaaatga	tgtgggccag	1020
aaatthttatc	tagacactgg	tgatgccagt	aatthttgcac	gttggaggta	taagggtatct	1080
gtcacactgt	ctggaaaaaa	ggttacagga	cacatactag	tttctttgtt	cggaaataaa	1140
ggaaactcta	agcagtatga	aatthttcaag	ggcactctca	aaccagatag	tactcattcc	1200
aatgaatttg	actcagatgt	ggatgttggg	gacttgcaga	tggttaaatt	tatttggtat	1260
aacaatgtga	tcaacccaac	tttacctaga	gtgggagcat	ccaagattat	agtggagaca	1320
aatgttggaa	aacagttcaa	cttctgtagt	ccagaaaccg	tcaggaggga	agttctgctc	1380
accctcacac	cgtgttagga	gactactgtt	atthtgacaa	tgaattgact	tctaataaaa	1440
tctagtggtg	atgc					1454

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/30366

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) : C12Q 1/68; C07H 21/02, 21/04; C12N 15/00 US CL : 435/6, 536/23.1, 24.3; 935/76, 77, 78 According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 536/23.1, 24.3; 935/76, 77, 78 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	US 5,840,484 A (SEILHAMER et al) 24 November 1998, see entire document.	1-24 and 26-29		
Y	GAO et al. Role of Fatty acid metabolites in cancer metastasis and gene regulation. Cancer Molecular Biology. 1994 ,Vol. 1, No. 6, pages 345-356, see entire document.	1-24 and 26-29		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
<table border="0"> <tr> <td>           * Special categories of cited documents:            "A" document defining the general state of the art which is not considered to be of particular relevance            "B" earlier document published on or after the international filing date            "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            "O" document referring to an oral disclosure, use, exhibition or other means            "P" document published prior to the international filing date but later than the priority date claimed         </td> <td>           "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention            "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone            "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art            "Z" document member of the same patent family         </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family			
Date of the actual completion of the international search 31 OCTOBER 2001		Date of mailing of the international search report 20 DEC 2001		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 505-3230		Authorized officer <i>Janice Ford for</i> ETHAN WHISENANT, Ph.D. (FSA) Telephone No. (703) 308-0196		

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/30366

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 25  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
Claim 25 does not claim an embodiment of the invention, rather it simply recites the names of 15 genes associated with lipid metabolism.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US01/30366

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

USPATFULL, EUROPATFULL, Medline, CAplus

tumor or tumour and lipid? or lipid metabolism or synthesis and gene adj expression or express\$ and array